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The life expectancy of the general western population has increased
dramatically in the last 200 years (1) and is generally expected to continue
this rise. Many people reach a high age, but at the same time on average
25% of the lifespan is spent in disability. For virtually all common diseases,
age is the primary risk factor. The process of ageing is complex, generally
considered as the consequence of accumulation of damage to
macromolecules which occurs at a variable rate in different individuals, and
affects organs in different ways, ultimately leading to physiological
heterogeneity of elderly individuals, populations and patient groups. The
scientific human ageing field focuses on identifying biomarkers that monitor
the rate of ageing, markers of the biological age rather than just the
chronological age of individuals. Either such markers are causally involved
in ageing or can be used as tools to discover biological mechanisms that
determine the ageing rate and the ability to age healthily and become long-
lived.
Longevity determinants
The maximum and mean lifespan of animal models can be manipulated by
intervening in a number of pathways (2-4) that indicate a role in lifespan
regulation especially for nutrient sensing systems involving insulin/IGF (IIS)
and target of rapamycin (TOR) signaling. These determinants have been
investigated as candidate genes and pathways in human studies aimed at
identifying determinants of human lifespan regulation. In particular, genetic
association studies, in which gene frequencies are compared in highly aged
cases and younger controls, provided positive associations for genes in the
IIS pathway (5). For example, genetic variation in AKT and FOXO3a (6;7)
has been shown to have an effect on human longevity. Until now however,
the only locus widely confirmed to affect human mortality risk up to the
highest ages is the APOE locus on chromosome 19 (8-10).
Biomarkers for human ageing
Studies for biomarkers of human ageing have mainly investigated the
relation of physiological and molecular phenotypes with chronological age
to identify changes in these phenotypes representative of normative
ageing. Since many molecular changes occur as a function of chronological
age, a more valuable biomarker of human ageing would also associate with
morbidity and mortality in prospective studies (11) and thereby reflecting
biological ageing. An example of such a biomarker is leukocyte telomere
length (LTL) which associates with metabolic health and mortality in various
human cohort studies including prospective analyses (12;13).
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Nevertheless, this biomarker may not necessarily be a determinant of
ageing since a causal role for telomere length in human normative ageing
has not been established yet.
One strategy to find candidate biomarkers for human ageing is to compare
molecular traits in normative and healthy ageing groups within the human
population. The healthy ageing individuals can be selected from families in
which the longevity trait is clustered. In the Longevity Genes Project such
families have been collected by selection for centenarian single cases (14)
whereas in the Leiden Longevity Study selection has been focused on
nonagenarian siblings (15). As compared to normative controls, the middle-
aged descendants of these centenarians and nonagenarians have a low
prevalence of metabolic diseases such as insulin resistance, type 2
diabetes, hypertension and myocardial infarction (16) and lower mortality
risk (15;17) and are therefore regarded as healthy agers.
Biomarker studies comparing the healthy ageing offspring of the long-lived
to normative ageing controls have indicated that despite the absence of
difference in body mass index and lifestyle between the groups, the
offspring displays a healthier intrinsic metabolism reflected by serum lipid
profiles (14;18), adiponectin levels (19) and markers of glucose metabolism
(20). These measures of intrinsic metabolism are currently considered as
candidate biomarkers for human ageing in middle age. For elderly
populations however, the predictive power of these biomarkers for
morbidity and mortality is less clear.
The transcriptome
Besides the serum parameters as candidate biomarkers for human ageing,
an additional source for biomarkers may come from variation in gene
expression. Genes and functionally coherent gene sets of which the gene
expression changes with chronological age could set the profile for
normative ageing, providing a first insight into the mechanisms of ageing
processes and age-related disease (21). The last decade gene expression
changes with age have regularly been investigated both in animal models
and humans, using different designs, phenotypes and techniques. This
work has been reviewed for studies until 2008 in chapter 2 of this thesis. In
short, in different tissues in humans, the top most differentially expressed
genes with chronological age have been enriched for biological terms like
immune response, energy metabolism and mitochondrial processes. After
2008, explorative studies on age-related changes in the human
transcriptome have fundamentally increased their power by increasing
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sample sizes by mainly investigating RNA isolated from blood (21-23).
While at the single gene level the mutual overlap of transcriptional changes
with chronological age between different studies is limited, the enrichment
is similar. The major consistent additional enrichment among the top list of
genes of which gene expression changes with age since 2009 is for post-
transcriptional regulation. Thus processes involved in immune response,
energy metabolism, mitochondrial processes and post-transcriptional
regulation may harbor potential biomarkers for the rate of normative ageing.
For practical reasons the largest human studies into gene expression
changes with chronological age are naturally performed in blood. Smaller
studies indicated that common gene sets are differentially expressed with
ageing over different tissues (22;24). The similarities in age-affected
pathways across tissues and species suggests that the analysis of the
ageing transcriptome by functionally grouped gene sets in blood is a
promising approach to discover biomarkers and determinants of biological
ageing in humans.
Aim and outline of this thesis
The aim of this thesis was to identify in the human blood transcriptome,
potential biomarker profiles that associate with chronological age and
discriminate between ‘healthy agers’ from long-lived families and normative
ageing controls. Such profiles may harbour determinants of the biological
ageing rate.
The design for our study is based on the Leiden Longevity Study (LLS), a
Dutch cohort in which families have been included on the basis of
nonagenarian sibling pairs (15). The LLS consists of 420 Caucasian
families with at least two long-lived siblings (n = 944), together with their
middle-aged offspring (n = 1671) and the partners of this offspring (n = 744)
which will act as controls in this study (Figure 2 of chapter 2 of this thesis).
We have explored the blood transcriptome to recognize genes of which the
expression marks chronological ageing (comparing groups of young and
elderly individuals) and to identify which of those genes also mark familial
longevity (comparing among middle-aged individuals groups of healthy and
normative agers) (Chapter 3). Based on the top hits and most interesting
findings from these explorative analyses we extended, within the Leiden
Longevity Study, our analysis to a larger set of samples and genes
belonging to the IL7R pathway (Chapter 4) and to the MTOR pathway
(Chapter 5). The results of the latter study were followed by studies in
primary fibroblasts cultures from donors of the LLS (Chapter 6). Finally to
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improve and generate more robust and specific hypotheses for markers of
normative ageing we performed an explorative meta-analysis in three large
transcriptomic datasets using an integrative co-expressed network
approach (Chapter 7).
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Genome-wide and hypothesis-based approaches to the study of ageing
and longevity have been dominated by genetic investigations. To identify
essential mechanisms of a complex trait such as ageing in higher species,
a holistic understanding of interacting pathways is required. More
information on such interactions is expected to be obtained from global
gene expression analysis if combined with genetic studies. Genetic
sequence variation often provides a functional gene marker for the trait,
whereas a gene expression profile may provide a quantitative biomarker
representing complex cellular pathway interactions contributing to the trait.
Thus far, gene expression studies have associated multiple pathways to
ageing including mitochondrial electron transport and the oxidative stress
response. However, most of the studies are underpowered to detect small
age-changes. A systematic survey of gene expression changes as a
function of age in human individuals and animal models is lacking. Well-
designed gene expression studies, especially at the level of biological
processes, will provide hypotheses on gene-environmental interactions
determining biological ageing rate. Cross-sectional studies monitoring the
profile as a chronological marker of ageing must be integrated with
prospective studies indicating which profiles represent biomarkers
preceding and predicting physiological decline and mortality. New study
designs such as the Leiden Longevity Study, including two generations of
subjects from longevity families, aim to achieve these combined
approaches.
Introduction
The most prevalent diseases in Western societies have in common that
age is a major risk factor. The process of ageing across different species is
marked by the occurrence of molecular and physiological changes in all
cells and tissues. It is not clear which of these changes are causal to
ageing, but the accumulation of damaged molecules and loss of
homeostasis is generally considered to be central to the rate of the ageing
process, generating lifespan variation even in genetically identical
individuals in a common environment (1;2). Although different age-related
diseases may arise by different pathophysiological mechanisms, it is not
unlikely that common mechanisms of ageing influence the onset of different
age-dependent diseases and the lifespan. This may be explained if these
mechanisms affect the accumulation of damaged molecules and eventually
the homeostasis of the organism. Indications that such mechanisms exist
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come from the observation that the occurrence of multiple age-dependent
disease conditions is simultaneously postponed in caloric restricted
laboratory rodents (3) and from the offspring of human centenarians. These
individuals are expected to have inherited longevity assurance mechanisms
that attenuate their ageing rate and protect from disease (4). For more than
two decades there is an ongoing search for mechanisms driving the ageing
process in different species. Phenotypic features of ageing that are usually
investigated include the mean and maximum population lifespan and the
occurrence of age-dependent disease. True intermediate phenotypes, or
biomarkers which mark the rate of biological ageing and the mortality risk of
individuals in a pre-clinical phase of life, have hardly been identified. The
availability of such biomarkers, comparable to the way bone mineral density
is a biomarker predicting the risk for osteoporosis (5), would help in the
search for mechanisms underpinning ageing.
Successfully applied genetic approaches in ageing research mainly involve
the identification of genetic variation influencing intra-species differences in
lifespan. These genetic studies revealed that some mechanisms of lifespan
regulation, such as the insulin/insulin-like growth factor I signalling (IIS)
pathway, are common to species ranging from nematodes to mice (see
(3;6) for reviews). Genetically modified ageing mutants in these studies
have increased life spans by more than two fold. Other mechanisms so far
identified by genetic research in model systems include mitochondrial
function and histone modification control (7). Genetic association studies of
insulin signalling genes and other candidate loci with human longevity have
given contradictory results (see (8;9) for reviews). The gene most
consistently associating with human longevity in all studies is the apoE
locus (10), which is poorly investigated in lifespan studies in animals. In
general, the population based cross-sectional analysis of gene frequencies
with age has thus far provided few consistent results. This may be
explained by the fact that the mean life expectancy in western societies has
increased dramatically in the last 100 years, and that the current variation
in lifespan in such populations, therefore, is mainly determined by non-
genetic factors (75%, (11;12)). Genetic influences on human longevity are
much higher in families containing a clustering of long-lived individuals (13-
15) and these observations have resulted in new genetic studies based on
familial longevity.
Far less effort than on genetics has been put into obtaining an
understanding of the gene expression profiles that are associated with
lifespan and how this relates to the genetic variation associated with
longevity. To achieve this goal, a systematic survey of gene expression
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changes that occur in somatic tissues throughout the lifetime of individuals
is required. Such profiles may reflect the interaction of the genome with
environmental challenges that occur during the ageing process. Increased
power in genetic studies must be accomplished, to uncover information on
the interactive effects of multiple loci in ageing of higher species, which is
expected to be essential in complex traits. It is thus the combination of
approaches that promises most success in unravelling ageing as a complex
trait.
In transcriptomic research, changes in gene expression profiles in various
tissues are being explored mainly as comparisons of diseased and healthy
individuals. Gene expression studies have been performed on a large scale
in research into cancer (16;17), stroke (18;19), immune diseases (20-23)
and other age-related diseases (24;25). In cancer research, expression
profiles were indicated to be able to identify specific types of cancer,
classify tumour stage or severity, disease progression and the response to
certain treatments (26-31). The basic design in most cancer research is
relatively simple compared to other disease research, because target and
healthy tissue from patients can directly be compared and the changes in
gene expression are often large. For a complex trait like human ageing, the
primary affected cells or tissues are unknown and the gene expression
changes are probably small and thus more difficult to find. Therefore, this
paper serves two functions, (i) to review and discuss the gene expression
studies performed in the ageing field and the insights into the biological
process involved in ageing and longevity they have revealed, and (ii) to
draft up future recommendations for this research field.
Transcriptomics in human ageing
Until now, transcriptomics studies into human ageing utilise candidate
gene-based and explorative approaches to identify which mRNA
expression levels are regulated in an age-dependent fashion. Study
designs mainly consist of comparisons between young and elderly
individuals, sometimes including centenarians, or a comparison of RNA
expression profiles in patients with progeroid syndromes to young and
elderly individuals. Transcriptomic studies into human cancers require
several tens of samples to identify significant expression patterns changing
at least two fold between cancer and healthy tissue from the same patient
(32). The expected differences due to ageing are much smaller and more
difficult to detect given the large inter-individual genomic variation in
humans that is not due to ageing (33). Large experimental groups as well
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as a good study designs are required to enable reproducible conclusions to
be made from studies of gene expression and ageing.
Candidate gene-based studies
Research based on candidate genes is generally performed in a cross-
sectional design using cultured skin fibroblasts (34;35), lymphocytes (36),
and peripheral blood mononuclear cells (PBMC) (37). The majority of the
studies were performed by quantitative PCR methods (34;35;37), others
use Northern blot analysis (36) to investigate specific candidate genes,
such as heat shock protein HSP70 (36), osteoclastogenesis inhibitory
factor (OCIF) (34), several proteasome subunits (35) and caspases (37).
Some statistically significant results were obtained from candidate gene-
based studies (34-36) investigating a small number of genes in only 2-5
healthy females per group. Centenarians appeared to have an expression
level that resembles that of young (<40 yrs) individuals more than that of
elderly individuals (65-80 yrs) (34-36). The authors interpreted this result as
an indication that the expression levels of these genes of long-lived
individuals as well as in younger ones reflects the healthier condition of
these individuals as compared to elderly individuals.
In a relatively large study of 246 individuals aged 10-102 years old, Lacelle
et al. (37) investigated gene expression of 4 caspases as a function of
chronological age. In general, their results indicated a larger variation within
an age category than across categories. Caspase-1 expression is
increased in elderly (70-89 yrs) and long-lived (90+ yrs) individuals
compared to younger (≤69 yrs) individuals. Caspase-8 expression was
increased in the elderly only and caspase-3 in the long-lived individuals
only, when compared to the younger age group. Expression of caspase-10
was similar across all age groups. In this cohort, a high level of caspase-8
is the biosignature for elderly individuals, while high levels of caspase-3
and low levels of caspase-8 mRNA expressions were the hallmark
biosignature for nonagenarians and centenarians. With regard to both
caspase-1 and -3, population profiles revealed a slow shift with age toward
higher levels of caspase mRNA expression. The authors hypothesize that
these age-related shifts are important, as they may indicate that a subgroup
of individuals within the younger population, expressing high levels of
caspase-3 mRNA in their PBMC, is favoured to attain longevity. In the
cross-sectional design of this study, however, such hypotheses can not be
tested, as it is not possible to establish whether the changes observed were
the cause or the consequence of an older age. A large prospective study of
individuals followed from middle age onwards for medical history and
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lifestyle until the date of death would be able to reveal whether expression
changes predict a decline of health and mortality risk. Such large human
epidemiological studies do exist, and their follow up period is 15 to over 50
years (38;39).
Genome-wide studies
The introduction of the whole genome microarrays for gene expression
research provided the opportunity to investigate the expression of the
whole human transcriptome. Transcriptomic studies with an explorative
approach could provide useful information about co-related genes and
biological processes involved in ageing, including those that are not yet
considered as candidates. Explorative expression studies have been
performed on home-spotted microarrays containing ~4.000-6.000
transcripts (40-42) and on commercial Affymetrix microarrays, with 12.000
(43;44) to ~54.000 (45-49) transcripts on each array. The design commonly
used was the cross-sectional comparison of young and elderly healthy
individuals, about eight individuals maximum per group or an analysis of
individuals across an age-range. Various tissues were investigated in these
studies, such as cultured lymphocytes (40), fibroblast cell lines (41;42;46),
brain (43;44), kidney (48), and skeletal muscle (45;47;49).
Several pathways were highlighted by differentially expressed genes
between young (19-29 yrs) and elderly (65-85 yrs) individuals (40),
including energy metabolism, cell cycle, signal transduction, and DNA
repair (see Table 1 for a summary)(45;49). Other studies additionally
included the comparison of individuals with progeria, which are genetic
disorders that cause segmental premature ageing such as Werner
syndrome (WS) (41) and Hutchinson-Gilford progeria syndrome (HGPS)
(42), to represent ageing mechanisms in the general population. These
studies showed that genes from important pathways act similarly in old (87-
96 yrs) individuals and progeria patients (7-37 yrs) suggesting that some
but not all normal ageing mechanisms are accelerated in progeroid
syndromes. There is still debate as to whether progeria is a good model for
human ageing (50).
Only four large transcriptomic studies were performed investigating age
ranges from 13-106 years (43;44;47;48), using sample sizes from 30-81
individuals. Applying Affymetrix microarrays with ~12.000-54.000
transcripts per array, these groups found 250-985 transcripts that differ
significantly in gene expression as a function of age in several tissues of
healthy donors, with fold changes below two (43;44). Biological pathways
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found to be changed with age are listed in table 1 and includes genes
involved in the mitochondrial electron transport chain, cell cycle and
extracellular matrix.
In addition to limited sample sizes, a major problem in gene expression
studies of healthy humans is the restricted availability of relevant human
tissue. Zahn et al. (47) performed a meta-analysis on data of multiple
studies investigating RNA from muscle, kidney and brain in a cross-
sectional design. There was almost no correlation between the expression
levels, or changes with age of individual genes in the different tissues,
meaning that in each tissue different individual genes change their
expression with age. Importantly, using pathway analysis, gene expression
changes influencing six pathways were consistently found in all three
investigated tissues (the first six pathways that are listed in Table 1). These
results indicate that these pathways, but not particularly individual genes,
are common elements in the age-related expression changes of different
tissues. This may implicate that in addition to tissue specific effects, a
common ageing signature may be found in any tissue that reflects the age
of the whole organism. This would give major implications for human
epidemiological studies, for which frequently only blood is available.
Table 1. Pathways found to be changed by ageing in explorative human
transcriptomic studies.
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Apoptosis Erraji-Benckekroun et al.2005 (44) 39 Kyng et al. 2003 (41) 5 / 6
Energy metabolism Erraji-Benckekroun et al.2005 (44) 39
Welle et al. 2003
(49) 8 / 8
Hormonal Lu et al. 2004 (43) 30 Welle et al. 2003(49) 8 / 8
Synaptic transmission Lu et al. 2004 (43) 30
Vesicular transport Lu et al. 2004 (43) 30
A striking observation in the genome-wide studies was that individuals
younger than 30 yrs showed very similar expression patterns (43). Also, the
age group older than 90 yrs of age showed very similar expression
patterns, although this homogenous pattern is different from that of the age
group younger than 30 yrs. However, the individuals aged between 30 and
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90 showed highly variable expression patterns of which some are more
similar to the young age group and others to the old age group. This may
coincide with individuals diverging in their rates of ageing as they go
through middle age and later their diversity in age at death. The
heterogeneity in gene expression that becomes detectable from the age of
30 onwards may be an intermediate phenotype or biomarker, on the
condition that it would represent biological differences in the ageing
process of individuals that precede and contribute to disease and mortality.
Two studies (48)provided proof that this indeed was the case, by showing
that the gene expression profiles of human muscle and kidney
corresponded to the measured physiological functionality (the ‘biological
age’) of the tissue rather than to the chronological age of the subject (47).
Animal ageing models
A large number of studies have investigated the changes in gene
expression in relation to ageing and longevity in laboratory animals using
commercially available microarrays. The most frequently used animal
model for this research is the mouse (51-54), but nematodes (55), flies (55-
57), rats (58) and monkeys (59;60) have also been investigated. A range of
tissues were studied such as liver, heart, muscle, aorta and brain. Across
all species and in most experimental designs there is a gender effect on
ageing features and gene expression (59;61).
The main design for measuring chronological age-changes, as in humans,
was a comparison of young and old individuals, using on average three
animals per group. Since such studies are usually performed in inbred
strains, the variation between individual animals is smaller than among
human individuals. A meta-analysis showed that, among many observed
effects that were not comparable between species, the mitochondrial
electron transport chain genes showed a consistent overall decrease in
expression with chronological age in humans, mice, and flies, but not in
nematodes (47). Interestingly, this pathway also consistently changed with
age in different human tissues as mentioned above (47). Another meta-
analysis found that genes involved in the oxidative stress response were
similarly changed with age in human, mouse and rat brain as well as in
nematodes (43).
Together these studies will eventually provide insight in the gene
expression changes just associated with chronological age, those with
biological contribution to the ageing process of each species and those
pointing at evolutionary conserved mechanisms of longevity. Some short-
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lived mutants are expected to represent a model for human progeria,
whereas long-lived mutants and caloric restricted animals may represent
familial and sporadic (non-familial) human longevity, respectively. Caloric
Restriction (CR) refers to a diet with fewer calories than is typical, but which
contains all the necessary nutrients and vitamins to support life. The
comparison of caloric restricted rodents and littermates that did not receive
CR showed that CR resulted in a partial inhibition of age-related changes in
gene expression (51-54;58). This indicates that CR, as it prolongs lifespan,
also influences the age-related changes in expression profiles in a way that
may point to a decreased rate of biological ageing. These results were
consistent among mice, flies and nematodes but could not be confirmed in
monkeys (60).
The question is whether pathways affected by CR were also affected by
mutations inducing increased lifespan in these species. A recent study
compared gene expression profiles associated with mutations inducing
longevity by reduced IIS signalling in nematodes, flies and mice (62).
Conservation of the IIS related longevity regulation was tested at the level
of individual orthologous genes, for paralogous gene sets and at the level
of biological processes reflected by gene classes. There was hardly any
conservation of IIS regulation at the gene level between the species.
However, the process analysis revealed that the conserved element in IIS
regulation of the long-lived mutants associated with up-regulation of sugar
catabolism and energy generation, with cellular detoxification pathways and
with down-regulation of protein biosynthesis and translation. The authors
suggested that of these IIS regulated processes those that most likely
reflect the longevity regulation, because of findings in other ageing studies,
are lowered protein biosynthesis and increased cellular detoxification
reflected by Glutathione-S-transferase (GST) activity.
Future directions for human research
Clearly, genomic studies in animal models generate many hypotheses that
are worth testing in humans, where the possibilities for investigating healthy
individuals are very limited. Here we will discuss what improvements may
be accomplished.
Sample size
As for genetic association studies, the sample size of a gene expression
study in humans greatly determines the credibility of the results, especially
concerning the multiple testing performed in genome-wide explorative
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analyses. A review from Allison et al. (63) nicely summarised the main
statistical issues in expression studies. Minimal sample size calculations
depend on design, the total background variation within the data, the
magnitude of the expression change that is to be detected, the desired
statistical power or probability to detect differentially expressed genes, the
specified error rate, and the statistical method being used to detect the
changes in gene expression. They advocated that the minimal, and
certainly not optimal, sample size to be used in expression studies is five
biological cases per group. This amount is only useable when testing for
differential expression with fold changes of three and up (64), and then the
reproducibility of the results is still questionable. Since fold changes in
differential gene expression are expected to be below two in human ageing,
it has been suggested that a minimum of 25 individuals per group is
required in the analysis of a case control design (65;66). Large sample
sizes are thus required. As a consequence, the primary studies aimed at
the identification of biological processes relevant for human ageing by gene
expression approaches are bound to be performed on easily available
tissue from healthy individuals such as blood, buccal cells from the mouth
and skin fibroblasts.
The value of studying whole blood in transcriptomics
Because blood is an easily available tissue, several studies have
investigated gene expression profiles in whole human blood. Whole blood
mRNA was used for studies into Huntington disease, Down syndrome,
multiple sclerosis, psoriatic arthritis, Alzheimer’s disease and epilepsy (67-
70). In a candidate gene study for schizophrenia, 21 out of the 31 candidate
genes expressed in the brain were similarly expressed in whole blood (67).
Gene expression in blood is also shown to mirror disease state in multiple
sclerosis (20). In general, the expression levels of genes as investigated on
a 34K Affymetrix microarray show an average correlation of 0.5 when
comparing blood and other tissues (67). Blood has also been successfully
used for classification of disease subgroups, for progression prediction and
to investigate the effects of medical treatment (71-74). It is expected that
blood reflects a limited proportion of the biological processes relevant for
ageing and longevity. However, ageing does not affect one specific tissue
and blood both initiates and reflects processes that affect the whole body.
Therefore, studying gene expression in blood cells is a good start for
finding the relevant intermediate phenotype that emerges from genetic
variation for ageing and longevity. Gene expression profiles in blood were
found to be highly similar in monozygotic and moderately similar in
dizygotic twin pairs, with a heritability of 0.33 (75-77). Variation in gene
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expression in healthy unrelated individuals is found to be limited and
detected as a result of blood cell subsets, gender, age, time of day and
individual differences (78-80).
Figure 1. Gene expression in whole blood of volunteers.
Two-dimensional unsupervised hierarchical cluster analysis of 1548 most differentially
expressed genes between individuals is shown. Each column represents a sample and each
row a gene. The colorgram depicts high (red) and low (green) relative levels of gene
expression. Grey means the data is not available. The four different time points of one
individual clustered together, and so did the males and females (from left to right: female 1,
2 and 3 and male 1, 2 and 3, each colour on the bottom axis represents one individual).
As an illustration to the latter point, we compared gene expression profiles
of mRNA isolated from whole blood samples obtained from three healthy
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married volunteer couples (61-76 yrs). Blood was taken on four occasions;
on two different days (three weeks apart) and in the morning (10 a.m.) as
well as in the afternoon (2 p.m.). Gene expression was measured using
CodeLink whole genome microarrays (~54.000 transcripts). Figure 1
provides an overview of the 1548 genes most variable between the
individuals, which showed very similar expression patterns at the four time
points within an individual, suggesting a stable expression profile over this
time interval. In addition, statistical analysis of this pilot comparison
revealed that the expression of very few genes was influenced by the time
of day, or day at which the blood was collected. Most differentially
expressed genes were associated with individual variation, including
gender.
All in all, current data justifies the use of whole blood in the study of human
ageing. However, as will be the case for including only one tissue, much of
the relevant biological context will be missed. Therefore, such
investigations should be linked to parallel studies in animal models. These
models can show what interactions between biological processes with each
other and with environmental stimuli are reflected in blood. As has been
shown in animal studies, the human studies will become more informative if
study designs allow for a combined analysis of genetic variation, gene
expression and environmental variation.
Study design
Cross-sectional designs comparing young and elderly individuals are thus
far most frequently used in gene expression studies of human ageing. In
these designs there is no possibility to distinguish causal changes that are
of major importance in determining biological ageing, mortality and
longevity of individuals, and chronological changes that reflect effects
thereof. Prospective study designs are available in large epidemiological
human cohort studies of 20-30 years to follow up, that may indicate which
RNA profiles (if cells are available in the study) precede and predict
changes in physiological health and mortality risk. Twin studies will add vital
information as to how genetic variation and environmental factors relevant
for human ageing influence gene expression profiles throughout life.
Comparable to long-lived strains in animal models, human lifespan
variation is studied also in families of exceptional longevity. Especially the
offspring of long-lived individuals may reflect which RNA profiles associate
to the familial longevity trait at middle age (13). The middle aged offspring
of centenarians do express part of the beneficial phenotype already in the
sense that they have a life-long decreased risk of mortality from coronary
Chapter 2
26
heart disease, diabetes and cancer. This can be viewed as secondary to a
decreased rate of biological ageing (4) occurring in longevity families.
As an illustration of how new designs can be used in genomic
investigations of human ageing and longevity we will now discuss the
concerted genetic and gene expression studies in the Leiden Longevity
Study. The aim of this research is to identify genomic and biochemical
parameters associated with human longevity by combining research in
familial long-lived individuals and their family members and in sporadic
long-lived individuals from the general population. The Leiden Longevity
Study (Figure 2) consists of 420 Caucasian families with at least two long-
lived siblings (men aged 89 years or above; women aged 91 years or
above, n=960), the middle aged offspring (n=1764) and the partners of this
offspring (n=757). In 2001, less than 0.5% of the Dutch population fulfilled
these sex-specific criteria (14). The survival benefit of the long-lived
families is marked by a 30% decreased mortality risk observed in the
survival analysis of three generations, the parents of the sibling pairs, their
deceased siblings and their offspring (14). The familial survival advantage
thereby exceeds the increased lifespan expectancy in the last generations
of western societies due to non-genetic factors (improved nutrition, hygiene
and health care). Therefore, this selected population is enriched for
heritable familial longevity. An ongoing genome-wide association study
using Affymetrix 500k SNP arrays should reveal which genetic variation is
associated with familial longevity and which individuals carry this variation.
Figure 2. Design of the Leiden Longevity study
Long-lived families were recruited if they included a long-lived sibling pair with males aged
89 y or older and women aged 91 y or older.
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For the purpose of biomarker identification, including gene expression
profiling, a cross-sectional comparison of young controls (partners of
offspring) and elderly cases (long-lived siblings) may be performed.
Chronological age changes will also be observed in an analysis of the age
range of each subgroup: long-lived siblings (89-103 yrs), offspring (34-80
yrs) and partners (30-79 yrs). Biologically relevant age-changes in
biomarkers will emerge from a comparison of offspring and partners. The
offspring can be viewed as cases with a higher susceptibility to become
long-lived and their partners, representatives of the general population, as
controls (14). The key advantage of this design is that the offspring and
their partners are of similar age and have a similar environment. Therefore,
differentially expressed genes in the comparison of these two groups could
represent processes associating to familial longevity detectable at middle
age and thereby preceding the long-lived phenotype. Some of these genes
will become even more marked in their differential expression when studied
in a comparison of the elderly long-lived cases and controls. This
methodology has revealed metabolic markers (81;82) as potential
biomarkers and is now being used for gene expression studies. Whole
blood RNA samples from 150 individuals of the Leiden Longevity study are
being analysed (50 long-lived siblings, 50 offspring and 50 partners). At the
level of the individual, the expression profile or expression level of specific
genes can be linked to the genetic variation that was found to associate to
familial longevity in the genetic studies. This analysis is expected to reveal
causal changes in biological processes associated with longevity. As stated
before, to obtain an understanding of the biology of ageing, it is highly
relevant to investigate interactions of genomic (genetic and gene
expression) variation with the environmental component. For this purpose
data on nutrition, lifestyle and socioeconomic status are being collected.
Although in human studies the biological depth of such information is
limited, those are the factors that may be beneficially manipulated to
improve health.
The proof of the pudding for a parameter to be a biomarker of biological
ageing will be established only if it predicts decline of physiological health
and mortality risk in a prospective survey of the middle aged offspring and
partners. A study of such a marker in a prospective population based
cohort study, such as the Leiden 85+ study (83), will reveal whether it
marks ageing mechanisms relevant only for familial longevity or also for
population wide longevity. To illustrate the value of this methodology, we
have recently observed that low concentrations of small LDL (Low Density
Lipoprotein) particles is a feature of familial longevity, detectable at middle
age and is expressed especially in healthy familial nonagenarians (health
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based on scores on the Activity of Daily Living questionnaire), but also in
sporadic nonagenarians in the population (82).
Concluding remarks
Genetic and transcriptomic approaches have both provided insight into the
biological processes involved in ageing. Transcriptomic studies identified a
number of promising pathways that may be affected by ageing in different
species, including humans, and across different tissues within a species,
among which the electron transport chain and oxidative stress response
promising. These pathways are connected because when synthesizing
ATP, the mitochondrial electron transport chain releases electrons which
can reduce oxygen, forming reactive oxygen species (ROS) such as
superoxide. These ROS can induce oxidative stress and may contribute to
the decline in mitochondrial function associated with the ageing process
(84). Caloric restriction has been found to not only increase the life-span of
rodents, but also to reduce ROS production (85). This can be explained
when high amounts of energy are available, mitochondria do not operate
very efficiently and generate more ROS, while when calorie restricted,
energy is conserved and there is less free radical generation. Glutathione-
S-transferases are involved in cellular detoxification and have recently been
linked to longevity across species (62). Glutathione-S-transferase (GST)
can act as an antioxidative enzyme by protecting against damaging ROS
and thereby decreasing oxidative stress in cells (86).
Gene expression studies in animal models have identified various biological
processes that can serve as hypotheses in human studies. However, for a
true testing of such hypotheses and the identification of human pathways,
improvements in methodology are vital. These include larger sample sizes,
the concerted application of population/patients based designs and familial
designs that can distinguish chronological age effects from biological
ageing. Highly relevant is also the combined analysis of genetic variation,
gene expression variation and environmental factors. Figure 3 represents a
scheme depicting how genomic studies may be integrated in research
aimed at disentangling the complex biology of ageing. Any input study of
lifespan variation whether associated with naturally occurring genetic
variation (human cohorts, or different animal strains), induced by mutations
or by modulation of the environment (such as in caloric restriction) may be

























Figure 3. Scheme depicting the integration of genomic studies into the biology of
ageing
Gene expression studies may directly reveal leads to relevant mechanisms
in a species, but especially the integration of gene expression studies at the
level of biological processes (such as in (62)) will provide hypotheses as to
whether and which gene-environmental interactions associate to common
processes determining biological ageing rate. It is also necessary to
integrate cross-sectional studies monitoring the profile as a chronological
marker of ageing, and prospective studies indicating which of these is a
biomarker preceding and predicting physiological decline and mortality. The
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integration of such information with knowledge emerging from gene-
environmental interactions will reveal causal mechanisms for ageing that
can be tested simultaneously in animal models and in humans.
Human studies should include larger sample sizes to increase the power of
the analyses and reliability of the results, better systematic surveys of gene
expression changes over a lifetime and designs that allow a good
integration with genetic studies. Understanding the aetiology of a complex
trait such as longevity will require more than just transcriptomics. There will
be a need to combine genetics, transcriptomics, proteomics and
metabolomics in order to gain further knowledge about biological processes
involved in ageing and longevity.
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The Leiden Longevity Study consists of families that express extended
survival across generations, decreased morbidity in middle-age, and
beneficial metabolic profiles. To identify which pathways drive this complex
phenotype of familial longevity and healthy aging, we performed a genome-
wide gene expression study within this cohort to screen for mRNAs whose
expression changes with age and associates with longevity. We first
compared gene expression profiles from whole blood samples between 50
nonagenarians and 50 middle-aged controls, resulting in identification of
2,953 probes that associated with age. Next, we determined which of these
probes associated with longevity by comparing the offspring of the
nonagenarians (50 subjects) and the middle-aged controls. The expression
of 360 probes was found to change differentially with age in members of
the long-lived families. In a RT-qPCR replication experiment utilizing 312
controls, 332 offspring and 79 nonagenarians, we confirmed a
nonagenarian specific expression profile for 21 genes out of 25 tested.
Since only some of the offspring will have inherited the beneficial longevity
profile from their long-lived parents, the contrast between offspring and
controls is expected to be weak. Despite this dilution of the longevity
effects, reduced expression levels of two genes, ASF1A and IL7R, involved
in maintenance of chromatin structure and the immune system, associated
with familial longevity already in middle-age. The size of this association
increased when controls were compared to a subfraction of the offspring
that had the highest probability to age healthily and become long-lived
according to beneficial metabolic parameters. In conclusion, an “aging-
signature” formed of 21 genes was identified, of which reduced expression
of ASF1A and IL7R marked familial longevity already in middle-age. This
indicates that expression changes of genes involved in metabolism,
epigenetic control and immune function occur as a function of age, and
some of these, like ASF1A and IL7R, represent early features of familial
longevity and healthy ageing.
Introduction
Nonagenarians and centenarians delay or escape age-related diseases (1),
their first degree family members have a life-long survival advantage (2;3)
and their middle-aged offspring have a decreased prevalence of and
mortality from coronary heart disease, type 2 diabetes, and cancer (4;5). In
addition, the offspring of long-lived individuals have beneficial physiological
characteristics for lipid and lipoprotein particle profiles (6;7), glucose
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metabolism and insulin sensitivity (8;9). However, they do not differ from
controls with respect to body mass index, serum IGF-1 levels, height and
lifestyle factors such as physical activity levels and smoking behavior
(8;10). Although familial longevity is a complex phenotype, identifying
transcriptional targets that may contribute to the physiological benefits
observed in long-lived families will increase our understanding of which
pathways can influence susceptibility to and protection from age-related
disease.
Previous studies have investigated whether there are gene expression
changes that occur with age in brain, lymphocyte, kidney and skeletal
muscle tissues (11-16). The expression of some genes were found not only
to change with age but also to reflect the biological function of the source
organs (13;14). These studies have demonstrated that gene expression
levels are not only markers of chronological age but also of tissue function.
However, these studies cannot discriminate between genes showing
expression changes in mid-life that may contribute to the aging process,
from those showing expression changes later in life as a consequence of
the aging process.
Here we report transcriptional profiling of whole blood samples from
participants of the Leiden Longevity Study which is based in the
Netherlands and comprises nonagenarian sibling pairs, their middle-aged
offspring and the partners of the offspring as population controls. A
comparison of gene expression profiles between the nonagenarian siblings
and controls identified profiles that associate with age. The subsequent
comparison of the middle-aged offspring and the controls enabled the
identification of genes that mark the propensity to become long-lived in
middle-age.
Results
Whole genome microarrays and analysis design
Gene expression profiles were generated from 150 whole blood total RNA
samples collected from 50 families belonging to the Leiden Longevity Study
(LLS). From each family, one nonagenarian sibling, one of their offspring
and the offspring’s partner (Table 1) were profiled. We identified 47,209
probes (88% of the total number of probes) which were expressed in at
least 10% of the samples. Of these, 45,164 probes (containing at least
17,896 unique genes) could be mapped to a chromosomal position and
were, therefore, used for further analyses.
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Figure 1. Flowchart of gene expression analyses.
The order of analyses is shown for the explorative analysis (top half of the figure) and the
replication analysis (bottom half of the figure). The probes/genes are depicted in the boxes
and to the left thereof are the techniques or analyses used.
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The explorative analysis is divided in two parts (Figure 1). The first analysis
focused on the comparison between the long-lived nonagenarians and the
population controls (the partners of the offspring). Using this design we
aimed to find genes whose expression changed with increasing age and
among these, those that were differentially expressed in long-lived families.
In the second analysis we investigated which of the differentially expressed
genes emerging from the first analysis were already differentially expressed
between long-lived family members and controls in middle-age. Therefore
we compared the offspring to the controls for mean gene expression
differences and also for the interaction between the two groups with age to
identify genes whose expression changed differentially with age between
offspring and controls. Following the explorative analysis, we performed
replication analyses in an extended group of the LLS using RT-qPCR on a
selected subset of the differentially expressed genes.




N 50 50 50
Males / females (% males) 24 / 26 (48%) 25 / 25 (50%) 26 / 24 (52%)
Mean age in years (range) 61.9 (43.7 – 78.8) 60.8 (42.8 – 74.8) 93.4 (89.3 – 102.2)
B RT-qPCR experiment
N 312 332 79
Males / females (% males) 143 / 169 (45.8%) 190 / 142 (57.2%) 34 /45 (43.0%)
Mean age in years (range) 61.3 (40.9 – 81.4) 61.3 (33.6 – 78.3) 94.1 (89.0 – 101.2)
Differential gene expression associating with age
To investigate the differences in gene expression levels between the
nonagenarian subjects and the middle-aged controls a linear regression
model was applied to the probe data. With adjustments for gender and
batch effects (Model 1, see Materials and Methods) 2,953 probes (of which
1,853 represented known genes) were found to be differentially expressed
at a false discovery rate (FDR) of 0.05 (Figure 2 and Supplementary Table
S1). The expression levels of 1,046 probes were increased and 1,907
decreased in the nonagenarians compared to the younger controls. The
probe that associated with age with the highest significance (FDR adjusted
p-value = 5 x 10-10) is located in the leucine rich repeat neuronal 3 gene
(LRRN3, 7q31.1) and showed a 3.1-fold decreased expression in
nonagenarians, which was also the largest difference in expression level
between the two groups. The largest increase in expression level was 2-
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fold for a probe targeting the interferon, alpha-inducible protein 27 isoform
(IFI27, 14q32.13) gene locus. This probe could also target SYTL1, but
since the levels of a specific probe for SYTL1 did not correlate with the
IFI27 probe (Pearson correlation = -0.14), while a unique probe for IFI27
did correlate (Pearson correlation = 0.96), the result suggests that IFI27
mRNA is responsible for the association. Average expression levels of the
2,953 probes show a distribution over the whole range of measured
intensities (Supplementary Figure S1) and 89.5% of these probes were
detected in ≥ 95% of the samples.
If a group of differentially expressed genes act in the same pathway or
biological function this could lead to an additive or even synergistic effect
on cellular function. Furthermore, the interpretation of transcriptional data in
a pathway context is a more robust signal to noise measurement. The
Gene Ontology (GO) consortium (17) provides structured vocabularies and
classification of genes, covering several domains of molecular and cellular
biology. Hence, GO terms were tested for differences between
nonagenarians and controls using the Globaltest methodology (18;19).
Globaltest determines whether the expression pattern of genes within a set
as a whole is associated with an outcome, in this case being nonagenarian
or not, without testing single probes. We assayed 1,808 GO gene sets,
representing groups of genes closely related in their biological function or
process, containing at least 10 probes per GO term, again using Model 1.
The Globaltest showed that 109 GO term gene sets were significantly
differentially expressed between nonagenarians and controls at a family-
wise error rate (FWER) of ≤ 0.05 (Supplementary Table S2). FWER is used
because the gene sets for GO terms are partly overlapping and therefore
not independent. These 109 GO terms include 73 biological processes, 31
molecular functions and 5 cellular components. The biological processes
identified under the higher level GO classifications were ‘lymphocyte
activation’, ‘anatomical structure development’, ‘response to stimulus’
(including ‘immune response’), ‘regulation of gene expression’, and
‘regulation of signal transduction’. For the molecular functions list, pathways
involved in protein binding were the most abundant.
Differential gene expression in middle-age associating with longevity
The nonagenarian participants in the LLS each exhibit the longevity
phenotype and their offspring, as a group, carry the potential to become
long-lived as demonstrated by beneficial physiological characteristics and
decreased morbidity of that generation (5;6;20). The physiological
differences between offspring and controls are small since not all individual
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offspring may have inherited the longevity trait. To distinguish which of the
2,953 probes that associated with age also reflect familial longevity already
in middle-age, gene expression levels were compared between the 50
offspring of the nonagenarians and the 50 controls (Table 1). In a linear
regression model adjusting for age, gender and batch effects (Model 2, see
Materials and Methods), we observed no significant differences in the
average expression levels between the offspring and controls. Next, we
investigated differential expression changes as a function of age between
the offspring and the controls by testing the interaction between group and
age (Model 3, see Materials and Methods). Differential expression (FDR ≤
0.1) between offspring and controls across the age-range (43 – 79 years)
was observed for 360 probes, representing 244 unique genes
(Supplementary Table S3). Of these probes, 359 had a fold change below
1, indicating that expression levels had either a weaker increase with age
or a stronger decrease with age in the offspring compared to controls.
These age-related expression differences may represent early
characteristics of human longevity.
The most significant differentially expressed probe (FDR adjusted p-value =
0.050, 1.6-fold decrease every ten years) corresponded to the zinc finger
protein 331 gene (ZNF331, 19q13.33) whereas the largest decrease in
expression level was for a probe targeting a mRNA at chromosome 1q43
(no known corresponding gene); this had a 2.1-fold decreased expression
in offspring every ten years relative to controls. The only probe that
demonstrated a significant increase in expression with age in the offspring
(a 1.3-fold change every ten years) targeted an EST at 20q13.2 (no known
corresponding gene, NCBI Build 36). We observed no differential
expression between offspring and controls for LRRN3 and IFI27, which had
the most extreme changes with age in the first analysis in which
nonagenarians and controls were compared.
To investigate differential expression changes with age in a set of genes
acting in the same pathway or having the same function, we implemented
Model 3 in GlobalAncova (21); a method similar to the Globaltest for GO
terms but additionally suited for models including interaction terms. The GO
biological process that was most prominent among the longevity associated
gene expression profile was the Rho protein signal transduction pathway
(GO:0007266) (FWER = 0.079).
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Figure 2. Expression profiles of 2,953 probes that differed between nonagenarians
and middle-aged controls.
Expression intensities of the 2,953 probes were analyzed by one-dimensional hierarchical
clustering. Each probe is represented by a row; each subject by a column. Samples are
organized left to right by increasing age which is indicated for a few individuals for reference.
The largest cluster of probes exhibits reduced expression (transition from red to blue), and
another cluster exhibits increased expression (transition from blue to red) in nonagenarians
compared to controls. Mean centered expression values of probes are displayed according
to the color scale in which red represents above average expression levels and blue below
average expression levels. Fold changes of individual probes are given in Supplementary
Table S1.
Extensive replication study
To replicate our results we measured the expression levels of a subset of
genes via RT-qPCR in 79 nonagenarians, 332 offspring and 312 controls
(Table 1 and Materials and Methods). We first selected two genes on the
basis of their effect size and significance in the analysis between
nonagenarians and controls (i.e. LRRN3 and IFI27) and the gene different
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between offspring and controls (i.e. ZNF331). We added 22 genes that
were differentially expressed in the offspring compared to controls which
additionally associated with the concept “cell aging” in literature using the
text-mining tool Anni 2.0 (22, http://biosemantics.org/anni/). In total 25
genes (Figure 1), including the WRN progeria gene, the MYC cancer gene
and the longevity MTOR (also known as FRAP1) gene, were selected for
replication analyses.
Table 2. RT-qPCR results.
Nonagenarians vs. controls Offspring vs. controls
N = 79 312 332 312
Gene name Assay FC p FC p
Top genes
1 IFI27 Hs01086373_g1 1.41 2.6x10-4 NA NA
2 LRRN3 Hs00539582_s1 0.56 <10-6 NA NA
3 ZNF331 Hs00218578_m1 0.93 1.0x10-4 0.99 0.574
Cell aging associated genes
4 ADAMTS5 Hs00199841_m1 1.01 0.008 1.00 0.872
5 ASF1A Hs01011627_m1 0.85 <10-6 0.88 0.002
6 CCR6 Hs01890706_s1 0.68 <10-6 1.06 0.265
7 CD248 Hs00535586_s1 >10 0.322 1.04 0.736
8 CDK6 Hs00608037_m1 0.95 0.053 0.95 0.015
9 ENO2 Hs00157360_m1 0.99 <10-6 0.99 0.044
10 FLT3LG Hs00181740_m1 0.25 0.029 0.63 0.202
11 HK3 Hs01092843_g1 1.17 <10-6 1.00 0.929
12 IL7R Hs00902338_g1 0.76 <10-6 0.89 0.001
13 LEF1 AI6Q1P7 0.64 <10-6 0.97 0.565
14 MLLT3 Hs00971090_m1 0.80 <10-6 0.95 0.087
15 MTOR(FRAP1) Hs00234508_m1 0.97 6.0x10
-6 0.99 0.337
16 MYC Hs00153408_m1 0.78 <10-6 0.98 0.547
17 NOLC1 Hs01102319_g1 0.89 1.0x10-6 0.95 0.082
18 NR3C2 Hs00230906_m1 0.78 <10-6 0.95 0.059
19 RUVBL2 AI7ZZWF 0.79 6.0x10-5 1.07 0.469
20 SIDT1 Hs00214475_m1 0.70 5.0x10-6 0.91 0.301
21 SMAD3 Hs00706299_s1 0.87 <10-6 0.99 0.825
22 SMYD5 Hs00300181_m1 0.93 <10-6 0.98 0.229
23 TCF12 Hs00918972_m1 0.90 <10-6 0.97 0.127
24 TCF4 Hs00972428_g1 0.88 1.5x10-5 1.01 0.872
25 WRN Hs02561119_s1 0.76 <10-6 1.02 0.791
FC: fold change between groups; a FC above 1 indicates an increase in expression and a
FC below 1 indicates a decrease in expression compared to the controls. p: unadjusted p
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values. Bold indicate p values are below the significant level of 0.05 after Bonferroni
correction for multiple testing (threshold p = 0.002).
As replication of the first analysis, the comparison between nonagenarians
and controls, the expression of 21 out of 25 genes was in concordance with
the observations in the microarray dataset and hence the RT-qPCR results
confirmed the microarray findings (Table 2). LRRN3 again showed the
largest significant decreased expression in the nonagenarian siblings and
IFI27 the largest increased expression. The analysis to test for replication
of the novel samples only (58 nonagenarians and 281controls) resulted in
the same observations (Supplementary Table S4).
To identify longevity associated genes in middle-age, we replicated the
second analysis by comparing the mean expression levels of 23 genes
between the offspring of the nonagenarians and the controls (Model 2, see
Materials & Methods). We excluded LRRN3 and IFI27 from this analysis
since expression of these two genes was not different between offspring
and controls in the microarray dataset. Two genes showed significant
differential expression after Bonferroni correction for multiple testing:
ASF1A and IL7R (Table 2, p < 0.0022). These two genes showed a
significant decrease in expression in samples from the long-lived families
compared to controls, in concordance with the microarray results.
Analysis of healthy offspring
We noticed that the effect sizes of the differential expressed genes in the
comparison between offspring and controls were small. Since the offspring
are composed of individuals who carry the longevity trait and those that do
not, the detectable effect of the longevity trait is diluted in the comparison
between offspring and controls. We hypothesize that the effect of the
longevity trait will increase if we compare the same controls to a subfraction
of offspring with the highest probability to age healthily and become long-
lived. Therefore we selected the offspring with the most beneficial
metabolic profile.
Offspring of long-lived parents exhibit as a group at least six beneficial
serum characteristics including: low levels of glucose (8;10), triglycerides
(23), total cholesterol over HDL cholesterol ratio (23;24), free
triiodothyronine (25), and large low-density lipoprotein (LDL) particles (23),
complemented by high adiponectin (26). The beneficial metabolic profile is
also reflected by the lower Framingham risk scores (24) which indicates a
lower risk of cardiovascular disease over the course of 10 years.
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We selected a subfraction of the offspring, consisting of the 5% beneficial
tail of the distribution of each metabolic parameter, separately for men and
women, resulting in 78 offspring which we consider the best proxy for the
true long-lived cases. For these offspring ASF1A and IL7R gene expression
was compared to that of 312 controls: this comparison resulted respectively
in a 5.0% and 1.2% additional decrease of mean gene expression relative
to the effect observed in the comparison between all offspring and controls
(Table 3).
Table 3. Gene expression levels of ASF1A and IL7R in all as well as subfraction of
offspring compared to controls.
ASF1A IL7R
n Mean p Mean p
Controls All 312 1.85 6.18
Offspring All 332 1.65 0.0022 5.98 0.0012
Subfraction1 78 1.57 0.0093 5.91 0.0103
Mean: relative expression in fold change to reference value. 1: subfraction of offspring most
probable to age healthily (for more details, see Materials and Methods), 2: p value of
comparison between controls and all offspring, 3: p value of comparison between controls
and subfraction of offspring (best 5% men and women per parameter taken together). Bold
indicated p values are below the significant level of 0.05 after Bonferroni correction for
multiple testing.
Discussion
We have identified a transcriptional profile of 244 genes that represent a
potential “longevity-signature”. In an extensive biological replication study of
nonagenarians, middle-aged offspring and controls, we focused on a
subset of 25 genes in RT-PCR experiments. An “aging-signature” was
formed by the expression pattern of 21 genes. Two genes, ASF1A and
IL7R, represented a “longevity-signature” since members of long-lived
families expressed at middle-age a 1.14-fold and 1.12-fold lower level of
these genes compared to controls respectively. The effect size of this
association with longevity was stronger for offspring of nonagenarians with
a beneficial metabolic profile characterized by 6 serum parameters and the
Framingham Risk Score, which we considered to be the best proxy for the
true long-lived case group. The decreased expression of these two genes
is therefore likely to mark metabolic health and it might precede or even
contribute to human longevity. ASF1A is a histone chaperone that is
important in the remodeling of chromatin structure during replication, DNA
repair, and cellular senescence (27-29). Interestingly, histone acetylation is
among the processes regulated by signaling through the IL7 receptor,
which is required for development and maintenance of the immune system
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(30). Our results may point at the importance of interactions between
immune response, metabolic state, and epigenetic control for human aging
and longevity.
The genome-wide expression analysis between nonagenarians and
controls resulted in the identification of 2,953 probes associated with age.
RT-qPCR replication experiments with a large sample size resulted in
replication of 21 out of 25 genes identified by the microarray analysis as
differentially expressed with age. Five of these genes (LRRN3, ZNF331,
ASF1A, MLLT3 and SIDT1) have previously been reported to associate
with age in a microarray study of T cell mRNA (31), although this study had
a relatively small number of samples (25 male subjects). The largest age-
related effects observed in our study were for the IFI27 and LRRN3 genes.
IFI27 encodes interferon alpha-inducible protein 27 whose biological
function is currently unknown. Leucine rich repeat neuronal 3 (LRRN3) is
mainly involved in activation of MAPK activity and endocytosis (17) and,
further supporting our findings, also showed the largest age-related
decrease in expression in a large study on lymphocytes (15). This “aging-
signature” included decreased expression of several well-known genes
involved in aging and lifespan, like MYC, WRN and MTOR. The MYC
protein is a transcription factor that regulates transcription of specific target
genes and overexpression of the MYC gene has been associated with a
variety of cancers (32-34). Defects in the WRN gene cause the Werner
progeria syndrome, an autosomal recessive disorder characterized by
premature aging and genetic variation in or near this gene have been
associated with several age-related diseases and survival (35-38). The
MTOR gene encodes a serine/threonine kinase and its downregulation is
associated with extended lifespan in model organisms (39-41) and elevated
mTOR activity has been implicated in different forms of human cancer
(reviewed in 42;43). We conclude from our data that, from all significantly
differentially expressed genes at least 21 genes distinguish nonagenarians
from middle-aged controls. In addition, our study is the first to include an
extensive biological replication sample set validating these results.
The main cellular pathways that changed with age in the microarray dataset
were ‘response to stimulus’ (including ‘immune response’ and ‘response to
stress’), ‘signal transduction’, ‘gene expression’ and ‘protein binding’. These
GO terms have previously been found to associate with aging, suggesting
that these are systemic age-related processes. The only pathway that
associated with longevity at middle-age in the offspring-control comparison
was the ‘Rho protein signal transduction’ pathway, which is part of the GO
term ‘signal transduction’. The Rho family of GTPases are small GTPases
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that regulate a wide variety of processes in the cell including growth,
cytoskeletal organization, transcription and lipid metabolism (44;45). Rho
signaling is regulated by the mTOR complex 2, a part of the mTOR
pathway which is shown to influence lifespan and health. All associated
pathways are general processes, indicating that regulation of the system
seem to be an important process involved in aging and longevity.
Research into human familial longevity and healthy ageing is complex in
the sense that there are no controls from the same birth cohort to compare
to long-lived persons since such controls would have died twenty years
ago. We investigated offspring as a proxy for the nonagenarian case group
since these can be compared to controls from the same birth cohort.
However, in the offspring the longevity phenotype will undoubtedly be
diluted as compared to the nonagenarians, since only a part of the offspring
will become long-lived and a part will age comparable to controls. The
consequence of the dilution of the longevity cases is that effect sizes are
underestimated. Indeed the effect size of the association with longevity
increased when the healthiest offspring was compared to the controls.
Future follow-up data on age of death will reveal which offspring carries the
longevity phenotype.
In this study we investigated expression profiles in whole blood samples of
participants because blood is an easily accessible tissue. This allows us to
investigate the large sample sizes required to detect small effect sizes. An
advantage of using blood compared to other tissues is that cell subsets can
easily be measured and used to select samples or used as covariates in
analyses whereas different cell subsets present in other tissues are difficult
to quantify and can not be taken into account in any analyses. In our
microarray study we selected samples from offspring and controls with
similar cell counts. Furthermore, since aging affects the whole organism
and since blood is in contact with all tissues, blood may reflect in part the
physical health of the whole body. Disease state is mirrored by gene
expression profiles in blood (summarized in 16), which at least partial
overlap with expression profiles in other tissues (46). Thus, although tissue-
specific effects will undoubtedly be missed, investigating blood is valuable
and practical for researching human aging.
In conclusion, we identified a transcriptional signature in whole blood
consisting of 21 genes that repeatedly differentiated between
nonagenarians and middle-aged controls. The expression level of two of
these genes, ASF1A and IL7R marked familial longevity already in middle-
age and the effect size was enhanced in the subset of longevity family
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members with a beneficial metabolic marker profile. Functional and
longitudinal studies are necessary to establish which of these genes are
true biomarkers for healthy ageing and which contribute causally to this
trait. Our findings illustrate that gene expression changes occurring as a
function of age may partly represent early detectable features of human
longevity and healthy ageing.
Materials and methods
Study population
The individuals investigated in this study are participants of the Leiden
Longevity Study. The families participating in this study have at least two
siblings with a minimum age for men of 89 years and for women of 91
years (2). The offspring of these long-lived individuals, who have an
increased potential to become long-lived individuals, were also included. In
addition, the partners of the offspring were included as population controls
of similar age and environmental exposures as the offspring, and as a
young control group for the nonagenarian siblings. Blood samples were
taken from all the participants. The Leiden Longevity Study was approved
by the medical ethical committee of the Leiden University Medical Centre
and all participants gave written informed consent.
Sample collection and RNA preparation
One long-lived sibling, one of their offspring and the partner of the offspring
were selected from 50 families for the current study (Table 1). These trios
were randomly selected, but in such a way that age and gender were
balanced between the groups and the age range for the offspring and
partners was as large as possible. Additionally, individuals with outlying cell
counts (beyond 3 SDs below or above the standard error of the mean) were
excluded. From the 150 selected non-fasted individuals, peripheral blood
was harvested using PAXgeneTM tubes (Qiagen, Venlo, The Netherlands).
The tubes were frozen and kept at -20°C for ~3-5 years. After thawing at
room temperature for at least 2 hours, total RNA was extracted from the
approximately 2.5 ml of peripheral blood in each tube following the
manufacturer’s recommended protocol (PAXgene Blood RNA Kit
Handbook, Qiagen, Venlo, The Netherlands). The quality and integrity of
the total RNA was evaluated on the 2100 Bioanalyzer (Agilent
Technologies, Amstelveen, The Netherlands) and the concentration was
measured using a NanoDrop spectrophotometer (NanoDrop Technologies,
Wilmington, DE, USA). Quality criteria included a 28S/18S ratio as
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measured by the Bioanalyzer of at least 1.2, and a total RNA yield of at
least 3 µg.
Oligonucleotide microarrays
The 150 samples that met the RNA quality criteria were hybridized onto 54k
CodeLink Human Whole Genome Bioarrays (GE Healthcare, Bucks, UK,
cat. No. 300026, currently of Applied Microarrays). cDNA synthesis,
amplification, biotin labeling and hybridization onto the microarrays were
performed according to the manufacturer’s instructions using the Codelink
iExpress reagent kit (cat. No. 67601000). The slides were scanned with a
MicroArray Scanner G2505B scanner (Agilent Technologies, South
Queensferry, UK) and the image was quantified with the CodeLink
Expression software (version 4.2).
Microarray data pre-processing
Raw intensities were background subtracted, set to 0.5 when results were
negative and normalized using the Cyclic Loess method in the Codelink
software package (47) of the Bioconductor R software (48)
(http://www.bioconductor.org). After normalization, we used log2-
transformed expression intensities for all subsequent analyses. Raw and
normalized microarray data are stored in the GEO online database record
GSE16717 in compliance to MIAME guidelines. A principal component
analysis (PCA) was performed on all samples (GeneSpring software,
Agilent Technologies, South Queensferry, UK) and hybridization date was
identified as a confounding factor causing a deviation in the data, which
was attributed to a scanner maintenance check during the measurements
of the samples (data not shown). Therefore, all subsequent analyses were
adjusted for hybridization date coded as the 14 days of hybridization as
categorical variable, which was sufficient to adjust for this technically
induced variation. Since samples were randomly hybridized, no
confounding with group was present. None of the other tested parameters,
like RNA quality, isolation date and time of blood draw appeared to be a
significant confounder of the expression data.
Probe annotation and filtering
The 54,243 probes on the CodeLink Bioarray were newly annotated to
Entrez Gene ID’s and GO identifiers in two steps. First, all probe
sequences were mapped to Unigene and dbEst sequences with BLAT
while allowing for, at most, one mismatching nucleotide. Subsequently, all
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Probe to Unigene annotations were transformed to probe to Entrez Gene
ID and probe to GO ID annotations using Entrez Gene-to-Unigene and
Entrez Gene-to-GO ID mappings available on the ftp server of NCBI.
Probe-to-EST annotations were treated in a similar way, except that ESTs
were first mapped to RefSeq Gene IDs by aligning ESTs to RefSeq exons
using galaxy and the genomic alignments of ESTs and RefSeq genes from
UCSC (hg18). All EST to RefSeq mappings with a sequence similarity
>95% were maintained for further mappings of ESTs-to-Entrez Gene IDs
using the Entrez Gene-to-RefSeq Gene ID mappings available at NCBI. All
information used was downloaded in October 2008, using versions NCBI
Build 36.1 or UCSC hg18.
Probes without a “Good” flag indicating that the mRNA is detected, as
determined by the CodeLink Expression software, in at least 10% of the
samples (7,034 probes) and/or probes without at least a known
chromosome band location according to the new annotation (an additional
2,045) were excluded from the analysis, resulting in 45,164 remaining
probes.
Single gene analysis
All single gene analyses were performed using the Limma (Linear models
for microarray data) package in R (49;50). To determine changes in
expression levels of each probe with age, we used the following linear
regression model:
ijijijijjij HybGenderGroupY   3210 (model 1)
where Yij is the base 2 logarithm of the expression level of probe j in
sample i, Groupi is the group (0 for control or 1 for long-lived nonagenarian)
of subject contributing sample i, Genderi corresponds to the gender of the
ith sample (0 for male, or 1 for female), Hybi is the categorical term of
hybridization day on which the sample i was measured and εij represents
an error term. The coefficients β1j represents by how much gene expression
increases between the groups, β2j represents the change in expression for
a female in comparison with a male sample, β3j represents the change of
expression across hybridization dates, and β0j represents the baseline
regression level of the probe, for male control samples on the first
hybridization date. Resulting p-values were adjusted for multiple testing
using Benjamini and Hochberg’s False Discovery Rate (FDR) method (51).
One-dimensional hierarchical clustering of probes was performed using
Chapter 3
53
GeneSpring (version GX 7.3.1) gene tree clustering, using Pearson
correlation and average linkage.
To find longevity-related differences between offspring and controls, the
following model was used:
ijijijijijjij HybGenderAgeGroupY   43210 (model 2)
where Groupi corresponds to the offspring/control status of the ith sample
(0 for control, 1 for offspring) and β1j is the change of expression with group
status. For each probe j, we determined the coefficient with respect to
group status (β1j).
To test differences in biological aging rate in offspring and controls, we












where Groupi*Agei corresponds to the slope of expression with age of the
jth probe set for offspring or controls, Agei*Genderi corresponds to the
slope of expression with age of the jth probe set for males or females,
Groupi*Genderi indicates the interaction of group and gender of the jth
probe set for the ith sample, β4j represents the change of expression with
age for offspring in comparison to control, β5j represents the change of
expression with age for a female in comparison with a male sample, β6j
represents the change of expression with gender between offspring and
controls. The interaction between group and offspring in comparison to
control (β2j for the intercept, β4j for the other groups) was determined and
resulting p-values were corrected for multiple testing using the FDR
method.
Pathway analysis
The Globaltest methodology was designed to determine whether the
common expression pattern of genes within a pre-defined set is
significantly related to clinical outcome (18;19;52). A generalized linear
model is used to estimate a "Q-statistic" for each gene set, which describes
the correlation between gene expression profiles, X, and clinical outcomes,
Y. The Q-statistic for a gene set is the average of the Q-statistics for each
gene in the set. The Globaltest method was used to perform pathway
analysis on Model 1.
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When performing pathway analysis on Model 3 we used GlobalAncova,
which is a method similar to Globaltest suited for models including
interaction terms (21;53). Resulting p-values from both methods were
corrected for multiple testing using Holm’s procedure for controlling the
Family-Wise Error Rate (FWER) method (54).
RT-qPCR
To confirm the accuracy of the measured expression profiles, we compared
the expression level of 25 probes from the CodeLink Bioarrays with
corresponding Taqman® assay (Applied Biosystems, Table 2). Samples
included 18 nonagenarians, 16 offspring and 21 controls that have been
measured on the microarray and additional novel replication samples of
randomly chosen 61 nonagenarians, 316 offspring and 291 controls.
Reverse transcription was performed by using total RNA from blood of in
total 723 samples, excluding individuals with outlying cell counts (outside
3SD of the mean), which passed QC and processed with the First Strand
cDNA Synthesis Kit according to the manufacturer’s protocol (Roche
Applied Science). cDNA was amplified using the DNA Engine Tetrad® 2
Peltier Thermal Cycler (Bio-Rad). qPCR was then performed with the
Taqman® method using the BiomarkTM 48.48 and 96.96 Dynamic Arrays
(Fluidigm). Relative gene expressions of the BioMark™ Array data were
calculated by using the 2-ΔΔCt method, in which Ct indicates cycle threshold,
the fractional cycle number where the fluorescent signal reaches detection
threshold (55). YKT6 was used as internal control and commercially
available human total reference RNA (Clontech Laboratories, Mountain
View, CA, USA) as reference RNA. Differences in expression level between
long-lived siblings, their offspring and the partners of their offspring were
assessed using linear regression. In these analyses, expression level was
the dependent variable and the two groups of individuals (either
nonagenarians vs. controls or offspring vs. controls) were included in the
model as a categorical variable together with age (in offspring vs. controls
only) and gender and their interaction as covariates. To take into account
dependencies within sibships, robust standard errors were used, i.e. the
variance was computed from the between family variation. P-values were
also based on these robust standard errors. Analyses were performed




Analysis of healthy offspring
To further investigate the candidate genes, their expression level was again
tested for association with longevity, but only including the offspring with
most beneficial profile of seven published longevity markers: a low level of
non-fasted serum glucose (mmol/L) (8;10), triglycerides (mmol/L) (23) and
free triiodothyronine levels (pmol/L) (25), a small ratio of total cholesterol
(mmol/L) over HDL cholesterol (mmol/L) (23;24), small low-density
lipoprotein (LDL) particle sizes (nm) (23), a high level of adiponectin (mg/L)
[26], and a low Framingham risk score (FRS) which is based on the factors
age, sex, total cholesterol level, HDL cholesterol level, systolic blood
pressure (mm/Hg), and whether the person smokes (24). The FRS is a well
known test reflecting the risk of cardiovascular disease over the course of
10 years.
All serum measurements were performed with fully automated equipment.
For glucose, triglycerides, total cholesterol, HDL-cholesterol, adiponectin
and free triiodothyronine, the Hitachi Modular or the Cobas Integra 800,
both from Roche, Almere, the Netherlands were applied. CVs of these
measurements were all below 5 %. Lipoprotein particle sizes have been
analyzed in 165 families from the Leiden Longevity Study using a 400-MHz
proton NMR analyzer at LipoScience.
To select that subfraction of offspring with the highest probability to age
healthily and become long-lived because of their metabolic risk profile in
middle-age, we identified the subjects, separately for men and women,
within the lower 5% tail of the distribution for glucose, triglycerides, free
triiodothyronine, ratio of total cholesterol over HDL cholesterol and the
FRS. Additionally we identified for LDL particle size and adiponectin those
subjects, separately for men and women, within the upper 5% tail of the
distribution. This resulted in a total of 78 offspring out of 332 from which
gene expression levels of ASF1A and IL7R was compared to the levels in
312 controls using linear regression. In this analysis, expression level was
the dependent variable and the two groups of individuals (offspring vs.
controls) were included in the model as a categorical variable together with
age and gender and their interaction as covariates. To take into account
dependencies within sibships, robust standard errors were used, i.e. the
variance was computed from the between family variation. P-values were
also based on these robust standard errors. Analyses were performed
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The level of expression of the interleukin 7 receptor (IL7R) gene in blood
was recently found to be associated with familial longevity and healthy
ageing. The IL7R is crucial for T cell development and important for
immune competence. To further investigate the IL7R pathway in ageing we
identified the closest interacting genes to construct an IL7R gene network
that consisted of IL7R and six interacting genes: IL2RG, IL7, TSLP, CRLF2,
JAK1 and JAK3. This network was explored for association with
chronological age, familial longevity and immune-related diseases (type 2
diabetes, COPD and rheumatoid arthritis) in 87 nonagenarians, 337 of their
middle-aged offspring and 321 middle-aged controls from the Leiden
Longevity Study (LLS). We observed that expression level of the IL7R gene
network as a whole was significantly different between the nonagenarians
and middle aged controls (P=4.6 x 10-4) being driven by a significantly lower
level of expression of IL7R, IL2RG and IL7 in the elderly. After correction
for multiple testing and blood cell subsets, only IL7R was found to be
associated with familial longevity exhibiting lower levels in middle aged
offspring of nonagenarian siblings than in age matched controls (P=0.006).
Higher IL7R gene expression in these groups associated with a higher
prevalence of immune-related disease (P=0.001). Together our results
indicate a positive correlation of IL7R gene expression with biological age.
Paradoxically however a higher IL7R gene expression level associated with
better prospective survival both in nonagenarians (HR=0.63, P=0.037) and
the middle aged individuals (HR=0.33, P=1.9 x 10-4). We conclude that the
IL7R network reflected by gene expression levels in blood may influence
the biological age and health status of elderly individuals.
Introduction
Ageing is considered to be the consequence of an accumulation of
physiological changes over time eventually increasing the mortality risk.
Although ageing is the major risk factor for reduced health status and the
most common human diseases of Western societies, treatment of elderly
patients may be improved by understanding their biological age, the rate at
which a person ages, and health status better than just by indicating their
chronological age.
Many potential biomarkers of biological age have been suggested and are
being tested for their association with chronological age, diseases and
prospective mortality (1). In a search for new transcriptomic biomarkers of
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ageing we found that the expression in blood of 1853 genes was
associated with chronological age, 244 of which were associated with
familial longevity, being differentially expressed between middle aged
offspring of nonagenarian siblings and controls in the Leiden Longevity
Study (LLS). Of the latter group of genes, a low expression level of the
interleukin 7 (IL7) receptor (IL7R) associates with low disease prevalence
among these offspring (2). The IL7 receptor is important for the body’s
innate and adaptive immune responses, and plays a role in regulating
development, differentiation and survival of T cells (3;4). The IL7R is
required for IL7 signaling, which in mice was shown to be crucial for early T
cell development, as well as for homeostasis of naïve and memory CD8+ T
cells (5;6). Previously, we observed that the offspring of nonagenarian
siblings avoid the usual age-related reduction of percentages and numbers
of naïve T cells in the periphery (7). Reduction of proinflammatory IL7
signaling may contribute to this better retention of naïve T cells and may
thereby influence the biological age and health status of elderly individuals,
given that possessing a fuller naive T cell repertoire would be expected to
protect better against new pathogens.
To explore whether the expression profiles of other genes in the close
vicinity of IL7R may exhibit even better ageing biomarker properties, we
first identified the six interaction partners of IL7R using the STRING protein-
protein-interaction database. Next, gene expression levels of all seven
genes in the IL7R network were determined in 87 nonagenarians also
having a nonagenarian sibling, 337 of their offspring and 321 controls of the
LLS. We tested whether the level of expression of the IL7R network genes
associated with chronological age by comparing the nonagenarians with
the middle-aged controls. Differential expression in this comparison may be
explained by the age difference between these groups, early environmental
factors, or by the longevity trait in these nonagenarians which is not present
in controls. To further investigate whether the expression of the age-
associated genes also associates with biological age and disease
prevalence, we compared the controls with the similarly aged offspring of
the nonagenarians, representing individuals with a reduced biological age
marked by lower prevalence of common age-related disease and beneficial
metabolic profiles (8;9). Additionally, we explored whether the expression of
the IL7R interaction partners is associated with common immune-related
diseases in middle-aged individuals. Finally, we performed survival analysis
in the nonagenarians to determine the relationship between expression of
these genes and mortality. Because whole blood consists of multiple cell






To identify proteins interacting with the IL7 receptor, we searched for
known and predicted protein-protein interactions using the freely-accessible
STRING 9.0 data base (http://string-db.org/) in May 2012. Interactions
based on text mining were excluded, while predicted interactions based on
experimental data with the highest confidence (score > 0.900) were taken
into account. This approach resulted in an IL7R network that consists of
IL7R and the following six interacting proteins: IL2RG, IL7, TSLP, CRLF2,
JAK1 and JAK3 (Figure 1).
Figure 1. IL7R STRING network
Gene expression in whole blood
We measured gene expression levels for each of the seven genes using
RT-qPCR on whole blood samples from 87 nonagenarians, 337 of their
middle-aged offspring and 321 middle-aged controls (Table 1). To test for
associations between expression of genes in the IL7R network and
chronological age, we compared long-lived individuals to the middle-aged
controls for differential expression of the total gene set of the IL7R network
using a global test (10;11). We observed that the expression level of the
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IL7R gene set as a whole was significantly different between the groups (P-
value=4.6 x 10-4).
Table 1. Subject characteristics
Nonagenarians Offspring Controls
Number 87 337 321
Mean Age 94.3 61.3 61.2
Age Range 89.0 - 101.7 33.6 - 78.3 32.4 - 81.4
Women (%) 47 (54.0%) 143 (42.4%) 175 (54.5%)
N T2D (%) NA 17 (5.0%) 26 (8.1%)
N COPD (%) NA 19 (5.6%) 10 (3.1%)
N RA (%) NA 3 (0.9%) 2 (0.6%)
N T2D: number of known patients with Type 2 Diabetes, N COPD: number of known
patients with chronic obstructive pulmonary disease, N RA: number of known patients with
rheumatoid arthritis, NA: data not available.
To investigate which genes were primarily responsible for the association of
the IL7R network with age, we tested single gene expression levels using
linear regression of the seven genes in the IL7R network (Table 2). After
Bonferroni correction for multiple testing, three genes showed significant
differential expression with at least a 5% difference between nonagenarians
and middle aged controls, namely IL7R, IL2RG and IL7. We observed that
expression of the IL receptor complex/ligand genes IL7R, IL2RG, IL7, TSLP
and CRLF2 were all lower in nonagenarians, while expression of JAK1 and
JAK3 was increased.
Table 2. Gene expression of nonagenarians compared to controls by linear
regression analysis.
Gene Coef FC P Bonferroni
IL7R -0.40 0.76 <10-6 0.000
IL2RG -2.09 0.23 0.007 0.049
IL7 -0.81 0.57 <10-6 0.000
TSLP -0.01 0.99 0.013 0.091
CRLF2 -0.15 0.90 0.040 0.280
JAK1 0.21 1.16 0.046 0.322
JAK3 1.68 3.20 0.009 0.063
Coef: coefficient from linear regression model. FC: fold change, above one indicated higher
expression in long-lived individuals. p: raw p value from linear regression model. Bonferroni:
p value after adjustment for multiple testing (n=7) by the Bonferroni method. Genes
significantly differentially expressed with at least 5% are depicted in bold.
Because differential expression in these comparisons may be explained by
the age difference between the two groups, cohort effects, or by the
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longevity trait in these families which is not present in controls, we
investigated whether the differences in expression of the seven IL7R
network genes was characteristic for these long-lived families, exhibiting a
lower biological age, and not just a marker for chronological age. Therefore,
we compared the expression in the middle-aged offspring of nonagenarians
to their partners serving as controls matched for age and adult lifestyle and
environmental conditions. Expression of all the IL7R complex/ligands IL7R,
IL2RG, IL7, and TSLP and of JAK3 was found to be lower in offspring of
nonagenarians than in controls. Of these, IL7R remained significant after
Bonferroni correction for multiple testing (Table 3), indicating its association
with familial longevity and biological age. Similar results were obtained after
adjustment for blood cell counts (Supplementary Table S1). Expression of
JAK1 was higher in offspring as compared to controls. The direction of the
differential gene expression was the same as for nonagenarians, except for
JAK3 for which the expression was increased in nonagenarians and
decreased in their offspring relative to controls.
Table 3. Gene expression of offspring from nonagenarians compared to controls by
linear regression analysis.
Gene Coef FC P Bonferroni
IL7R -0.18 0.89 0.001 0.006
IL2RG -0.72 0.61 0.563 1.000
IL7 -0.39 0.77 0.050 0.350
TSLP -0.01 0.99 0.140 0.980
CRLF2 -0.04 0.97 0.742 1.000
JAK1 0.08 1.05 0.557 1.000
JAK3 -0.30 0.81 0.650 1.000
Coef: coefficient from linear regression model. FC: fold change, above one indicated higher
expression in offspring from long-lived individuals. p: raw p value from linear regression
model. Bonferroni: p value after adjustment for multiple testing (n=7) by the Bonferroni
method. Genes significantly differentially expressed with at least 5% are depicted in bold.
Relation of IL7R gene expression in whole blood with membrane-
bound IL7R protein in PBMCs
Since decreased IL7R gene expression associates with familial longevity
already in middle-age, the question arises whether this reflects soluble or
membrane-bound IL7R protein, also known as cd127. We were able to
investigate membrane-bound cd127 levels in PBMCs of 71 offspring and 73
controls. We observed no correlation between IL7R gene expression in
whole blood and cd127 levels in PBMCs of the same individuals (Table 4)
and no difference in cd127 between offspring and controls (mean level
offspring=38.1, mean level controls=37.5, p-value=0.91). It is therefore less
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likely that the difference in gene expression levels reflect differences in
levels of membrane-bound cd127.
Table 4. Correlation of IL7R gene expression and cd127 expression in offspring from
nonagenarians and controls.
Offspring (n = 53) Controls (n = 53)
Subset Cor p Cor p
PBMC 0.161 0.250 -0.171 0.221
Lymphocytes 0.169 0.226 -0.135 0.336
T cells 0.174 0.212 -0.159 0.256
Non-T cells 0.152 0.278 -0.130 0.353
CD4+ cells 0.169 0.227 -0.151 0.281
CD8+ cells 0.167 0.231 -0.135 0.336
Cor: Pearson Correlation. p: raw p value from Pearson Correlation.
Association of IL7R gene expression with immune-related disease
Because IL7R and IL7 signaling have been implicated in the etiology of
immune-related disease (12-15), the observed differences in gene
expression with biological age might also be associated with different
immune-related disease prevalence between the groups (Table 1). We
investigated expression levels of IL7R relative to disease status for type 2
diabetes (T2D), chronic obstructive pulmonary disease (COPD) and
rheumatoid arthritis (RA) in the offspring of long-lived individuals and
controls. Table 5 shows that higher IL7R expression is associated with a
higher prevalence of immune-related diseases. However, the difference in
IL7R expression between offspring and controls did not change when
adjusted for prevalence of T2D, COPD and RA (Supplementary Table S2).
Thus, the IL7R expression levels in blood associate with immune-related
disease on the one hand and familial longevity on the other, independent of
these immune-related diseases.
Table 5. Association of IL7R gene expression with immune-related diseases in middle
aged subjects
T2D (n=43) COPD (n=29) RA (n=5) Sumscore (n=70)
Gene Coef p Coef p Coef P Coef p
IL7R 0.22 0.029 0.35 9.9E-05 -0.09 0.391 0.21 0.001
Total: total prevalence of T2D, COPD or RA. Coef: coefficient from linear regression model.
FC: fold change, above one indicated positive association between gene expression and
disease prevalence (patient = 1, control = 0). p: raw p value from linear regression model.
Number of known patients is mentioned in table, the total number of offspring and controls is
658. Significant associations are depicted in bold.
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Association of IL7R gene expression with mortality
Many markers indicating health status in middle age (such as blood
pressure) associate also with mortality at higher ages, albeit not always in
the expected direction (16). We examined whether the IL7R gene
expression level is associated with prospective mortality in the subset of
LLS participants for which we have measured expression levels. We
performed a survival analysis using a Cox-proportional hazard model for
low versus high gene expression levels in 81 nonagenarians (Model 1) and
619 offspring and partners (Model 2). The hazard ratio among the
nonagenarians was 0.63 (95%CI 0.40-0.97) with a P-value of 0.037, and
the hazard ratio among the middle aged individuals was 0.33 (95%CI 0.18-
0.59) with a P-value of 1.91 x 10-4. Unexpectedly, higher IL7R gene






























Figure 2. Kaplan-Meier curve for high (dotted line) and low (solid line) IL7R gene expression
in nonagenarians (left panel) and middle aged subjects (right panel).
Discussion
Gene expression levels in blood of the IL7 geneset as a whole correlates
negatively with chronological age. The expression of the IL7R gene in
particular was found to be indicative for biological age and immune-related
diseases. Relative to controls, reduced IL7R expression characterized
members of longevity families, both middle aged offspring and
nonagenarian siblings, whereas increased expression associated with
prevalence of immune-related diseases in these groups (T2D and COPD).
Paradoxically, however, higher IL7R gene expression levels associated
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with better survival in a prospective analysis of both the nonagenarians and
middle aged subjects. The mechanism underlying these observations
requires further investigation, and especially whether regulation of IL7R
gene expression has a causal role as determinant of biological ageing.
The notion that low IL7R expression levels are beneficial for reaching old
age healthily corresponds with previous observations that autoimmune
disease patients express increased levels of the IL receptor/ligand complex
genes (12;13;15) and that antagonizing IL7 or IL7R may offer possible
treatment (14;15). An increase in systemic inflammation has generally been
reported with increasing age, so-called “inflamm-ageing” (17). Long-lived
individuals such as LLS nonagenarians can be seen as slow or healthy
agers who do not show the commonly observed age-related characteristics
of “immunosenescence” and display relatively low levels of pro-
inflammatory markers (7). Our results may suggest that nonagenarian
members of long-lived families have more efficient IL7 signaling since they
seem to require less compensation because of their remaining naïve T cell
population, resulting in greater reserve capacity to cope with infections in
old age. On the other hand, very low IL7R signaling has been observed in
severe combined immunodeficiency (SCID) (18) and in HIV infection
(19;20). We conclude that, besides the troublesome effect of the absence
of IL7 signaling, a somewhat lower baseline level of IL7R gene expression,
and potentially IL7 signaling, may contribute to healthy aging.
Despite these observations, the expression of the IL7R gene network was
negatively correlated with age suggesting that low expression levels
correlate with decreasing health, consistent with our observations that low
IL7R gene expression associates with higher prospective mortality. Clearly
this finding is inconsistent with the observation that in the same group of
subjects low IL7R gene expression level is associated with familial
longevity and decreased disease risk. A similar paradox has been found in
PBMCs, where a lower frequency of naïve T cells (and a higher frequency
of differentiated T cells) was associated with better survival in elderly
individuals while a higher frequency was found in offspring of
nonagenarians compared to the controls suggesting an association with
lower biological age (7;21). This might be interpreted as follows: if the
individual is able to counter the reduction of IL7R gene expression with age
by keeping the level of differentiated T cells high as memory cells to control
disease, this may be associated with healthy old age.
Contributing to the paradox may be the fact that there are two forms of
IL7R exerting different functions, membrane-bound and soluble IL7R.
Chapter 4
70
Membrane-bound IL7R may transduce IL7 signaling, while soluble IL7R
may represent a negative compensatory mechanism regulating IL7
signaling (20;22;23). Because we used the recommended Taqman assay
for the measurement of IL7R gene expression that cannot distinguish
between the IL7R splice forms, we are unable to interpret how IL7 signaling
is affected by the gene expression changes. Since IL7R gene expression
levels and membrane-bound IL7R protein did not correlate in offspring or
controls, and also the protein levels did not show a difference between the
two groups, our results might suggest that the decrease in IL7R gene
expression reflects mainly a decrease in the mRNA coding for soluble IL7R,
resulting in more efficient IL7 signaling.
We showed that IL7R gene expression in blood is associated with immune-
related disease. Previous meta-analysis and GWAS studies showed that
genetic variation in the IL7R gene is associated with ulcerative colitis (24),
multiple sclerosis (25-27), primary biliary cirrhosis (28), and type 1 diabetes
(29). These results may suggest that genetic variation in and the
expression of the IL7R gene is involved in auto-immune and chronic
inflammation disease. Hence optimal response of the immune system may
contribute to human longevity.
Further evidence that IL7 signaling may contribute to biological ageing and
longevity is that it is closely connected to mTOR signaling, a pathway
known for its effects on lifespan in animal models and which is now also
implicated in human aging and longevity (30;31). Several studies in mice
provided evidence for the connection between IL7 and mTOR signaling. IL7
induces phosphorylation of the mTOR complex 1 (mTORC1) downstream
targets S6 and 4EBP1, an effect antagonized by the mTOR inhibitor
rapamycin. The reverse may occur as well: rapamycin inhibits proliferation
and induces apoptosis of pre-B acute lymphoblastic leukemia (ALL), effects
which are abrogated by IL7 (32). Functional studies validated IL7R as a
FoxO1 target gene (33). Acute deletion of FoxO1 induced a rapid and
profound downregulation of IL7R expression associated with a significant
reduction of IL7R mRNA (34). Also, cytokine (including IL7) stimulation
induces FoxO1 phosphorylation and decreased transcription of target
genes (34). In B cells, it has been shown that the mTOR complex 2
(mTORC2) suppresses IL7R gene expression by regulating FoxO1
phosphorylation (35). Taken together, decreased IL7 levels and decreased
mTORC1 activity seem to go hand-in-hand, further implying that decreased
IL7 levels are beneficial because decreased mTORC1 increases lifespan.
The same is true for decreased IL7R and increased mTORC2, the latter we
have recently shown to be associated with human longevity (31). Gene
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expression levels of several of the mTOR-related genes are indeed
positively and significantly correlated with IL7R expression in the LLS,
which included RPTOR, FOXO1 and MTOR. Considering the clear
connections with IL7 signaling and similar findings on the level of gene
expression variations, mTOR signaling might also be involved in “inflamm-
ageing” as part of its lifespan-regulating effect.
In a previous study within the LLS families Dekker et al (36) found in the
cultured skin fibroblasts of the offspring of the nonagenarians more
apoptotic activity and less senescence than in those of controls. Flow
cytometric analysis in HIV-infected individuals demonstrated that CD8 cells
expressing high levels of IL7R also expressed slightly higher levels of anti-
apoptotic markers, whereas nearly all apoptotic cells had low levels of IL7R
(37). Our finding of decreased IL7R expression in members of long-lived
families fits well with these previous results.
In conclusion, an overall lower expression level in blood of genes belonging
to the IL7R network was found to be associated with higher chronological
age. Yet, low IL7R gene expression was significantly associated with
familial longevity in middle-age independent of blood cell counts and high
expression level with prevalence of T2D, COPD and RA. Intriguingly
nonetheless, higher IL7R gene expression associates with better
prospective survival. The level of expression of the IL7R gene in the blood
is a very promising marker for healthy ageing in long lived families,
although further research is required to understand how IL7R gene




The individuals investigated in this study are participants of the Leiden
Longevity Study. The families participating in this study have at least two
siblings with a minimum age for men of 89 years and for women of 91
years (38). The offspring of these long-lived individuals, who have an
increased chance of becoming long-lived (30% reduced standardized
mortality rate), were also included. In addition, the partners of the offspring
were included as population controls of similar age and environmental
exposures as the offspring, and as a young control group for the
nonagenarian siblings. Blood samples were taken from all the participants.
The Leiden Longevity Study was approved by the Medical Ethical
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Committee of Leiden University Medical Centre and all participants gave
written informed consent.
Sample collection and RNA preparation
87 non-related long-lived siblings, 337 offspring and 321 partners belonging
to 281 nuclear families were selected for the current study (Table 1 and
Supplementary Table S5). These samples were randomly selected, but in
such a way that age and gender were balanced between the groups and
age range was as large as possible. Only individuals without outlying cell
counts (beyond 3 SDs below or above the standard error of the mean) were
included. This subpopulation is representative for the whole LLS regarding
disease prevalence and parameters involved in metabolic syndrome
(Supplementary Table S5) (9;39). From these non-fasted individuals,
peripheral blood was harvested using PAXgeneTM tubes (Qiagen, Venlo,
The Netherlands). The tubes were frozen and kept at -20°C for ~3-5 years.
After thawing at room temperature for at least 2 hours, total RNA was
extracted from the approximately 2.5 ml of peripheral blood in each tube
following the manufacturer’s recommended protocol (PAXgene Blood RNA
Kit Handbook, Qiagen, Venlo, The Netherlands). The quality and integrity of
the total RNA was evaluated on the 2100 Bioanalyzer (Agilent
Technologies, Amstelveen, The Netherlands) and the concentration was
measured using a NanoDrop spectrophotometer (NanoDrop Technologies,
Wilmington, DE, USA). Quality criteria included a 28S/18S ratio as
measured by the Bioanalyzer of at least 1.2, and a total RNA yield of at
least 3 µg.
RT-qPCR
For all 7 IL7R network genes the suggested Taqman® assay (Applied
Biosystems) was selected. Reverse transcription was performed with total
RNA from blood of in total 745 samples, which passed QC using the First
Strand cDNA Synthesis Kit according to the manufacturer’s protocol
(Roche Applied Science). cDNA was amplified using the DNA Engine
Tetrad® 2 Peltier Thermal Cycler (Bio-Rad). qPCR was then performed
with the Taqman® method using the BiomarkTM 48.48 and 96.96 Dynamic
Arrays (Fluidigm). Relative gene expression of the BioMark™ Array data
were calculated by using the 2-ΔΔCt method, in which Ct indicates cycle
threshold, the fractional cycle number where the fluorescent signal reaches
the detection threshold (40). YKT6 was used as internal control and
commercially available human total reference RNA (Clontech Laboratories,
Mountain View, CA, USA) as reference RNA.
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Geneset analysis of gene expression data
The Globaltest methodology was designed to determine whether the
common expression pattern of genes within a pre-defined set is
significantly related to clinical outcome (10;41). A generalized linear model
is used to estimate a "Q-statistic" for each gene set, which describes the
correlation between gene expression profiles, X, and clinical outcomes, Y.
The Q-statistic for a gene set is the average of the Q-statistics for each
gene in the set. The Globaltest method was used to perform geneset
analysis comparing two groups of individuals (either nonagenarians vs.
controls or offspring vs. controls) including age (in offspring vs. controls
only) and gender and their interaction as covariates. Global test package in
R (10) has been used to perform analyses.
Single gene analysis of gene expression data
Differences in expression level between nonagenarians, their offspring and
the partners of their offspring were assessed using linear regression. In
these analyses, expression level was the dependent variable and the two
groups of individuals (either nonagenarians vs. controls or offspring vs.
controls) were included in the model as a categorical variable together with
age (in offspring vs. controls only), gender and their interaction as
covariates. To take into account dependencies within sibships, robust
standard errors were used, i.e. the variance was computed from the
between family variation. P-values were also based on these robust
standard errors. Analyses were performed using the software package
STATA/SE 11.0 (DPC Software, StataCorp 2009).
Blood cell subtypes
To further investigate the candidate genes, their expression level was
associated with several blood cell counts. In the whole blood samples of
the participants the following cell subtypes were counted using the
automated Siemens ADVIA 1200 system (SMSD, Tarrytown, NY) in the
Leiden Medical Diagnostics Center: leukocytes, thrombocytes, neutrophils,
lymphocytes, monocytes, basophils and eosinophils. Next, both the
comparison between nonagenarians and controls and between offspring




Cryopreserved peripheral blood mononuclear cells (PBMC) were thawed
and treated with human immunoglobulin (GAMUNEX;
TalecrisBiotherapeuthics) and ethidiummonoazide (EMA, Invitrogen) to
block Fc receptors and stain dead cells followed by an indirect staining for
CD3 using an OKT3 supernatant and a pacific-orange-cojugated anti-
mouse IgG (Invitrogen). After blocking unbound secondary antibodies with
mouse serum (Chemicon, Millipore), cells were surface-stained with CD4-
Pacifid Blue, CD127-Alexa Fluor 647 (BioLegend, San Diego, USA) and
CD8-PerCP (BD Biosciences, Heidelberg, Germany). Cells were measured
immediately using an LSR-II (BD).
For data analysis, EMA+ dead cells were excluded and lymphocytes were
gated using an FSC-vs.-SSC dot plot based on their size and granularity. T-
cells and non-T-cells were characterized as CD3+ and CD3- cells within the
lymphocyte gate. In the CD3+ gate, CD4 and CD8 cells were characterized
in an CD4-vs.-CD8 dot plot as CD4+CD8- and CD4-CD8+ cells,
respectively. The mean fluorescence intensity (MFI) of Alexa-Fluor647
(CD127) was determined on total lymphocytes, CD3-, CD3+, CD4+ and
CD8+ cells. To standardize for fluctuation of the instrument over the
measurement period of a few weeks, MFI of each studied population was
standardized against the MFI of an unstained control PBMC for each
experimental day, by dividing the MFI of each population by that of the cells
in the lymphocyte gate of the unstained control. Flow cytometry data
analysis was performed using the FlowJo software (Tristar, San Diego,
USA).
Association of gene expression with immune-related diseases
Information on medical history was requested from the participants' general
practitioners. Gene expression of IL7R and IL7 was associated with
prevalence of T2D, COPD and RA and the sum score of these diseases.
The sum score indicates the number of patients with T2D, COPD or RA or
a combination thereof. Next, the comparison between offspring and
controls for IL7R and IL7 expression association with longevity was





Prospective analysis of IL7R-related genes was performed with 81
nonagenarians (Model 1), 313 offspring and 306 controls (Model 2). After a
mean follow-up time of 7.40 (nonagenarians) and 6.15 years (offspring and
controls), 87.7% (n = 71, nonagenarians) and 4.5% (n = 28, offspring and
controls) of the individuals had died. Mortality analyses were performed
with STATA⁄SE 11.2 (StataCorp LP, TX, USA) using an age at inclusion,
sex and white blood cell count-adjusted, left-truncated Cox proportional
hazards model to adjust for late entry into the dataset according to age.
Model 1: λ(t) ~ λ0(t) exp(β1*age at inclusion + β2*sex +
β3*lymphocyte count+ β4*neutrophil count + β5*monocyte
count + β6*eosinophil count + β7*basophil count + β8*Gene)
Model 2: λ(t) ~ λ0(t) exp(β1*age at inclusion + β2*sex + β3(age*sex) +
β4*group + β5*lymphocyte count + β6*neutrophil count +
β7*monocyte count + β8*eosinophil count + β9*basophil
count + β10*Gene)
Age at inclusion was coded in years, sex was coded as 1 (male) or 2
(female) and group was coded as 1 (control) or 2 (offspring). Robust
standard errors were used to account for sibship relations.
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Table S1. Linear regression results of gene expression of offspring from long-lived
individuals compared to controls, adjusted for blood cell numbers.
No adjustment Neutrophils Lymphocytes Monocytes Eosinophils Basophils
Gene Coef p Coef p Coef p Coef p Coef p Coef p
IL7R -0.18 0.001 -0.16 0.003 -0.15 0.004 -0.17 0.001 -0.18 0.001 -0.17 0.001
IL2RG -0.72 0.563 -0.34 0.787 -0.19 0.877 -0.19 0.882 -0.51 0.687 -0.52 0.681
IL7 -0.39 0.050 -0.38 0.049 -0.35 0.070 -0.44 0.032 -0.45 0.024 -0.44 0.030
TSLP -0.01 0.140 -0.01 0.121 -0.01 0.134 -0.01 0.103 -0.01 0.112 -0.01 0.092
CRLF2 -0.04 0.742 -0.05 0.715 -0.04 0.765 -0.05 0.713 -0.06 0.651 -0.09 0.515
JAK1 0.08 0.557 0.08 0.530 0.08 0.541 0.15 0.245 0.10 0.471 0.08 0.530
JAK3 -0.30 0.650 -0.36 0.593 -0.37 0.593 -0.08 0.905 -0.30 0.668 -0.29 0.680
Coef: coefficient from linear regression model. FC: fold change, above one indicated higher
expression in offspring from long-lived individuals. p: raw p value from linear regression
model. Genes significantly differentially expressed with at least 5% are depicted in bold.
Table S2. Linear regression results of IL7R gene expression of offspring from long-
lived individuals compared to controls, adjusted for prevalence of immune-related
diseases.
No adjustment Adjusted forT2D
Adjusted for
COPD Adjusted for RA
Adjusted for
total
Gene Coef p Coef p Coef p Coef p Coef p
IL7R -0.18 0.001 -0.17 0.001 -0.19 2.4E-4 -0.18 0.001 -0.18 0.001
Total: total prevalence of T2D, COPD or RA. Coef: coefficient from linear regression model.
FC: fold change, above one indicated higher expression in offspring from long-lived
individuals. p: raw p value from linear regression model. Genes significantly differentially
expressed with at least 5% are depicted in bold.
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mTOR signalling is implicated in the development of disease and in lifespan
extension in model organisms. This pathway has been associated with
human diseases such as diabetes and cancer, but has not been
investigated for its impact on longevity per se. Here, we investigated
whether transcriptional variation within the mTOR pathway is associated
with human longevity using whole blood samples from the Leiden Longevity
Study (LLS). This is an unique cohort of Dutch families with extended
survival across generations, decreased morbidity and beneficial metabolic
profiles in middle-age. By comparing mRNA levels of nonagenarians and
middle-aged controls, the mTOR signalling gene set was found to associate
with old age (p=4.6 x 10-7). Single gene analysis showed that seven out of
40 mTOR pathway genes had a significant differential expression of at least
5%. Of these, the RPTOR (Raptor) gene was found to be differentially
expressed also when the offspring of nonagenarians was compared to their
spouses, indicating association with familial longevity in middle-age. This
association was not explained by variation between the groups in the
prevalence of type 2 diabetes and cancer or glucose levels. Thus, the
mTOR pathway not only plays a role in the regulation of disease and aging
in animal models, but also in human health and longevity.
Introduction
Mammalian target of rapamycin (mTOR) is an evolutionarily conserved
nutrient-sensing protein kinase that belongs to the phosphoinositide 3-
kinase (PI3K)-related protein kinase family and acts as a central regulator
of growth and cell division (1). The core kinase mTOR is present in two
distinct multiprotein complexes called mTOR complex 1 (mTORC1) and
mTOR complex 2 (mTORC2), each with different functions (2), although
their exact respective roles remain to be elucidated. The main known
functions of mTORC1 include translation initiation, protein synthesis and
autophagy, while those of mTORC2 include cytoskeletal organization (3). In
addition, the two complexes are connected in that mTORC2 regulates Akt
phosphorylation, part of an upstream pathway that controls activation of
mTORC1 (1). Inhibition of the mTOR signalling pathway in yeast (4), worms
(5), flies (6) and mice (7) results in lifespan extension. In mouse models,
inhibition of the mTOR signalling pathway provides cardiovascular benefits
and improved metabolic function (1). Additionally, a primary hallmark of
calorie restriction (CR) in rodents, which leads to inhibition of the mTORC1
pathway, is a dramatic reduction in age-associated cancer incidence and
Chapter 5
83
growth rate (8), implying that enhanced mTOR signalling plays a central
role in cancer progression. In rats, the mTOR pathway has also been
implicated in both Type 1 and Type 2 diabetes, with chronic activity of
mTORC1 contributing to obesity and insulin insensitivity (9). Because
reduced mTOR signalling in model organisms extends lifespan and is
associated with better metabolic health, we postulated that a similar
reduction in this signalling pathway may also contribute to longevity and
healthy ageing in humans.
Thus far, mTOR signalling has been investigated in humans mainly by
studying disease. Its activity has been found to be elevated in different
cancers including lymphomas, melanomas, breast and prostate (1;10).
Elevated mTOR signalling in human tumours is correlated with poor tumor
prognosis, and inhibitors of this pathway are showing promising results in
clinical trials (11-13). Additionally, intermediate phenotype insulin-
resistance in human diabetes can be prevented by mTOR inhibitors (14).
Metformin, a commonly-prescribed anti-diabetic drug which inhibits
mTORC1 downstream pathways through activation of AMP kinase, has
also been shown to reduce tumour growth (15). Human CR studies used as
model for down-regulation of mTOR are much more short-term in
comparison to animal studies, but nevertheless CR may reduce the risk of
age-related diseases even in non-obese humans (16;17). Thus,
accumulating evidence is showing that mTOR signalling can play an
important role in human disease. In contrast, it has not been investigated
whether natural variation in mTOR signalling could also contribute to
disease risk.
Recently, we have identified 360 genes, the expression of which was
associated with human longevity (18). MTOR (also known as FRAP1) was
among these, suggesting a role for the mTOR signalling pathway in human
longevity. In the current study, we investigated whether common natural
genetic and transcriptional variation among the 40 genes of the mTOR
pathway (Figure 1) was associated with human longevity. To do this, we
took advantage of the Leiden Longevity Study (LLS), a Dutch cohort in
which families are selected on the basis of nonagenarian sibling pairs (19).
The middle-aged offspring of these nonagenarians have a decreased
prevalence of myocardial infarction and type 2 diabetes (20), and display
healthier intrinsic metabolism reflected by lipid profiles (21;22), glucose
metabolism and preservation of insulin sensitivity (23;24) than aged
matched controls. They also have different immune profiles in that they fail
to show a lower number of CD8+ naive T cells and a higher number of
CD8+ late-stage differentiated memory cells dependent on cytomegalovirus
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infection often seen as a hallmark of immune aging (25). To investigate
whether expression in mTOR signalling genes is associated with familial
longevity, we compared the levels of mRNA for these genes in peripheral
blood of nonagenarians from families enriched for longevity and younger
controls. In addition, genetic variation of mTOR pathway genes of LLS
nonagenarians is compared to that of younger controls. Next, mRNA levels
of the top longevity-associated genes were compared between the
offspring of the nonagenarians and similarly aged controls to exclude the
possibility that differential expression of these genes did not simply mark
old age, but are a defining characteristic of the long-lived families in middle-
age. Finally, we examined whether the association of the expression of
mTOR signalling genes with longevity is independent of metabolic health
parameters, namely plasma glucose levels, and the prevalence of type 2
diabetes and cancer, because these factors are known characteristics of
the long-lived families and are suggested to be influenced by mTOR
signalling.
Results
Selection of mTOR pathway genes
For the mTOR pathway, we selected 40 genes encoding proteins that
belong to the well-described core of the mammalian mTOR pathway. First
we selected the two mTOR complexes mTORC1 and mTORC2 including
their downstream targets often described in literature (2;3). Next, we
included the direct activators and inhibitors of these two complexes. Figure
1 shows the mTOR pathway as we investigated.
Gene expression in whole blood: nonagenarians vs controls
We measured gene expression levels for each of the 40 mTOR signalling
genes using RT-qPCR on whole blood samples from 87 LLS
nonagenarians, 337 of their middle-aged offspring and 321 middle-aged
LLS controls (Table 1). When comparing long-lived individuals to younger
controls differentially expressed genes may associate either with calendar
age, familial longevity, or both. We tested the total gene set for such
association using the globaltest method (26). We observed that the gene
expression levels of the mTOR signalling gene set did associate




Second, to investigate which genes are primarily responsible for this
association, single gene analysis using linear regression was performed on
all 40 mTOR signalling genes (Table 2). After Bonferroni correction for
multiple testing, seven genes showed significant differential expression with
at least a 5% expression difference: FOXO1 and RPTOR were expressed
at a lower level, and EIF4EBP1, LAMTOR2, AKT1S1, PRR5L, and RHOA
at a higher level in nonagenarians.
Figure 1. mTOR signalling pathway of which genetic variation and expression of 40
genes are investigated for their association with human ageing and longevity.
mTORC1 receives signals from growth factors, nutrients, energy status, and a range of
stressors and positively regulates cell growth and proliferation by promoting many anabolic
processes, including biosynthesis of proteins, lipids and organelles, and by limiting catabolic
processes such as autophagy (44). mTORC2 phosphorylates and activates Akt, serum- and
glucocorticoid-regulated kinase (sGK), RhoA and protein kinase C (PKC), which regulate
cell survival, cell cycle progression and cytoskeleton organization (45-47).
Table 1 Analyzed samples: gene expression
Samples Number Mean Age Age Range Men/Women
Long-lived individuals 87 94.3 89-102 40/47
Offspring 337 61.3 34-78 194/143
Controls 321 61.2 32-81 146/175
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Genetic analysis: nonagenarians vs controls
Since we had GWAS data available in the LLS study, we analyzed the set
of GWAS-based SNPs within a 10-kb window around the 40 mTOR
signalling genes for differences in variation between 417 unrelated
nonagenarian participants and 476 younger controls from the Leiden
Longevity Study (LLS) (Supplementary Table S1) (27). By using the PLINK
set-based test we investigated 1,018 SNPs in the 40 mTOR signalling
genes simultaneously in one test (p-value <0.05 for significance)
(Supplementary Table S2). We observed a significant association of
genetic variation in the mTOR pathway as a whole with familial longevity
(p=0.009). However, the single gene analysis (of 40 SNP sets), for which
the significance level for p values after Bonferroni correction for multiple
testing is 0.00125, did not result in significant associations. (Supplementary
Table S3), suggesting that effects of single common variation in mTOR
signalling genes on familial longevity is very small.
Table 2. Linear regression results of gene expression of long-lived individuals
compared to controls.
Protein Genename N cases N controls Mean SD FC p
4EBP1 EIF4EBP1 76 303 2.37 0.048 1.19 2.1 x 10-8
AKT AKT1 76 303 2.27 0.103 1.18 0.030
ATG101 C12orf44 71 296 1.02 0.020 1.00 0.644
ATG13 ATG13 71 296 1.10 0.019 0.99 0.095
Deptor DEPTOR 70 296 0.05 0.001 1.00 0.001
eIF4B EIF4B 70 295 0.47 0.018 1.00 0.572
eIF4E EIF4E 71 296 1.10 0.045 0.94 0.012
FIP200 RB1CC1 71 295 2.41 0.153 1.29 0.005
FOXO1 FOXO1 71 296 1.50 0.034 0.90 1.0 x 10-11
FOXO3 FOXO3 71 296 1.73 0.057 1.05 0.166
HIF1a HIF1A 71 296 4.05 0.322 1.90 0.005
mLST8 MLST8 71 296 0.42 0.010 1.00 0.446
MP1 MAPKSP1 71 296 1.64 0.039 0.97 0.112
mSIN1 MAPKAP1 70 294 1.42 0.018 0.98 0.002
mTOR MTOR 68 294 0.71 0.013 0.97 6.0E-06
p14 LAMTOR2 71 296 1.50 0.049 1.08 9.1 x 10-5
p18 CDKN2C 70 295 0.71 0.020 1.00 0.630
PGC1a PPARGC1A 66 287 0.02 0.003 1.00 0.762
PKCa PRKCA 71 296 0.57 0.016 0.95 5.4 x 10-9
PPARg PPARG 70 294 0.03 0.002 1.01 8.4 x 10-5
PRAS40 AKT1S1 70 296 0.87 0.049 1.14 1.9 x 10-4
Protor1 PRR5 71 296 4.47 0.197 0.82 0.035
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Protor2 PRR5L 71 296 7.03 0.211 1.81 4.9 x 10-5
RagA RRAGA 71 295 1.09 0.038 0.95 0.009
RagB RRAGB 71 296 0.67 0.019 0.99 0.028
RagC RRAGC 71 296 1.69 0.041 1.02 0.231
RagD RRAGD 70 296 0.66 0.015 1.02 0.035
Raptor RPTOR 79 312 0.70 0.037 0.92 0.001
Rheb RHEB 71 296 0.73 0.028 0.97 0.060
RhoA RHOA 71 296 2.15 0.037 1.08 5.6 x 10-5
Rictor RICTOR 71 296 6.24 0.182 0.99 0.874
S6 RPS6 71 295 1.92 0.073 0.93 0.055
S6K1 RPS6KB1 76 303 3.05 0.110 0.94 0.648
SGK SGK1 71 296 0.79 0.019 1.01 0.247
SKAR POLDIP3 67 260 1.00 0.020 1.05 1.3 x 10-4
SREBP SREBF1 71 296 0.72 0.031 1.00 0.758
TSC1 TSC1 71 296 1.02 0.020 0.98 0.019
TSC2 TSC2 71 296 0.78 0.021 1.04 3.8 x 10-4
ULK1 ULK1 76 303 2.47 0.081 1.19 0.002
YY1 YY1 71 296 1.73 0.037 1.01 0.740
Mean: mean relative expression level. SD: standard deviation of relative expression level.
FC: fold change, above one indicated higher expression in long-lived individuals. p: raw p
value from linear regression model. Significance level for p value after Bonferroni correction
for multiple testing is 0.00125. Genes significantly differentially expressed with at least 5%
are depicted in bold.
Gene expression in whole blood: offspring of nonagenarians vs
controls
To investigate whether the differences in expression of the seven genes
differentially expressed between nonagenarians and controls are a
characteristic of the long-lived families and not just a marker of old age, we
compared their expression in the middle-aged offspring of nonagenarians
to the controls of similar age (Supplementary Table S5). While the
association for six genes was not significant after correction for multiple
testing, as compared to the controls, the offspring expressed significantly
less RPTOR mRNA (Table 3). Thus in two generations the RPTOR gene
expression was decreased as compared to controls. Since association of
PRR5L was borderline significant and displayed the largest effect size (FC
= 0.74), we also included PRR5L for further follow up in this paper. Gene
expression levels of PRR5L were increased in the nonagenarians, but
decreased in their offspring. The gene expression differences between
offspring and control groups may be due to variation in gene expression
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level indeed or could (partially) be explained by differences in between the
groups in blood cell subsets or in disease prevalence.
Table 3. Linear regression results of gene expression of offspring compared to
controls.
Protein Genename N cases N controls Mean SD FC p
4EBP1 EIF4EBP1 320 303 2.03 0.295 1.03 0.311
FOXO1 FOXO1 311 296 2.18 0.238 1.00 0.878
p14 LAMTOR2 311 296 1.93 0.397 0.99 0.852
PRAS40 AKT1S1 311 296 1.67 0.278 0.96 0.282
Protor2 PRR5L 311 296 5.59 1.143 0.74 0.041
Raptor RPTOR 332 312 0.99 0.184 0.92 0.001
RhoA RHOA 311 296 2.15 0.265 1.00 0.927
Mean: mean relative expression level. SD: standard deviation of relative expression level.
FC: fold change, above one indicated higher expression in offspring of nonagenarians. p:
raw p value from linear regression model. Significance level for p value after Bonferroni
correction for multiple testing is 0.00714. Genes significantly differentially expressed with at
least 5% are depicted in bold.
Relation of gene expression in whole blood with cell subtypes
Whole blood consists of several cell subtypes and subsets of differentiated
immune cells that may have different mRNA expression profiles. To
investigate whether the proportions of different blood cell types could
explain differential expression levels of RPTOR and PRRL5, the
comparisons between offspring and controls were corrected for the relative
counts of leukocytes, thrombocytes, neutrophils, lymphocytes, monocytes,
basophils or eosinophils present in the whole blood samples (see
Experimental procedures). We observed that variation between cell counts
in offspring and controls did not influence the associations of the gene
expression with familial longevity.
Recently an increasingly important role for mTOR in directing T cell
activation and differentiation has become apparent (25). We therefore
examined whether the difference in expression levels of RPTOR and
PRR5L between offspring and partners is influenced by the level of T cell
differentiation reflected in the distribution of different T cell phenotypes. To
this end, the frequency of naïve (CD45RA+CCR7+CD27+CD28+), central
memory (CD45RA-CCR7+CD27+CD28+), effector memory (CD45RA-
CCR7-CD27-CD28-) and late-stage differentiated (CD45RA+CCR7-CD27-
CD28-) T cells was assessed in 71 offspring and 73 controls. The largest
effect was seen when correcting for the relative amount of effector memory
T cells present in this sample; it reduced the expression difference between
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offspring and controls for PRR5L by about 60% (the beta changed from -
0.44 to -0.17, Supplementary Table S4). This indicated that differences in
the proportion of effector memory T cells in these groups explained about
half of the differential gene expression effect for PRR5L. No remarkable
changes in effect size were found for RPTOR when correcting for the
above-mentioned T cell differentiation markers (Supplementary Table S4).
Association of gene expression in whole blood with disease and
glucose phenotypes
Since in literature expression levels of mTOR pathway proteins have been
implicated in the pathogenesis of type 2 diabetes (9) and progression of
cancer (1;10) and since the prevalence of diabetes differed between LLS
offspring and controls (20)) we tested whether RPTOR and PRR5L
expression were simply marking differences in disease prevalence. We
therefore performed the same analysis between offspring and controls
without known diabetics and cancer patients, which yielded similar
associations to those described above (Supplementary Table S6).
Because glucose levels differed between offspring and controls
(Supplementary Table S5), we investigated whether the mRNA differences
of RPTOR and PRR5L depended on glucose levels in non-diabetic
participants. The association of familial longevity with RPTOR was not
affected by adjustment for glucose levels and the association with PRR5L
expression gained significance (Supplementary Table S7). Thus, the
expression level of the RPTOR gene in blood mark familial longevity
independent of the prevalence of type 2 diabetes and cancer and glucose
levels. Due to the influence of T cell differentiation, glucose levels and
diabetes prevalence on its gene expression, the association of PRRL5 with
familial longevity is more complex.
Discussion
By comparing mRNA levels in blood of nonagenarians and middle-aged
controls from the Leiden Longevity Study, we found that the mTOR
signalling gene is differentially expressed in old age. Single gene analysis
showed that seven out of 40 mTOR pathway genes had a significant
differential expression of at least 5%, up to 1.81-fold. The expression of the
genes EIF4EBP1, LAMTOR2, AKT1S1, PRR5L and RHOA were higher in
nonagenarians, whereas FOXO1 and RPTOR were lower. The directions of
these differential gene expressions indicate separate effects on mTORC1
and mTORC2 complexes. Two of the seven differentially expressed genes,
RPTOR and PRR5L, were expressed to a lower level in middle-aged
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members of the longevity families as compared to similarly aged controls.
The significant differential expression of RPTOR and suggestive differential
PRR5L expression indicate that expression of these genes may not just
mark old age but familial longevity per se.
We also compared nonagenarians and controls in a genetic approach.
Variation in the mTOR gene set associated with longevity in the LLS due to
the joint contribution of small effects in several genes. This association
could not pinpoint the main effector genes or SNPs, so we conclude that
this finding must be replicated in much larger studies to test whether
genetic variation in the pathway and specific genes truly associate with
familial longevity.
Decreased mTORC1 protein activity is associated with lower glucose levels
and a lower prevalence of diabetes in humans (14;28), while impaired
mTORC2 is associated with glucose intolerance and insulin resistance (29).
The offspring of the nonagenarian siblings in the Leiden Longevity Study
have a lower prevalence of diabetes and lower glucose levels than similarly
aged controls. Since adjustment for glucose levels and excluding diabetic
patients provides similar associations, differences in the prevalence of type
2 diabetes or plasma glucose levels between offspring and controls did not
explain the association of RPTOR and PRR5L mRNA level with familial
longevity.
Our results could be explained if RPTOR gene expression in blood marks
familial longevity and metabolic health in middle-age and would thus be an
early marker of familial longevity. The altered gene expression levels in the
longevity family members may be the consequence of ageing, or merely a
trait shared by the long-lived families or may truly contribute to human
longevity. In view of the findings in animal models (4-7), it is not unlikely
that a familial and genetic background contributing to low mTORC1
signalling activity (and preservation of low mTOR throughout life)
contributes to metabolic health and an extended life expectancy across
species.
In our study we found RPTOR, AKT1S1 and EIF4EBP1 to be associated
with old age and/or familial longevity, and the directions of association
indicate a transcriptional down-regulation of mTORC1. Even in middle-age
a down-regulation of RPTOR mRNA was associated with familial longevity,
providing another example of the highly conserved role mTOR signalling
has in lifespan regulation across different species.
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Not only mTORC1, but also mTORC2 activity has been linked to health and
lifespan. Rictor, an important component of mTORC2, contributes to
glucose homeostasis in murine muscle tissue (30), TORC2 C. elegans
mutants show modulation of lifespan by affecting feeding and metabolism
of different diets (31), TORC2 is a mediator of proliferative and survival
signals in cancer cells (32) and a study in mouse embryonic fibroblasts
showed that mTORC2 regulates the TLR-mediated inflammatory response
via FoxO1 (33). In addition, PRR5L, which is part of mTORC2, has been
suggested to play a role in apoptosis in HeLa cells, but whether it is pro-
apoptotic or anti-apoptotic remains unclear (34). Recently, Lamming et al.
showed that disruption of mTORC2 can result in glucose intolerance and
insulin resistance in rodents and may be relevant in the pathogenesis of
type 2 diabetes and metabolic syndrome (29). Our results regarding the
association of PRR5L, RHOA and FOXO1 with old age and/or familial
longevity suggest a transcriptional up-regulation of mTORC2 which would
be in concordance with these earlier findings in animal models. As we
provide the first evidence that mTORC2 is beneficial for healthy ageing in
humans, further research is required to replicate these findings.
We observed that PRR5L expression was higher in nonagenarians, but
lower in their offspring as compared to the controls. If expression of a gene
is associated with familial longevity in this population, we would expect to
find a similar direction in both long-lived nonagenarians as well as their
offspring. Late-differentiated memory T cells accumulate with age and this
hallmark feature of immunosenescence is believed to contribute to the
weakened immune status in the elderly. It has also been shown that
offspring of the long-lived nonagenarians have less accumulation of these
effector memory T cells in comparison to controls (25). Therefore, varying
proportions of T cell subsets might influence observed PRR5L expression
levels in the different groups of the LLS. When testing for association with
cell subtype measurements in a subset of middle-aged LLS participants, we
found that PRR5L expression is positively associated with the amount of
CCR7-CD45RA-CD27-CD28- late-differentiated effector memory cells.
Data on T cell subset counts are not available for the LLS nonagenarians,
but Koch and colleagues showed the same subset of effector memory cells
to be increased in the elderly (35). This may explain the higher PRR5L
expression levels we found in the nonagenarians while lower amounts of
effector memory cells (25) and also lower PRR5L expression was found in
the middle-aged offspring compared to controls. From this we conclude that
PRR5L expression may be a marker for the differentiation state of T cells,
indicating a more late-differentiated T cell compartment in nonagenarians
as compared to younger controls, but a less-differentiated phenotype in the
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offspring in middle-age. The link between the mTOR pathway and T cell
activation and differentiation is perhaps not surprising when it is considered
that rapamycin was first identified and exploited as a T cell-directed
immunosuppressive agent in transplantation (36). The differential
distribution of T cell phenotypes contributed approximately to 60% of the
PRR5L effect, suggesting that PRR5L might have another role in longevity
other than marking/influencing T cell population subtypes; further research
is required to identify such a role.
In conclusion, the expression level in blood of genes belonging to the two
mTOR complexes 1 and 2 associated with old age showing down- and up-
regulation in the long-lived respectively. RPTOR gene expression was
further significantly associated with familial longevity in middle-age
independent of glucose levels and the prevalence of type 2 diabetes and
cancer. At the level of suggestive evidence this was also the case for
PRRL5. These results suggest that the mTOR pathway may not only be
involved in lifespan regulation in animal models, but also with the metabolic
health and extended lifespan of human longevity families.
Materials & Methods
Study population
The individuals investigated in this study are participants of the Leiden
Longevity Study. The families participating in this study have at least two
siblings with a minimum age for men of 89 years and for women of 91
years (19). The offspring of these long-lived individuals, who have an
increased potential to become long-lived individuals (30% reduced
standardized mortality rate), were also included. In addition, the partners of
the offspring were included as population controls of similar age and
environmental exposures as the offspring, and as a young control group for
the nonagenarian siblings. Blood samples were taken from all the
participants. The Leiden Longevity Study was approved by the Medical
Ethical Committee of Leiden University Medical Centre and all participants
gave written informed consent.
Selection of mTOR pathway
For the mTOR pathway, we selected 40 genes encoding proteins that
belong to the well-described core of the mammalian mTOR pathway. First
we selected the two mTOR complexes mTORC1 and mTORC2 including
their downstream targets often described in literature (2;3). Next, we
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included the direct activators and inhibitors of these two complexes. Figure
1 shows the mTOR pathway as we investigated.
Sample collection and RNA preparation
87 non-related long-lived siblings, 337 offspring and 321 partners belonging
to 281 nuclear families were selected for the current study (Table 1 and
Supplementary Table S5). These samples were randomly selected, but in
such a way that age and gender were balanced between the groups and
age range was as large as possible. Additionally, individuals with outlying
cell counts (beyond 3 SDs below or above the standard error of the mean)
were excluded. This subpopulation is representative for the whole LLS
regarding disease prevalence and parameters involved in metabolic
syndrome (Supplementary Table S5) (20;37). From these non-fasted
individuals, peripheral blood was harvested using PAXgeneTM tubes
(Qiagen, Venlo, The Netherlands). The tubes were frozen and kept at -
20°C for ~3-5 years. After thawing at room temperature for at least 2 hours,
total RNA was extracted from the approximately 2.5 ml of peripheral blood
in each tube following the manufacturer’s recommended protocol
(PAXgene Blood RNA Kit Handbook, Qiagen, Venlo, The Netherlands).
The quality and integrity of the total RNA was evaluated on the 2100
Bioanalyzer (Agilent Technologies, Amstelveen, The Netherlands) and the
concentration was measured using a NanoDrop spectrophotometer
(NanoDrop Technologies, Wilmington, DE, USA). Quality criteria included a
28S/18S ratio as measured by the Bioanalyzer of at least 1.2, and a total
RNA yield of at least 3 µg.
RT-qPCR
For all 40 mTOR signalling genes the suggested Taqman® assay (Applied
Biosystems, Bleiswijk, the Netherlands) was selected. Reverse
transcription was performed with total RNA from blood of in total 790
samples, which passed QC using the First Strand cDNA Synthesis Kit
according to the manufacturer’s protocol (Roche Applied Science, Almere,
the Netherlands). cDNA was amplified using the DNA Engine Tetrad® 2
Peltier Thermal Cycler (Bio-Rad, Veenendaal, the Netherlands). qPCR was
then performed with the Taqman® method using the BiomarkTM 48.48 and
96.96 Dynamic Arrays (Fluidigm, Amsterdam, the Netherlands). Relative
gene expression of the BioMark™ Array data were calculated by using the
2-ΔΔCt method, in which Ct indicates cycle threshold, the fractional cycle
number where the fluorescent signal reaches the detection threshold (38).
YKT6 was used as internal control and commercially available human total
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reference RNA (Clontech Laboratories, Mountain View, CA, USA) as
reference RNA.
Geneset analysis of gene expression data
The Globaltest methodology was designed to determine whether the
common expression pattern of genes within a pre-defined set is
significantly related to clinical outcome (39;40). A generalized linear model
is used to estimate a "Q-statistic" for each gene set, which describes the
correlation between gene expression profiles, X, and clinical outcomes, Y.
The Q-statistic for a gene set is the average of the Q-statistics for each
gene in the set. The Globaltest method was used to perform geneset
analysis comparing two groups of individuals (either nonagenarians vs.
controls or offspring vs. controls) including age (in offspring vs. controls
only) and gender and their interaction as covariates. Global test package in
R (41) has been used to perform analyses.
Single gene analysis of gene expression data
Differences in expression level between long-lived siblings, their offspring
and the partners of their offspring were assessed using linear regression. In
these analyses, expression level was the dependent variable and the two
groups of individuals (either nonagenarians vs. controls or offspring vs.
controls) were included in the model as a categorical variable together with
age (in offspring vs. controls only), gender and their interaction as
covariates. To take into account dependencies within sibships, robust
standard errors were used, i.e. the variance was computed from the
between family variation. P-values were also based on these robust
standard errors. Analyses were performed using the software package
STATA/SE 11.0 (DPC Software, StataCorp 2009).
Sample and SNP collection for genetic association analysis
The SNP set analysis was performed in the same manner as described in
Deelen et al. (42). We used the genotype data of 417 unrelated long-lived
individuals and 476 young controls from the LLS, typed with Illumina
HumanOmniExpress BeadChips (Supplementary Table S1). We removed
SNPs with a SNP call rate < 0.95, MAF < 0.01 or PHWE < 10−4 in
nonagenarian cases and controls and 1,018 analyzed SNPs within a 10-kb




PLINK set-based statistical analysis
In the PLINK set-based test (–set-test,
http://pngu.mgh.harvard.edu/purcell/plink; (43)), a SNP analysis of the
pathway or gene SNP set is performed. For the SNP set, a mean SNP
statistic is calculated from the single SNP statistics of a maximum amount
(–setmax) of independent SNPs below a certain P value threshold (–set-p).
If SNPs are not independent, i.e., in case linkage disequilibrium (r2) is
above a certain threshold (–set-r2), the SNP with the lowest P value in the
single SNP analysis is selected. The same analysis is performed with a
certain amount (–mperm) of simulated SNP sets in which the phenotype
status of the individuals is permuted. An empirical P value for the SNP set
is computed by calculating the number of times the test statistic of the
simulated SNP sets exceeds that of the original SNP set. For the analysis
in this study, the parameters were set to –setp 0.05 –set-r2 0.5, –set-max
99999, and –mperm 10,000. Bonferroni correction for the pathway analysis
is not necessary since it contains just one test. When SNP sets were tested
per gene (40 SNP sets), the significance level for p values after Bonferroni
correction for multiple testing is 0.00125.
Blood cell subtypes
To further investigate the candidate genes, their expression level was again
tested for association with familial longevity, but now adjusted for several
blood cell counts. In the whole blood samples of the participants the
following cell subtypes were counted using the automated Siemens ADVIA
1200 system (SMSD, Tarrytown, NY) in the Leiden Medical Diagnostical
Center: leukocytes, trombocytes, neutrophils, lymphocytes, monocytes,
basophils and eosinophils. Both longevity-associated genes in middle-age
were adjusted for each of these cell counts separately when associating
with familial longevity, which analysis is described above.
T cell differentiation measurements
Data on distribution of different T cell subsets were generated in 71
offspring and 73 controls, of whom also gene expression data were
available, as described previously (25). Briefly, PBMCs viably
cryopreserved with DMSO were thawed and treated with human Ig,
GAMUNEX (Bayer, Leverkusen, Germany), and ethidium monoazide
(EMA) (Invitrogen, Karlsruhe, Germany). Cells were first stained indirectly
for KLRG-1 using a primary antibody kindly provided by Prof. Hans-Peter
Pircher, Freiburg, Germany and a Pacific-Orange-conjugated secondary
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antibody (Invitrogen). After blocking with mouse serum
(Chemicon/Millipore, Schwalbach, Germany), the following directly
conjugated monoclonal antibodies were added: CD3-PE (Calltag;
Invitrogen), CD4- PerCP, CD8-allophycocyanin-Cy7, CCR7-PE-Cy7 (BD
Biosciences, Heidelberg, Germany), CD27-allophycocyanin, CD45RA-
Pacific Blue, CD28- Alexa Fluor 700, (BioLegend, San Diego, CA), and
CD57-FITC (Immunotools, Freiburg, Germany). After 20 min incubation on
ice, cells were washed and analyzed immediately on an LSR II cytometer
with FACSDiva software (BD Biosciences). The spectral overlap between
all channels was calculated automatically by the BD FACSDiva software,
after measuring negative and single-color controls. Data were analyzed
using FlowJo software (Tree Star, Portland, OR). For data analysis, EMA-
positive dead cells were excluded. T cells were characterized as naïve
(CD45RA+CCR7+CD27+CD28+), central memory (CD45RA-
CCR7+CD27+CD28+), effector memory (CD45RA-CCR7-CD27-CD28-)
and “terminally differentiated” effector memory (TEMRA; CD45RA+CCR7-
CD27-CD28-) T cells according to previously published models (35).
Associatin of gene expression with insulin-related phenotypes
Since the mTOR pathway has been implicated in insulin-related
phenotypes, their effect on the expression of the longevity-related genes
was further investigated. Blood samples were taken at baseline for the
determination of non-fasted serum parameters. For the serum
measurements, the Hitachi Modular or the Cobas Integra 800, both from
Roche, Almere, the Netherlands were applied. CVs of these measurements
were all below 5 %. Information on medical history was requested from the
participants' general practitioners. As described before, differences in
expression level between offspring and controls were assessed using linear
regression using the same model, but excluding known Type 2 diabetes
patients. The association of glucose and insulin levels with expression
levels of the 7 longevity-associated genes was also analyzed using linear
regression in controls only. To investigate the influence of glucose and
insulin levels on the association with longevity of these 7 genes, linear
regression between offspring and controls was performed again, including
one of these parameters as covariate.
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The Target of Rapamycin (TOR) pathway is an evolutionary conserved
signaling pathway involved in lifespan regulation. In a gene expression
study of whole blood, we recently reported that the mammalian TOR
pathway was associated with familial longevity in humans. The aim of the
present study was to investigate whether such an association can also be
found at the cellular level. For this purpose, primary fibroblasts from a
subset of our initial discovery cohort consisting of 40 middle aged members
of long-lived families and 40 controls of similar age were analyzed. The
protein expression, phosphorylation state, and gene expression of key
molecules within the mTOR pathway as well as total protein content and
markers for autophagy were measured. Although a significant effect on
total protein content was observed, that might reflect differences in cell
growth and proliferation, no differences were observed on the other
parameters. The variation in gene expression levels of mTOR genes in
cultured fibroblasts did not reflect at all the variation in these levels in whole
blood from the same individuals. We conclude that contribution of the
mTOR pathway to familial longevity cannot be studied in fibroblasts of
donors which do express marks of such contribution in blood.
Introduction
After extensive studies in animal models, mammalian target of rapamycin
(mTOR) signaling has recently also been implicated in human ageing and
familial longevity (1;2). Gene expression studies in blood showed that
expression changes of downstream targets of mTOR complex 1 (mTORC1)
are downregulated with aging (3;4). It has been suggested that, in line with
what is known in animal models, inhibition of mTOR signaling with
advancing age might be a survivor effect, since decreased mTOR signaling
is associated with increased survival (3). Our study investigating expression
levels of genes belonging to the mTOR pathway showed that familial
longevity in middle age associated with downregulation of the expression of
genes in the mTOR pathway (4). These results correspond with previous
studies showing that increased mTOR signaling is associated with
increased prevalence and progression of disease (5;6), and that reduced
mTOR signaling extends lifespan in model organisms (7-10) and is
associated with better metabolic health (11). Thus, taken together,
accumulating evidence suggests that mTOR signaling can play an
important role in human metabolic health and longevity.
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mTOR is an evolutionarily conserved nutrient-sensing protein kinase (6).
The core kinase is present in two distinct multiprotein complexes (mTORC1
and mTORC2), each with different functions (12), although their exact
respective roles remain to be elucidated. The main known functions of
mTORC1 include translation initiation, protein synthesis and autophagy,
while those of mTORC2 include cytoskeletal organization and stress
resistance (13). In addition, the two complexes are connected in that
mTORC2 regulates Akt phosphorylation, part of an upstream pathway that
controls activation of mTORC1 (6). The mTOR pathway has been
extensively studied in cell lines, including human and mouse fibroblasts
(14-18).
The mTOR pathway was found to be involved in human familial longevity in
the Leiden Longevity Study (LLS) in which nonagenarian siblings, their
offspring and the partners thereof were studied. Expression levels of mTOR
pathway related genes in blood differed between nonagenarian and middle
aged individuals and between middle aged offspring and similarly aged
partners as controls (4). The middle aged members of the long lived
families (offspring) have a decreased prevalence of myocardial infarction
and type 2 diabetes (19), and display a healthier metabolism reflected by
beneficial lipid profiles (20;21) and preservation of insulin sensitivity (22;23)
than the controls. Previously we demonstrated differences in the in vitro
cellular responses to stress of the offspring’s fibroblasts as compared to
controls, including a lower increase in senescence, but an increase in
apoptosis, which is seen as advantageous to the organism (24;25). To what
extent mTOR signaling contributes to human familial longevity is not yet
investigated at the protein and signaling level.
In this paper primary skin fibroblasts of members of long-lived families are
investigated in vitro for differences in mTOR signaling as compared to
similarly aged controls. The expression level of the most important proteins
in the mTOR pathway were determined, as well as the phosphorylation of
these proteins, total protein content and autophagy. We also inspected the
correlation between the transcription levels of mTOR related genes in
cultured skin fibroblasts and in blood from the same donors.
Results
The characteristics of the randomly selected fibroblast strains subset of
subjects from the Leiden Longevity Study are shown in Table 1. Offspring
of long-lived individuals and their partners, which will act as controls, were
of similar age. Experiments were performed in fibroblasts obtained from 37
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offspring and 36 controls, with a similar proportion of male and female
donors.
Table 1 Analyzed samples in this study
Samples Number Mean Age Age Range Women (%)
Offspring 37 63.0 45-78 20 (54.1%)
Controls 36 62.5 44-78 19 (52.8%)
Protein expression and phosphorylation in skin fibroblasts
To investigate whether gene expression differences in blood represent
lower mTOR signaling in peripheral tissues like the skin, we measured
protein expression and phosphorylation of the most important proteins in
this pathway (Figure 1) in skin fibroblasts using; mTOR, P70S6K, 4EBP1,
Raptor, Rictor and Akt. mTOR itself is part of both mTORC1 and mTORC2
with complex-specific proteins Raptor and Rictor respectively. P70S6K and
4EBP1 are downstream targets of mTORC1 and Akt is a downstream
target of mTORC2 as well as an upstream effector of mTORC1.
The comparison of offspring of long-lived individuals and controls for
association with familial longevity showed no significant difference in
expression or phosphorylation of any of the proteins after multiple testing
correction (Bonferroni p=0.005, Table 2).
Protein synthesis and autophagy
Biological processes regulated by the mTOR pathway include autophagy
and protein synthesis. Lower mTOR signaling, which is hypothesized to be
the case in familial longevity, results in higher autophagy levels. An
increase in autophagy levels could be indicated by a decrease in Light
Chain3-I-on-Light Chain3-II isoform (LC3-I-on-LC3-II) ratio. However, the
members of long-lived families show the same ratio as controls.
Although total protein content also reflects cell growth and differentiation,
we could speculate that decreased total protein levels might indicate a
decreased protein synthesis or an increased protein turnover to which a
decreased mTORC1 activity may have contributed. Furthermore, since a
lower mTOR signaling reduces protein synthesis, we speculate that total
protein yield from 106 cells, as a surrogate marker for protein synthesis,
might be decreased in members of long-lived families as compared to
controls. The skin fibroblasts of members of long-lived families indeed had
























Figure 1. Core of mTOR signaling pathway of which protein expression and
phosphorylation are investigated for their association with human longevity.
Phosphorylation at Ser2448 activates mTOR in both complexes mTORC1 and mTORC2.
mTORC1 inhibits 4EBP1 by phosphorylation at Thr37/46 and activates P70S6K by
phosphorylating Thr389. mTORC2 activates Akt by phosphorylation at Ser473 and Akt
indirectly activates mTORC1.
Gene expression and protein expression in skin fibroblasts
In blood we have previously established a difference between the offspring
and controls in mTOR related gene expression levels (4). To investigate
whether gene expression levels in skin fibroblasts correlate with protein
levels we additionally measured transcription levels of MTOR, RPTOR and
RPS6KB1 in 66 fibroblast samples using RT-qPCR. Pearson pairwise
correlation analysis of protein and gene expression levels in skin fibroblasts
of the same individuals showed unexpectedly no significant correlation
except for 4EBP1 (r=0.324, p=0.008 (Supplementary Table S1).
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Gene expression in blood and gene expression in skin fibroblasts
The observed gene expression differences in blood between members of
long-lived families and controls was apparently not reflected by any marked
difference in mTOR signaling in the skin fibroblasts of these groups. The
question raises therefore to what extent mTOR gene expression in blood
and fibroblasts of the same donor correlates. We tested gene expression
levels of the 40 mTOR genes in 72 individuals for such correlation by
Pearson correlation analysis. We found no significant correlation of
transcription levels for any of the genes in blood and skin fibroblasts of the
same individuals (Supplementary Table S2).
Table 2. Linear regression results of protein expression in skin fibroblasts of





p-mTOR (S2448) 0.113 0.024
P70S6K -0.003 0.938
p-P70S6K (T389) 0.003 0.967
p-4EBP1 (T37/46) 0.013 0.812
Raptor 0.039 0.504
Rictor -0.038 0.606
p-Akt (S473) 0.117 0.270
Protein synthesis
Total protein -0.065 0.007
Autophagy
LC3-I/LC3-II ratio -0.005 0.962
Coef: coefficient from linear regression of protein expression (arbitrary units), positive
indicated higher expression in offspring. p: raw p value from linear regression.
Discussion
The aim of this study was to further investigate our previous finding that
expression levels of genes from the mTOR pathway in blood are
associated with human familial longevity. In the skin fibroblasts of members
of long-lived families and controls, however, we found no differences in the
levels of proteins from the mTOR pathway nor their phosphorylation state.
Hence we conclude that we are not able to detect an effect of mTOR
signaling on human familial longevity in cultured skin fibroblasts. This is
also reflected by the similarity between members of long-lived families and
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controls in levels of autophagy as downstream effect of the mTOR
pathway. The total protein content in members of long-lived families as
compared to controls was slightly lower, potentially indicating
downregulation of mTOR signaling. But since gene expression and protein
levels of mTOR related genes in cultured skin fibroblasts and blood from
the same donors did not correlate, we conclude that cultured skin
fibroblasts may not be suitable to investigate the basis and consequences
of natural variation of mTOR related gene expression in blood that marked
familial longevity at a functional level.
Besides the biological explanation that mTOR signaling itself might differ
between blood and skin of the same donor, our lack of clear validation
might be due to the technical variations, of which the major one is that the
skin fibroblasts were cultured several passages in vitro before RNA
extraction, while blood was drawn and it’s RNA immediately stabilized and
frozen, representing the in vivo status. Thus, our current findings may
stress that mTOR signaling in cultured primary skin fibroblasts is different
from that in whole blood and therefore cannot provide sufficient insights
about the role of mTOR signaling in human ageing and familial longevity.
Another explanation for the lack of clear validation might be that
investigating natural occurring genetic variation in a primary cell system
does not result in clearly measurable changes in protein expression and
phosphorylation state. Most successful studies on mTOR signaling in skin
fibroblasts investigate the effects of the knockdown of genes (14;18), the
use of inhibiting compounds (17), mutant genes, overexpression of genes
(14), amino acid deprivation or induction of oxidative stress (15). Because
the effect of naturally occurring genetic variation is expected to be much
smaller than the effect of such challenges, it may be that that the culturing
of cells introduces too much background variation in mTOR signaling to
detect the subtle differences between members of long-lived families and
controls. Hence we may need to challenge the mTOR pathway to be able
to detect the differences associated with human familial longevity in
fibroblasts like was applied in the study of MTOR signaling in fibroblasts of
long lived mouse strains (15).
In summary, the gene expression differences in mTOR related genes in
blood associated with human familial longevity was not observed for
primary skin fibroblast. Moreover, we were not able to detect differences in
levels or phosphorylation status of mTOR proteins in skin fibroblast in
relation to human familial longevity. We conclude that under unchallenged
conditions cultured skin fibroblasts may not be suitable to investigate the
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basis and consequences of natural variation in mTOR signaling in humans
as determinant of human longevity. Potentially, cultured PBMCs better
resemble the effects found in blood, or the exploration of differential
response to a challenged mTOR pathway may provide functional insight in




The individuals investigated in this study are participants of the Leiden
Longevity Study. The families participating in this study have at least two
siblings with a minimum age for men of 89 years and for women of 91
years (28). The offspring of these long-lived individuals, who have an
increased potential to become long-lived individuals (30% reduced
standardized mortality rate), were also included. In addition, the partners of
the offspring were included as population controls of similar age and
environmental exposures as the offspring, and as a young control group for
the nonagenarian siblings. Blood samples were taken from all the
participants. During the period November 2006 and May 2008, a biobank
was established from fibroblasts cultivated skin biopsies from 150 offspring-
control pairs. Because it was expected that the difference in biological age
between the offspring and control groups would be small, a relatively large
sample size of 80 strains from 40 couples was chosen, consisting of 20
fibroblast strains from the 65 female offspring, 20 strains from the 86 male
offspring, as well as 20 strains from the 86 female controls and 20 strains
from the 63 male controls (Table 1).
Fibroblast cultures
Four mm skin biopsies were taken from the sun unexposed medial side of
the upper arm. Fibroblasts were grown in D-MEM:F-12 (1:1) medium
supplemented with 10% fetal calf serum (FCS), 1 mM MEM sodium
pyruvate, 10 mM HEPES, 2 mM glutamax I and antibiotics (100 U mL-1
penicillin, 100 μg mL-1 streptomycin and 0.25-2.5 μg mL-1 amphotericin B),
all obtained from Gibco (Breda, the Netherlands). One specific FCS batch
was used during the whole experiment (Bodinco, Alkmaar, the Netherlands,
batch no. 162229). Fibroblasts were incubated at 37 °C with 5% CO2 and
100% humidity. All cultures that are used in the present study were grown
under predefined, highly standardized conditions as published earlier (29)
and frozen at low passage. Of the 73 individuals from which the fibroblasts
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are tested, gene expression was measured in whole blood for 72 of them
(4).
Experiments were set up in batches of maximally eight fibroblasts strains
which were thawed from frozen stocks on day zero. On day one, the
medium was changed and on day 4 fibroblasts were passaged 1:4 and
passed further in equal numbers to have similar confluences for
experiments. On day 25, fibroblasts were seeded in 9 cm dishes and grown
for three days to similar confluences before harvesting cells for RNA or
protein isolation.
Western Blot preparation and analysis
Fibroblast cells were washed with PBS, lysed in EBSB buffer (4 mM
glycerol, 3% SDS, 100 mM TRIS-PO4 pH 6.8), boiled at 100 °C for 5
minutes and stored at -20 °C.
Whole cell lysates were prepared as described (30), and cleared by
centrifugation. Protein content was determined using a bicinchoninic acid
protein assay kit (Pierce, Rockford, IL). Expression and phosphorylation of
proteins were determined by SDS-PAGE Western Blotting. Antibodies
against total mTOR (#2972), P70S6K (#9202), LC3-I-on-LC3-II (#4108),
and phospho-specific mTOR-Ser2448 (#2971S), P70S6K-Thr389
(#9205S), 4EBP1-Thr37/46 (#9459), and Akt-Ser473 (#9271) were from
Cell Signalling Technology (Danvers, MA, USA). Antibodies against total
Raptor (sc-27744) and Rictor (sc-50676) were from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). Bound antibodies were visualized
by enhanced chemiluminescence and quantified by densitometry analysis
of scanned films (Image J 1.34S; National Institutes of Health, Bethesda,
MD, USA).
Statistical analysis was conducted with the software package STATA/SE
11.0 (DPC Software, StataCorp 2009). Differences in protein expression or
phosphorylation (in arbitrary units) between the offspring and controls were
determined with linear regression with age, gender and their interactions as
covariates and adjusted for cell batch, cell confluence and where applicable
western blot batch.
RNA sample preparation
From the 40 offspring and 40 controls RNA was extracted from both the
cultured fibroblasts and whole blood. Harvesting of fibroblast cells included
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washing with PBS and the cells were lysed in RLT buffer (Qiagen, Venlo,
the Netherlands) and stored at -80 °C. RNA from fibroblasts was extracted
using the RNeasy mini kit, RNA from whole blood (PAXgene tubes) was
extracted using PAXgene Blood RNA kit (both Qiagen, Venlo, the
Netherlands) following the manufacturer’s recommended protocols. The
quality and integrity of the total RNA was evaluated on the 2100
Bioanalyzer (Agilent Technologies, Amstelveen, The Netherlands) and the
concentration was measured using a NanoDrop spectrophotometer
(NanoDrop Technologies, Wilmington, DE, USA).
RT-qPCR and correlation analysis of gene expression data
For all 40 mTOR signaling genes the suggested Taqman® assay (Applied
Biosystems) was selected. Reverse transcription was performed with total
RNA from fibroblasts and blood of in total 80 individuals, using the First
Strand cDNA Synthesis Kit according to the manufacturer’s protocol
(Roche Applied Science). cDNA was amplified using the DNA Engine
Tetrad® 2 Peltier Thermal Cycler (Bio-Rad). qPCR was then performed
with the Taqman® method using the BiomarkTM 48.48 and 96.96 Dynamic
Arrays (Fluidigm). Relative gene expression of the BioMark™ Array data
were calculated by using the 2-ΔΔCt method, in which Ct indicates cycle
threshold, the fractional cycle number where the fluorescent signal reaches
the detection threshold (31). YKT6 was used as housekeeping gene and
commercially available human total reference RNA (Clontech Laboratories,
Mountain View, CA, USA) as reference RNA.
Gene expression and protein expression levels of 5 genes/proteins were
correlated between the two tissues, skin fibroblasts and whole blood, within
the same individuals using pairwise Pearson correlation in STATA adjusted
for age, gender, their interaction, cell batch and cell confluence (Table 3).
Relative gene expression levels of the 40 genes were also correlated
between the two tissues within the same individuals using pairwise Pearson
correlation in STATA adjusted for age, gender, their interaction, cell batch
and cell confluence (Table 4).
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Table S1 Pearson correlation between gene expression and protein expression in
fibroblasts of the same donors (n = 66)
Gene Protein Correlation P
MTOR mTOR -0.058 0.646
RPTOR Raptor -0.132 0.292
RPS6KB1 P70S6K -0.198 0.112
p: raw p value from 2-tailed Pearson correlation.
Table S2 Pearson correlation between gene expression in fibroblasts and gene
expression in whole blood of the same donors (n = 72)
Gene Protein Correlation P
EIF4EBP1 4EBP1 0.060 0.639
AKT1 AKT 0.070 0.585
C12orf44 ATG101 0.067 0.575
ATG13 ATG13 -0.130 0.276
DEPTOR Deptor -0.139 0.245
EIF4B eIF4B 0.074 0.538
EIF4E eIF4E 0.011 0.930
RB1CC1 FIP200 0.031 0.793
FOXO1 FOXO1 -0.072 0.550
FOXO3 FOXO3 0.030 0.803
HIF1A HIF1a -0.056 0.638
MLST8 mLST8 0.127 0.289
MAPKSP1 MP1 -0.107 0.370
MAPKAP1 mSIN1 0.140 0.249
MTOR mTOR 0.063 0.621
LAMTOR2 p14 0.075 0.530
CDKN2C p18 0.218 0.066
PPARGC1A PGC1a -0.056 0.651
PRKCA PKCa 0.105 0.381
PPARG PPARg -0.057 0.632
AKT1S1 PRAS40 0.046 0.701
PRR5 Protor1 -0.145 0.224
PRR5L Protor2 0.117 0.327
RRAGA RagA -0.088 0.467
RRAGB RagB 0.038 0.752
RRAGC RagC -0.110 0.356
RRAGD RagD -0.139 0.245
RPTOR Raptor -0.153 0.221
RHEB Rheb -0.057 0.632
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RHOA RhoA 0.032 0.787
RICTOR Rictor 0.113 0.344
RPS6 S6 0.034 0.777
RPS6KB1 S6K1 -0.070 0.581
SGK1 SGK -0.160 0.179
POLDIP3 SKAR -0.131 0.315
SREBF1 SREBP 0.149 0.210
TSC1 TSC1 -0.109 0.361
TSC2 TSC2 0.107 0.372
ULK1 ULK1 -0.074 0.559
YY1 YY1 0.033 0.786
p: raw p value from 2-tailed Pearson correlation
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The bodily decline that occurs with advancing age strongly impacts on the
prospects for future health and life expectancy. Despite the profound role of
age in disease etiology, knowledge about the molecular mechanisms
driving the process of ageing in humans is limited. Here we used an
integrative network-based approach for combining multiple large-scale
expression studies in blood (2,539 individuals) with Protein-Protein
Interaction (PPI) data for the detection of consistently co-expressed PPI
modules that may reflect key processes that change throughout the course
of normative ageing. Module detection followed by a meta-analysis on
chronological age identified fifteen consistently co-expressed PPI modules
associated with chronological age, including a highly significant module
(p=3.5×10-38) enriched for “T-cell activation” marking age-associated shifts
in lymphocyte blood cell counts (R2=0.603; p=1.9×10-10). Adjusting the
analysis in the compendium for the “T-cell activation” module showed five
consistently co-expressed PPI modules that robustly associated with
chronological age and included modules enriched for “Translational
elongation”, “Cytolysis” and “DNA metabolic process”. In an independent
study of 3,535 individuals, four out of five modules consistently associated
with chronological age, underpinning the robustness of the approach. We
found three out of five modules to be significantly enriched with ageing-
related genes, as defined by the GenAge database, and association with
prospective survival at high ages for one of the modules including ASF1A.
The hereby-detected age associated and consistently co-expressed PPI
modules therefore may provide a molecular basis for future research into
mechanisms underlying human ageing.
Introduction
A steadily growing life expectancy of the general western population
throughout the past two centuries (1) has imposed the urgency for
understanding the adverse effects of ageing for public health and its
relation to the observed large variation in healthy lifespan (2). Age-
dependent detrimental processes strongly attenuate prospects for future
health, with chronological age being the major risk factor for mortality and
virtually all common diseases in the western world (3). Ageing is a systemic
ailment marked by a gradual metabolic decline eventually leading to a state
of senescence on both the cellular and organismal level that seems to be
caused by the accumulation of damage over time (4). Despite their
profound role for disease etiology, the existing knowledge concerning the
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molecular mechanisms driving biological ageing processes in humans is
limited.
Construction of consistent age-associated signatures has proven to be
challenging as a multitude of gene expression studies have identified age
associated genes so far, though with limited mutual overlap (5;6). This
inconsistency is most likely due to variable technical circumstances, small
study sizes and low signal-to-noise ratios, typically observed when
analysing the ageing transcriptome. More similarity was observed at the
pathway level, across tissues and even species (7;8) suggesting that the
analysis of the ageing transcriptome by functionally grouped gene sets is a
promising alternative for the classical individual-gene analyses.
Rather than employing literature-based sets of genes sharing similar
biological functions, so-called network approaches are increasingly used,
which infer functional clusters of genes from the expression data itself by
exploiting gene co-expression patterns hidden within the data (9).
Alternatively, changes in these gene co-expression patterns that occur with
age might be used for inferring a functional grouping from the data (10).
However, co-expression patterns may contain spurious gene-gene
correlations (11), which make the use of multiple data-sources
simultaneously or the integration with other additional information sources
on functional relationships between genes desirable.
Established modulators of ageing processes in model organisms were
reported to spatially cluster within networks constructed of Protein-Protein
Interaction (PPI) data (12;13). Hence, PPI networks can be exploited for
prioritizing new ageing-associated genes (14;15) or for refining modules of
co-expressed genes that are correlated during the course of ageing (16).
We previously demonstrated that the inference of these so-called co-
expressed PPI modules has a high reproducibility across multiple
expression datasets in breast-cancer (17), and here we extend this
algorithm to combine multiple gene expression datasets on ageing.
Though many algorithms for network inference exist (18), relatively little
attention has gone to the problem of network inference and subsequent
associations with a phenotype using multiple heterogeneous expression
data sources simultaneously. Merging the expression data into a single set
and using this for network inference clearly surpasses the differences in
correlation structures present within each dataset. Irrespective of the type
of network inference chosen, we propose to handle such heterogeneity by
integrating the gene-gene similarity measures obtained across expression
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datasets using a suitable meta-analysis setting. Thus, in the approach
described in this paper we employ a meta-analysis for inferring a consistent
gene-gene network that serves as a basis for identifying consistently co-
expressed PPI modules, which are subsequently analysed with respect to
chronological age across datasets using again a meta-analysis.
To robustly characterize the changes of the blood transcriptome associated
with chronological age, we have build a compendium using three large-
scale transcriptomic studies (19-21) generated in blood comprising 2,539
individuals on which we applied our integrative network approach. For
comparison, two types of individual-gene meta-analyses were performed as
well, which in combination with an enrichment analysis yielded only broad
terms for age-associated cellular processes. Application of our integrative
network-based approach yielded five consistently co-expressed PPI
modules showing robust age associations and functional enrichments for
“Translational elongation”, “Cytolysis” and “DNA metabolic process”, that
seem to reflect downstream mTOR signaling events or cell-cycle
checkpoints. Finally, we show that four out of five modules replicate in an
independent cohort, that they are enriched for known longevity- and
ageing-related genes and that the expression of one module associates
with prospective survival at old age.
Results
The largest transcriptome compendium for normative ageing
To robustly characterize the changes of the blood transcriptome throughout
the course of normative ageing in the range of 15-94 years, we built a gene
expression compendium using three large-scale transcriptomic studies
performed in blood: the San Antonio Family Heart Study (SAFHS) (21), the
Icelandic Family Blood (IFB) cohort (19) and the Dietary, Lifestyle, and
Genetic determinants of Obesity and Metabolic syndrome (DILGOM) study
(20). Data of IFB was measured in two roughly equally sized batches, from
this point on referred to as IFB_A and IFB_B, and was treated as two
separate datasets in the downstream analysis. Data quality was critically
re-assessed and re-annotated yielding a compendium of 9,047 unique
genes expressed in 2,539 individuals divided over four datasets (SAFHS:
1,240, IFB_A: 411, IFB_B: 435, DILGOM: 454, Table 1).
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Table 1: Descriptives of the datasets composing the compendium


















1240 1240 506(40.8%) 39.3 15 94
IFB_A
Peripheral
blood Icelandic FamilyBlood (IFB) cohort
Caucasian
(Icelandic) 904

















B 454 195(43.0%) 51.6 30 70
* Expression and phenotypic data were obtained from ArrayExpress under accessions: E-
TABM-305, Number of individuals with matching phenotypic data per study when
obtained. (A) Data of IFB was measured in two batches. This figure indicates the total
number of individuals before preprocessing or removal of duplicates across batches. (B) A
small batch was detected and all samples belonging to it were removed. Statistics
computed after preprocessing.
Limited overlap of age-associated genes between studies within the
compendium
The most straightforward method for an integrative analysis across
datasets is to first compute the age-association genes per dataset and
subsequently inspect the overlap of significant results. A linear model
adjusted for gender yielded between 111 (1.2%) and 1,103 (12.2%)
significantly age-associated genes per dataset (Bonferroni correction, α ≤
0.05), of which 26 genes were significantly associated with age in all four
datasets (Figure 1 and Table S2). These results confirmed the high
discrepancy between lists of age-associated genes previously reported in
literature, though now observed in equal or similar tissues (5;6).
Rank-based integration of age-associated genes improves
consistency between studies
As repeatedly applied cutoffs across multiple heterogeneous datasets may
lead to high false exclusion rates of age-associated genes, we investigated
whether age-association rankings were consistently high across datasets
by applying a rank integration approach (5;22). From the 9,047 genes
present in the compendium, 247 consistently showed highly ranked
differential expressions with age across the four datasets, of which 195
remained significant after permutation tests (both at FDR<=0.05). Out of
these 195 genes, 128 (65.6%) showed decreased and 67 (34.4%) showed
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increased expression levels with age. The top 25 genes with increased and
decreased expression are displayed in Table 2 and Table 3 respectively
and include many of the age associated genes previously identified, like
LRNN3, LEF1, and SYT11 (23-25). Results for all 9,047 in the compendium
are provided in Table S3.
Figure 1: Significantly age-associated genes in studies of the blood compendium
A Venn analysis was performed for inspecting the overlap of the significantly age-associated
genes found within different studies. The majority of the consistently detected age-
associated genes (24 out of 26) show a decreased expression with advancing age and
include: ARH, BACH2, CCR7, ECRG4, EDAR, EPHA1, EPHX2, FAM102A, FAM134B,
FBLN2, FCGBP, FLNB, IL24, LRRN3, NELL2, NMT2, NRCAM, OXNAD1, PDE9A, PHGDH,
PIK3IP1, SIRPB2, SUSD3 and TSGA14. The remaining 2 consistently age-associated
genes showing increased expressions are ARP10 and SYT11. See Table S2 for more
details.
Functional enrichments of individual-gene analysis are not
informative for normative ageing
We next identified enriched functional groupings amongst genes
significantly associated with normative ageing using DAVID focusing on
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GO_FAT terms. Whereas the 26 genes from the overlap did not yield any
significantly enriched terms, the 195 significant genes obtained with the
rank integration approach yielded 11 significant enriched groupings when
run at default settings (Table S4 and S5 respectively). Interestingly,
enriched terms include “Glycosylation site:N-linked” (p=6.1×10-5, Benjamini
corrected), previously linked to the inflamm-ageing theory (26). However,
as most of the 11 identified terms are rather broadly defined, like “disulfide
bond” or “signal peptide”, little detailed knowledge is gained on potential
molecular mechanisms underlying normative ageing following the
individual-gene analysis approach.
Table 2. Top 25 genes according to the gene statistic (Ui) having increased
expression with age
Symbol GeneID p-value1 q-value1 p-value2 q-value2
GPR56 9289 5.3 × 10-09 4.8 × 10-05 1.0 × 10-06 0.0018
HF1 3075 2.3 × 10-08 8.1 × 10-05 1.0 × 10-06 0.0018
SYT11 23208 2.7 × 10-08 8.1 × 10-05 ≤ 5.0 × 10-7 0.0018
ARP10 164668 7.3 × 10-08 1.7 × 10-04 1.0 × 10-06 0.0018
B3GAT1 (CD57) 27087 1.1 × 10-07 2.0 × 10-04 3.0 × 10-06 0.0021
SLC1A7 6512 1.8 × 10-07 2.6 × 10-04 3.2 × 10-05 0.0110
IFNG 3458 5.0 × 10-07 6.4 × 10-04 1.1 × 10-05 0.0065
DSCR1L1 10231 6.1 × 10-07 6.8 × 10-04 2.0 × 10-06 0.0021
ARK5 9891 7.9 × 10-07 7.9 × 10-04 3.0 × 10-06 0.0021
PIG13 81563 9.3 × 10-07 8.8 × 10-04 1.0 × 10-06 0.0018
SPUVE 11098 1.1 × 10-06 8.8 × 10-04 1.2 × 10-05 0.0067
PDGFRB 5159 1.2 × 10-06 8.8 × 10-04 1.5 × 10-06 0.0021
EDG8 53637 1.4 × 10-06 9.4 × 10-04 7.8 × 10-05 0.015
MARLIN1 152789 1.5 × 10-06 9.4 × 10-04 5.0 × 10-06 0.0032
TGFBR3 7049 2.0 × 10-06 0.0012 2.8 × 10-05 0.011
GZMB 3002 2.4 × 10-06 0.0013 5.0 × 10-04 0.050
CX3CR1 1524 2.9 × 10-06 0.0014 2.9 × 10-05 0.011
STYK1 55359 3.3 × 10-06 0.0015 4.8 × 10-05 0.013
ADRB2 154 3.7 × 10-06 0.0016 3.0 × 10-06 0.0021
GAF1 26056 7.1 × 10-06 0.0029 7.2 × 10-05 0.015
CTSL 1514 7.7 × 10-06 0.0030 3.2 × 10-04 0.040
GFI1 2672 1.1 × 10-05 0.0040 3.0 × 10-06 0.0021
TTC38 55020 1.1 × 10-05 0.0040 7.6 × 10-05 0.015
AGPAT4 56895 1.2 × 10-05 0.0041 2.5 × 10-06 0.0021
GZMA 3001 1.4 × 10-05 0.0045 3.3 × 10-04 0.040
1p- and q-values determined using the gamma-distribution of the gene statistic, Ui , 2p- and
q-values determined using permutation of the gene statistic, Ui
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Table 3. Top 25 genes according to the gene statistic (Ui) having decreased
expression with age
Symbol GeneID p-value1 q-value1 p-value2 q-value2
LRRN3 54674 1.3 × 10-12 1.2 × 10-8 ≤ 5.0 × 10-7 3.2 × 10-4
FCGBP 8857 3.2 × 10-10 1.5 × 10-6 ≤ 5.0 × 10-7 3.2 × 10-4
CCR7 1236 1.1 × 10-9 3.2 × 10-6 ≤ 5.0 × 10-7 3.2 × 10-4
NELL2 4753 2.0 × 10-8 4.5 × 10-5 1.0 × 10-6 3.8 × 10-4
NRCAM 4897 3.1 × 10-8 5.6 × 10-5 ≤ 5.0 × 10-7 3.2 × 10-4
IGJ 3512 1.5 × 10-7 2.3 × 10-4 2.6 × 10-4 0.019
LEF1 51176 1.9 × 10-7 2.5 × 10-4 ≤ 5.0 × 10-7 3.2 × 10-4
FAM134B 54463 2.2 × 10-7 2.5 × 10-4 ≤ 5.0 × 10-7 3.2 × 10-4
PACAP 51237 2.5 × 10-7 2.5 × 10-4 1.5 × 10-6 4.8 × 10-4
ITM2C 81618 2.8 × 10-7 2.5 × 10-4 3.5 × 10-6 8.1 × 10-4
PIK3IP1 113791 3.0 × 10-7 2.5 × 10-4 1.0 × 10-6 3.8 × 10-4
PDE9A 5152 5.1 × 10-7 3.8 × 10-4 1.0 × 10-6 3.8 × 10-4
BACH2 60468 6.9 × 10-7 4.8 × 10-4 1.0 × 10-6 3.8 × 10-4
FLJ12895 65982 9.5 × 10-7 6.0 × 10-4 1.5 × 10-6 4.8 × 10-4
FAM102A 399665 1.1 × 10-6 6.0 × 10-4 ≤ 5.0 × 10-7 3.2 × 10-4
FBLN2 2199 1.1 × 10-6 6.0 × 10-4 ≤ 5.0 × 10-7 3.2 × 10-4
FLNB 2317 1.2 × 10-6 6.0 × 10-4 ≤ 5.0 × 10-7 3.2 × 10-4
APEG1 10290 1.2 × 10-6 6.0 × 10-4 1.0 × 10-6 3.8 × 10-4
EPHX2 2053 1.3 × 10-6 6.0 × 10-4 1.5 × 10-6 4.8 × 10-4
TNFRSF17 608 1.3 × 10-6 6.1 × 10-4 1.2 × 10-4 0.011
MYC 4609 1.6 × 10-6 6.6 × 10-4 3.5 × 10-6 8.1 × 10-4
NT5E 4907 1.7 × 10-6 6.6 × 10-4 1.0 × 10-6 3.8 × 10-4
TOSO 9214 1.7 × 10-6 6.6 × 10-4 1.0 × 10-6 3.8 × 10-4
ARH 26119 3.2 × 10-6 0.0012 2.0 × 10-6 6.2 × 10-4
OXNAD1 92106 3.3 × 10-6 0.0012 ≤ 5.0 × 10-7 3.2 × 10-4
1p- and q-values determined using the gamma-distribution of the gene statistic, Ui , 2p- and
q-values determined using permutation of the gene statistic, Ui
A novel integrative network approach for detecting consistent co-
expressed PPI modules
To improve robustness against noise and increase power, we used a novel
integrative network-based approach to explore functional age-associated
groupings of genes. The proposed approach detects consistently co-
expressed PPI modules across multiple datasets (for details see Materials
& Methods, and Supplemental Methods). Using the four transcriptomic
datasets mapped onto the PPI network, we detected a total of 162
consistently co-expressed PPI modules ranging in size from 2 to 37 genes
(see Figure S6 for a complete overview). The following steps in our
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analysis were limited to the subset of 27 co-expressed PPI modules
counting at least 5 genes. Application of DAVID yielded significant
functional enrichments for 19 out of the 27 identified co-expressed PPI
modules (Table S7), suggesting that the applied approach grouped genes
according to plausible biological functions.
Age-associated co-expressed PPI modules point towards T-cell
activation
To test whether transcriptional changes of the 27 identified modules
associate with chronological age, an expression profile for each module
was constructed by determining the mean expression of the genes within a
detected co-expressed PPI module per individual. As with the individual-
gene analysis, we proceeded by computing the associations of the module
expressions with age while adjusting for gender for each dataset
separately. Only one module (Figure 2A), enriched for “T-cell activation”,
was significantly associated with age in each of the four datasets of the
compendium. This module A contains genes commonly employed as
markers for assessing the differentiation status of T-cell lineages, such as
CCR7, CD28 and TNFRSF7 (CD27). A fixed-effect meta-analysis on the
expression of the different modules across the datasets showed again that
the “T-cell activation” module was most significantly associated with age
(Bonferroni corrected p=3.5×10-38). The consistent age association of the
“T-cell activation” module, however, raises the concern that the identified
modules reflect age-related changes in the proportions of cell populations
in blood, as previously reported (27), rather than changes in gene
expression.
T-cell activation module expression marks blood lymphocyte counts
To investigate the relation between the expression of the “T-cell activation”
module and the proportions of blood cell populations, for which we have no
data in the compendium, we revisited a transcriptomic dataset on
peripheral blood measured in the Leiden Longevity Study (LLS) (25)
(Supplemental Methods). Using the expression data of 50 middle-aged and
50 ninety-year-old individuals, we first confirmed the association with age of
the expression of the “T-cell activation” module (p=3.7×10-5), and
subsequently observed a significant correlation between the expression of
the “T-cell activation” module and lymphocyte counts (R2=0.603, p=1.9×10-
10). These findings suggest that the previously observed age associations in
the blood compendium are most probably confounded by the age-
associated decline in lymphocyte counts. We also conclude that the
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expression of the “T-cell activation” module could serve as a proxy for the
age-associated decline in lymphocyte counts in the compendium.
Figure 2: Overview main results of the integrative network-based approach
Panel 1: Overlap of the PPI network and cluster analysis of the transcriptomic data reveals
27 modules, 15 are significantly associated with age, 9 are significantly associated with age
when corrected for the “T-cell activation” module expression and the 5 most robust findings
are found in the overlap. Panel 2: The co-expressed PPI module that is enriched for “T-cell
activation”. Panel 3: B-F: 5 co-expressed PPI modules with expressions robustly associated
with age. B, C and F: modules enriched for “Translational elongation”, “Cytolysis” and “DNA
metabolic process”, respectively. Node’s shape and color reflect the results of the individual
gene statistic (Ui). The red and green colors denote a correlating or anti-correlating
relationship of gene expression with age, respectively. The intensity of the coloring indicates
the significance of the gamma distributed transformed rank product statistics. Nodes marked
by a thick bordering or a hexagon shaped bordering represent genes with FDR adjusted p-
values ≤ 0.05 for respectively the analytical and permutation-based approach.
Five co-expressed PPI modules associate with age independent of T-
cell activation
Based on these findings we adapted the fixed-effect meta-analysis to re-
analyse the 27 modules in the compendium while adjusting for gender as
well as the expression of the “T-cell activation” module. This revealed nine
modules significantly associated with chronological age, of which five also
showed a significant association without adjusting for “T-cell activation”
(Figure 2 B-F). These five modules thus exhibit the most robust expression
changes with age and include: 1) a large consistently down-regulated
ribosomal module (p=9.4×10-19), enriched for “Translational elongation”
(p=4.5×10-46); 2) an up-regulated module containing amongst others
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several granzymes and the perforin gene (p=2.9×10-24), enriched for
“Cytolysis” (p=9.4×10-05); and, 3) a down-regulated module containing the
PARP1 (ADPRT) gene (p=3.1×10-39) enriched for “DNA metabolic process”
(p=0.0036). The two remaining modules were both down-regulated with
advancing age and lacked any significant functional enrichments (Figure 2E
and 2F; p=3.9×10-11 and p=2.5×10-18, respectively).
Replication of Co-Expressed PPI Modules as Robust Markers for
Ageing
We conducted an independent replication study of the identified network
modules as robust markers for chronological age using gene expression
data from the Netherlands Twin Register and Netherlands Study of
Depression and Anxiety (NTR & NESDA) consortium (N=3,535) (28)
assayed on individuals within age range 17-79 years (Supplemental
Methods). An association analysis between the mean expression of a
module and chronological age, adjusted for sex and the mean expression
of the “T-cell activation” module, yielded significant results for four out of
the five identified modules, all with directions corresponding to those found
in the compendium (Table S8). These results emphasize the robustness of
the findings produced by our approach and confirm that the mean module
expression in whole blood of module B, C, E and F may be considered as
robust markers of chronological age.
Co-expressed PPI modules are enriched for GenAge longevity and
ageing genes
As a validation of the identified modules, we computed whether ageing-
related genes stored by GenAge (13), a database providing a
comprehensive overview of ageing-related genes in humans and model
systems, were enriched within modules A-F (Figure 2). Whereas module A
was supported by human derived annotations only (OR=12.1, 95% CI 2.88-
39.2, p=6.95×10-4), module B was solely based on knowledge derived from
model organisms (OR=16.9, 95% CI 7.26-39.1, p=2.52×10-10, Table S9).
Modules D, E and F had annotations balanced over both sources and
therefore the significance of the joint enrichment was assessed by using a
resampling approach (Supplemental Methods), which yielded significant
enrichments for modules E (p=0.016) and F (p=0.0029). These findings
provide additional evidence that the joint expression of these modules may



























Figure 3: Expression of ASF1A associates with prospective survival in nonagenarians
High expression of ASF1A confers a prospective survival benefit at old age.
Module F associates with prospective survival at old age
To investigate whether the identified modules could potentially serve as
biomarkers, we studied the microarray data assayed on 50 nonagenarian
individuals from the Leiden Longevity Study (25). A left truncated Cox
proportional hazard model adjusted for sex and cell counts indicates that
the mean expression of module F associates with prospective survival
beyond the age of 90 years (N=50, Ndeath=45, HR=0.265, 95% CI 0.12-0.57,
p=0.001). By showing that module F associates with prospective survival at
old age, we illustrate its potential biological relevance.
Interestingly, the ASF1A gene is part of module F and has previously been
identified by our group as one of the genes that was differentially expressed
in blood of members of long-lived families as compared to similarly aged
controls at middle age (25). To confirm that the expression of the ASF1A
gene in module F also associates with prospective survival at old age, we
analysed the gene expression of ASF1A measured with RT-qPCR in 74
nonagenarians from the Leiden Longevity Study (of which 24 overlapped
with the micro-array experiment) for association with prospective survival.
Since we observe a similar association (Ndeath=64, HR=0.54, 95% CI 0.34-
0.85, p=0.008, Figure 3), these results indicate that modules, of which the
expression in blood is consistently associated with chronological age
across various datasets, may associate with variation in lifespan, and
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therefore provide valid gene targets for studying relevant biological
endpoints in human ageing.
Discussion
Age associated changes in gene expression may provide meaningful leads
to pathways affected by and involved in ageing, however, are in general
difficult to detect consistently (5). Therefore, we constructed the largest
compendium of human whole blood expression studies (19-21) comprising
2,539 individuals on which we performed a novel integrative network-based
analysis. This yielded fifteen consistently age-associated co-expressed PPI
modules. Because the most significant age-associated module appeared to
correlate with lymphocyte cell counts in an independent gene expression
dataset, the expression of this module, enriched for “T-cell activation”, was
subsequently used as a proxy for possible confounding shifts in the
distribution of lymphocyte subsets. This enabled the identification of five
age-associated modules (Figure 2 Panel I and IV), including three modules
enriched for “Translational elongation”, “Cytolysis” and “DNA metabolic
process” (Figure 2B-D). Replication in an independent cohort confirmed
these findings for four out of five modules (Figure 2B, C, E and F),
underpinning the robustness of the proposed approach. The enrichments
against a database for ageing-related genes (Figure 2B, E & F) emphasize
the relevance of these biological findings for ageing research, which is even
further substantiated by the fact that the mean expression of module F
associates with prospective survival at old age.
Mitochondrion-related ageing
Two of the identified modules are down-regulated with age and seem to be
related to the mitochondrion, though lacking any significant functional
enrichment (Figure 2E-F). Despite the absence of functional enrichments,
both modules were significantly enriched for ageing-related genes, as
defined by GenAge, implying that known age-related single genes can be
put into a novel biological perspective by our network approach.
Module (Figure 2F) contains several mitochondrial factors and enzymes,
like, for instance, the mitochondrial transcription termination factor MTERF,
the ACADM enzyme used for fatty acid metabolism, or the mitochondrial
tRNA synthetase IARS2, whose homolog was shown to increase lifespan
upon disruption in worms (29). This module also includes several genes
previously associated with age or age-associated diseases such as the
mitotic checkpoint protein BUB3, previously associated with accelerated
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ageing in mice (30), and the cell-cycle checkpoint protein APPBP1 found in
increased quantities in the brain affected by Alzheimer’s disease (31). This
broad range of gene characteristics composing the module could be
explained by the fact that the functionality of mitochondria is not confined to
cellular energy metabolism alone, but also seems to make up an integral
part of multiple cell signaling cascades including cell-cycle control and cell
death (32).
Interestingly, module F also includes the ASF1A histone chaperone of
which we previously have shown that its expression associates with familial
longevity in the Leiden Longevity Study (25). We revisited the RT-qPCR
data assayed on 74 nonagenarians and now show that the expression of
ASF1A also associates with prospective survival. This result illustrates that
modules, of which the expression in blood is consistently associated with
chronological age across various datasets, may associate with variation in
lifespan, and therefore provide valid gene targets for studying relevant
biological endpoints in human ageing.
The other mitochondrion-related module (Figure 2E) contains the heat
shock protein HSPCA (HSP90) and the mitochondrial receptor TOMM20,
which jointly play a central role in translocating pre-proteins into the
mitochondria (33). They seem to be consistently co-expressed in blood with
EIF4A2, a eukaryotic translation initiation factor and DDX18, an ATP
dependent RNA helicase, of which the worm homologs were shown to
extent lifespan upon disruption (29;34). To summarize, this module seems
to relate to ageing by influencing protein translation and mitochondrial
translocation efficiency.
Age-associated limitation of protein synthesis
One of the identified modules predominantly consisted of ribosomal
proteins and translation elongation factors comprising part of the ribosomal
complex (Figure 2B). The module was significantly enriched for
“Translational elongation” and for previous findings in model organisms with
respect to ageing and longevity. In addition, the module was down-
regulated with advancing age fitting previous observations of the ageing
blood transcriptome (23-25), which could be interpreted as an attempt of
the cell to limit global protein synthesis in response to stress arising from
damage accumulating throughout lifespan (35). Whether caused by
response to stress or other factors, the change in protein translation may
be ascribed to the mTORC1 complex (36). This complex modulates cellular
growth and metabolisms by determining the balance between protein
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synthesis and degradation in response to nutrient availability. Inhibition of
mTOR signaling through the mTORC1 complex not only inhibits protein
synthesis, but also has been shown to positively affect the lifespan in
various invertebrates and mammals (37). Moreover, human blood
transcriptome studies showed that the gene expression of mTOR pathway
is down-regulated with chronological age (23;38) and is even associated
with human familial longevity (25). Hence, a consistently down-regulated
ribosomal module with advancing age corresponds with the age-associated
demise of mTOR signaling. Although it is well established that mTOR
signaling links to both lifespan regulation and “Translational elongation”, it
remains to be determined whether down-regulation of “Translational
elongation” is causal for human ageing.
WRN related cell-cycle checkpoint on DNA integrity
A module down-regulated with age and enriched for “DNA metabolic
process” identified in the compendium could not be replicated in the NTR &
NESDA cohort (Figure 2D). Interestingly, this module contains the PARP1
(ADPRT) gene, which directly binds to WRN to induce apoptosis upon
oxidative stress induced DNA damage and is as such a prime suspect for
Werner syndrome (39), a premature ageing disease. Furthermore, the
activity of the Parp1 protein in mononuclear cells has previously been
shown to positively correlate with the species-specific lifespan across 13
mammalian species (40). Taken together, findings in the compendium
suggest that the lowered transcription rate of PARP1 negatively affects
DNA integrity and thus life span, though more experiments are required to
investigate this hypothesis.
Age-associated shifts in T-cell composition
Another identified module is up-regulated with age and enriched for
“Cytolysis” (Figure 2C). It contains several genes used to dispatch virus-
infected cells and may reflect the decreased competence for fighting
infections in an early stage, caused by an age-related deterioration of the
immune system, known as immuno-senescence (41). We can, however,
not rule out that the age-associated expression of GZMA, GZMB and PRF1
that are part of this module point to an age-associated shift in T-cytotoxic
cells (27;42).
Though identified co-regulated PPI modules may show extensive
correlation with confounding factors, we should be careful to dismiss
modules as such only. For instance the “T-cell activation” module (Figure
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2A), which is down-regulated with age, also contained BNIP3, an inhibitor
of the mTORC1 complex shown to modulate lifespan in worms, flies and
mice (37); and FOXO1, also displaying an intricate interplay with both
complexes of mTOR (36), and shown to extent lifespan in various
invertebrates (43). Additionally, human mTOR signaling may play a central
role in orchestrating T-cell maturation and T-cell fate decisions (44), and
could thereby also explain the age-associated decline in lymphocytes as
marked by the “T-cell activation” module. Taken together, these examples
illustrate that what is confounding the analysis of the blood transcriptome
for molecular mechanisms associated to ageing is subjective to debate and
might even not be possible to determine given the complex interplay
between the different biological levels on which ageing acts.
The proposed network approach into perspective
Network analyses have clear advantages over individual gene analyses, as
they enable the incorporation of useful prior knowledge, which can be
exploited for improving the robustness of the analysis and the subsequent
interpretation of the results. The improved robustness of the network
approach over the individual-gene analyses was reflected by the low
mutual overlap between the individual gene results (Figure 1) as opposed
to the high concordance between the results obtained in the compendium
and replication cohort. The advantages for the interpretation were clearly
illustrated by the modest insights gained from the two different strategies
for individual gene analysis (“Glycosylation site:N-linked”), as opposed to
the detailed gene modules produced by our approach that can serve as a
novel basis for further investigation into the molecular mechanisms
underlying normative ageing. Moreover, our approach is capable of
inferring biological coherence from the data, without the explicit need of
predefined functional groupings, as was shown by the enrichments of the
identified modules found for genes within the GenAge database.
Though the analysis benefits from incorporating Protein-Protein Interaction
data, the type and source clearly affect the results. To be as inclusive as
possible for types and sources of PPI data, we have chosen to employ data
obtained from the STRING database, which systematically collects and
integrates interaction data derived from various sources for predicting
functional relations between gene pairs. This choice results in a vast and
comprehensive source of data. However, STRING data is not confined to
physical interactions, as is the case with for instance IntAct
(http://www.ebi.ac.uk/intact/) and unlike KEGG
(http://www.genome.jp/kegg/), STRING data is not manually curated. For
network inference, a trade-off exists between the sparsity and the quality of
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the employed gene-gene interactions. We made use of a threshold on the
quality of reported interactions that are created by STRING by
benchmarking the different interaction data sources to KEGG. Varying this
threshold would affect the size and nature of the obtained co-expressed
PPI modules. As the threshold determines the scale of the analysis, an
interesting observation is that the results can be confounded to parts of the
global network that do not necessarily overlap with the predefined known
biological pathways. The latter is illustrated by the fact that some of our
modules are not enriched for biological pathways and could basically be
valued as a strong point of our data-driven approach.
Conclusion
By applying a network approach to multiple blood transcriptomics datasets
we have identified five co-expression PPI modules that associate with
chronological age in humans. The confirmation of most of our findings in an
independent dataset underpins the robustness of our approach. The
modules are significantly enriched for ageing-related genes as curated by
the GenAge database. This implies that these age-related single genes, in
the absence of a clear understanding of their joint functioning belong to a
network that finds its basis in protein-protein interactions and will serve as
novel input for ageing research. We reinforced the biological relevance of
one of the modules by showing that it associates with prospective survival
beyond 90 years in humans as was observed also for a single known age-
related gene in this module (ASF1A). These findings collectively warrant
further investigations into the biological function of module F and its
potential as a biomarker for healthy ageing and human longevity.
Materials & Methods
Creating the blood expression compendium
Analyses were based on gene expression data derived from individuals
enrolled in three large cohort studies for which details on sample inclusion
and employed expression protocols are provided in depth in the original
publications (19-21). Gene expression and accompanying phenotypic data
was obtained from either the original authors or from the public data
repository ArrayExpress. Data quality was stringently re-examined per
dataset for the presence of outlier samples or outlier measurements and
annotated to a common annotation standard (EntrezGeneID). A detailed
description of the data processing and an overview on the resulting sample




A rank integration approach (5;22) was used to identify genes consistently
up- or down-regulated with age across multiple heterogeneous datasets.
This type of meta-analysis integrates individual-gene statistics across
datasets, by ranking the statistics per dataset and assessing the
significance of the observed combined ranking using a Gamma distribution
(45), or through permutation. Gender adjusted linear fits between
expression and age were used as gene statistics that were obtained by
fitting the following multivariate linear regression model:
ijkjkikjkikikijk AGE   210 (model 1)
where Eijk is the gene expression of gene i for individual j in the kth dataset,
with 1 ≤ i ≤ M, 1 ≤ j ≤ N and 1 ≤ k ≤ K, where Gjk and Ajk are the gender and
age of individual j in the kth dataset respectively and where εijk is the
residual error of gene i for individual j in the kth dataset. Genes were ranked
on the regression coefficients between age and expression, β2ik. The rank
position of gene i in dataset k is denoted by Rik. Ranks across the datasets
were integrated per gene by computing rank product statistics as previously









The significance of the observed rank products was assessed in two ways.
Following Koziol, rank products RPi were transformed using:
)1log(  MKRPU ii (model 3)
The significance of the U-statistics could be assessed by employing the
Gamma distribution (45) or through permutation as described in the
Supplemental Methods.
Extracting co-expressed PPI modules
Genes were mapped to the Protein-Protein Interaction network (STRING
v9.0), which yielded a compendium of about 81.3% of the initial set of
genes (N = 7,353) in the compendium. Ranked co-expression matrices
were computed for each dataset separately by computing a correlation
matrix composed of first order partial correlations between all pairs of
genes adjusted for sex and subsequently assigned a rank to each of them.
A higher positive correlation resulted in a higher ranking. The ranked co-
expression matrices were integrated by computing rank products as in the
section on individual-gene analysis. The resulting gene-gene rank product
matrix together with the PPI network matrix was subsequently used as
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input for the method that identifies co-expressed PPI sub-networks as
described in Van den Akker et al. (17), see also Supplemental Methods. In
short, a cluster analysis on the gene-gene rank product matrix yielded co-
expressed modules of genes. High confidence co-expressed genes were
obtained by applying a threshold on the gene-gene rank product matrix. We
obtained co-expressed PPI modules by intersecting the co-expressed
gene-modules with the PPI network matrix. Co-expressed PPI modules
were subsequently visualized using Cytoscape (Supplemental Methods).
Fixed effect meta-analysis on module expressions across the blood
compendium
Gene expression data was summarized per co-expressed PPI module for
each dataset separately by taking the mean expression per individual over
all genes in the module, resulting in a module expression for each dataset.
Associations with age were tested for each co-expressed PPI module, by
performing a fixed effect meta-analysis across the four datasets using a
first order partial correlation between age and the module expression,
computed with the controlling variable gender to adjust for sex differences.














where rakmk is the correlation between age and the expression of the n
th
module across individuals of the kth dataset;rakgk is the correlation between
age and gender across individuals of the kth dataset and rmkgk is the
correlation between expression of the mth module and gender of individuals
in the kth dataset. To correct for multiple controlling variables, higher order
partial correlations were computed by repeatedly computing first order
partial correlations as described above. The function metacor of R package
meta was used for integrating and testing the meta correlation statistic
between age and module expression across the four datasets using default
settings. Modules with significant correlations (bonferroni corrected p-value
≤ 0.05) were considered age dependent.
Acknowledgements
The research leading to these results has received funding from the
Medical Delta (COMO) and the European Union's Seventh Framework
Programme (FP7/2007-2011) IDEAL-ageing under grant agreement n°
Chapter 7
134
259679. This study was supported by a grant from the Innovation-Oriented
Research Program on Genomics (SenterNovem IGE05007), the Centre for
Medical Systems Biology, the Netherlands Consortium for Healthy Ageing
(Grant 050-060-810), all in the framework of the Netherlands Genomics
Initiative, Netherlands Organization for Scientific Research (NWO) and by
Unilever Colworth. The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
The authors thank the participants of the SAFHS, IFB, DILGOM, LLS, NTR
and NESDA studies for their contributions. Furthermore, we would like to
thank Michael Inouye for helpful discussions.
References
(1) Oeppen J, Vaupel JW. Demography. Broken limits to life expectancy. Science 2002
May 10;296(5570):1029-31.
(2) Hitt R, Young-Xu Y, Silver M, Perls T. Centenarians: the older you get, the healthier
you have been. Lancet 1999 August 21;354(9179):652.
(3) Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB.
Prediction of coronary heart disease using risk factor categories. Circulation 1998
May 12;97(18):1837-47.
(4) Kirkwood TB. Evolution of ageing. Nature 1977 November 24;270(5635):301-4.
(5) de Magalhaes JP, Curado J, Church GM. Meta-analysis of age-related gene
expression profiles identifies common signatures of aging. Bioinformatics 2009
April 1;25(7):875-81.
(6) Passtoors WM, Beekman M, Gunn D, Boer JM, Heijmans BT, Westendorp RG et
al. Genomic studies in ageing research: the need to integrate genetic and gene
expression approaches. J Intern Med 2008 February;263(2):153-66.
(7) Partridge L, Gems D. Mechanisms of ageing: public or private? Nat Rev Genet
2002 March;3(3):165-75.
(8) Zahn JM, Sonu R, Vogel H, Crane E, Mazan-Mamczarz K, Rabkin R et al.
Transcriptional profiling of aging in human muscle reveals a common aging
signature. PLoS Genet 2006 July;2(7):e115.
(9) Zhang B, Horvath S. A general framework for weighted gene co-expression
network analysis. Stat Appl Genet Mol Biol 2005;4:Article17.
(10) Southworth LK, Owen AB, Kim SK. Aging mice show a decreasing correlation of
gene expression within genetic modules. PLoS Genet 2009
December;5(12):e1000776.
(11) Stuart JM, Segal E, Koller D, Kim SK. A gene-coexpression network for global
discovery of conserved genetic modules. Science 2003 October 10;302(5643):249-
55.
(12) Bell R, Hubbard A, Chettier R, Chen D, Miller JP, Kapahi P et al. A human protein
interaction network shows conservation of aging processes between human and
invertebrate species. PLoS Genet 2009 March;5(3):e1000414.
Chapter 7
135
(13) de Magalhaes JP, Toussaint O. GenAge: a genomic and proteomic network map of
human ageing. FEBS Lett 2004 July 30;571(1-3):243-7.
(14) Tacutu R, Shore DE, Budovsky A, de Magalhaes JP, Ruvkun G, Fraifeld VE et al.
Prediction of C. elegans longevity genes by human and worm longevity networks.
PLoS One 2012;7(10):e48282.
(15) Witten TM, Bonchev D. Predicting aging/longevity-related genes in the nematode
Caenorhabditis elegans. Chem Biodivers 2007 November;4(11):2639-55.
(16) Xue H, Xian B, Dong D, Xia K, Zhu S, Zhang Z et al. A modular network model of
aging. Mol Syst Biol 2007;3:147.
(17) van den Akker EB, Verbruggen B, Heijmans BT, Beekman M, Kok JN, Slagboom
PE et al. Integrating protein-protein interaction networks with gene-gene co-
expression networks improves gene signatures for classifying breast cancer
metastasis. J Integr Bioinform 2011;8(2):188.
(18) Marbach D, Costello JC, Kuffner R, Vega NM, Prill RJ, Camacho DM et al. Wisdom
of crowds for robust gene network inference. Nat Methods 2012 August;9(8):796-
804.
(19) Emilsson V, Thorleifsson G, Zhang B, Leonardson AS, Zink F, Zhu J et al. Genetics
of gene expression and its effect on disease. Nature 2008 March
27;452(7186):423-8.
(20) Inouye M, Silander K, Hamalainen E, Salomaa V, Harald K, Jousilahti P et al. An
immune response network associated with blood lipid levels. PLoS Genet 2010
September;6(9).
(21) Goring HH, Curran JE, Johnson MP, Dyer TD, Charlesworth J, Cole SA et al.
Discovery of expression QTLs using large-scale transcriptional profiling in human
lymphocytes. Nat Genet 2007 October;39(10):1208-16.
(22) Breitling R, Armengaud P, Amtmann A, Herzyk P. Rank products: a simple, yet
powerful, new method to detect differentially regulated genes in replicated
microarray experiments. FEBS Lett 2004 August 27;573(1-3):83-92.
(23) Harries LW, Hernandez D, Henley W, Wood AR, Holly AC, Bradley-Smith RM et al.
Human aging is characterized by focused changes in gene expression and
deregulation of alternative splicing. Aging Cell 2011 October;10(5):868-78.
(24) Hong MG, Myers AJ, Magnusson PK, Prince JA. Transcriptome-wide assessment
of human brain and lymphocyte senescence. PLoS One 2008;3(8):e3024.
(25) Passtoors WM, Boer JM, Goeman JJ, van den Akker EB, Deelen J, Zwaan BJ et
al. Transcriptional Profiling of Human Familial Longevity Indicates a Role for
ASF1A and IL7R. PLoS One 2012;7(1):e27759.
(26) Dall'olio F, Vanhooren V, Chen CC, Slagboom PE, Wuhrer M, Franceschi C. N-
glycomic biomarkers of biological aging and longevity: A link with inflammaging.
Ageing Res Rev 2012 February 14.
(27) Derhovanessian E, Maier AB, Beck R, Jahn G, Hahnel K, Slagboom PE et al.
Hallmark features of immunosenescence are absent in familial longevity. J
Immunol 2010 October 15;185(8):4618-24.
(28) Boomsma DI, Willemsen G, Sullivan PF, Heutink P, Meijer P, Sondervan D et al.
Genome-wide association of major depression: description of samples for the GAIN
Chapter 7
136
Major Depressive Disorder Study: NTR and NESDA biobank projects. Eur J Hum
Genet 2008 March;16(3):335-42.
(29) Smith ED, Tsuchiya M, Fox LA, Dang N, Hu D, Kerr EO et al. Quantitative evidence
for conserved longevity pathways between divergent eukaryotic species. Genome
Res 2008 April;18(4):564-70.
(30) Baker DJ, Jeganathan KB, Malureanu L, Perez-Terzic C, Terzic A, van Deursen
JM. Early aging-associated phenotypes in Bub3/Rae1 haploinsufficient mice. J Cell
Biol 2006 February 13;172(4):529-40.
(31) Chen Y, Liu W, McPhie DL, Hassinger L, Neve RL. APP-BP1 mediates APP-
induced apoptosis and DNA synthesis and is increased in Alzheimer's disease
brain. J Cell Biol 2003 October 13;163(1):27-33.
(32) McBride HM, Neuspiel M, Wasiak S. Mitochondria: more than just a powerhouse.
Curr Biol 2006 July 25;16(14):R551-R560.
(33) Fan AC, Kozlov G, Hoegl A, Marcellus RC, Wong MJ, Gehring K et al. Interaction
between the human mitochondrial import receptors Tom20 and Tom70 in vitro
suggests a chaperone displacement mechanism. J Biol Chem 2011 September
16;286(37):32208-19.
(34) Curran SP, Ruvkun G. Lifespan regulation by evolutionarily conserved genes
essential for viability. PLoS Genet 2007 April 6;3(4):e56.
(35) Clemens MJ. Initiation factor eIF2 alpha phosphorylation in stress responses and
apoptosis. Prog Mol Subcell Biol 2001;27:57-89.
(36) Laplante M, Sabatini DM. mTOR signaling at a glance. J Cell Sci 2009 October
15;122(Pt 20):3589-94.
(37) Johnson SC, Rabinovitch PS, Kaeberlein M. mTOR is a key modulator of ageing
and age-related disease. Nature 2013 January 17;493(7432):338-45.
(38) Passtoors WM, Beekman M, Deelen J, van der Breggen R, Maier AB, Guigas B et
al. Gene expression analysis of mTOR pathway: association with human longevity.
Aging Cell 2013 February;12(1):24-31.
(39) von KC, Harrigan JA, May A, Opresko PL, Dawut L, Cheng WH et al. Central role
for the Werner syndrome protein/poly(ADP-ribose) polymerase 1 complex in the
poly(ADP-ribosyl)ation pathway after DNA damage. Mol Cell Biol 2003
December;23(23):8601-13.
(40) Grube K, Burkle A. Poly(ADP-ribose) polymerase activity in mononuclear
leukocytes of 13 mammalian species correlates with species-specific life span.
Proc Natl Acad Sci U S A 1992 December 15;89(24):11759-63.
(41) Pawelec G, Solana R. Immunosenescence. Immunol Today 1997
November;18(11):514-6.
(42) Napoli AM, Fast LD, Gardiner F, Nevola M, Machan JT. Increased granzyme levels
in cytotoxic T lymphocytes are associated with disease severity in emergency
department patients with severe sepsis. Shock 2012 March;37(3):257-62.
(43) Calnan DR, Brunet A. The FoxO code. Oncogene 2008 April 7;27(16):2276-88.




(45) Koziol JA. Comments on the rank product method for analyzing replicated
experiments. FEBS Lett 2010 March 5;584(5):941-4.
Supplementary information
Supplementary figure and tables can be found online:
http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111/acel.12160
Text S1 Supplemental Methods
Table S2 Results of 26 significantly age-associated genes in all four datasets
Table S3 Results of the individual-gene rank product test
Table S4 Enrichment analyses on the 26 significantly age-associated genes in all
four datasets
Table S5 Enrichment analyses on 195 significant genes obtained with an individual-
gene rank product test
Figure S6 Overview of detected consistently co-expressed PPI modules.
Table S7 Gene enrichment analyses using DAVID on the 27 consistently co-
expressed PPI modules counting at least 5 genes
Table S8 Replication of the identified modules as robust markers of chronological
age in the NTR & NESDA cohort.






The aim of this thesis was to identify in the human blood transcriptome,
relevant pathways and potential biomarker profiles that associate with
chronological age and discriminate between ‘healthy agers’ from long-lived
families and normative ageing controls. Such profiles may harbour
determinants of the biological ageing rate.
We studied genome-wide gene expression profiles in blood of members of
the Leiden Longevity Study (LLS) and replicated our findings by extended
sampling within the unique LLS cohort. The findings of the exploratory
analysis prompted us to investigate multiple genes in the IL7R and MTOR
pathways for association with familial longevity. The results obtained by
examining mRNA from blood samples brought us to study mTOR protein
levels and signalling in primary skin fibroblasts from the corresponding
donors in the LLS. Finally, to discover robust, biologically relevant gene
networks as markers of chronological ageing in larger sample sizes, we
performed an explorative network-based meta-analysis on large publicly
available transcriptomic datasets.
Main findings
Chapter 3 describes the genome-wide explorative transcriptomic study
performed within the Leiden Longevity Study cohort. The explorative study
resulted in 360 probes (259 genes) to be associated with familial longevity,
out of 2,953 probes (1,853 genes) differentially expressed in
nonagenarians and middle-aged controls. We selected 22 genes from the
259 for follow up studies by using a text mining tool applying criteria that
genes have known connections with cellular ageing. In Chapter 3 therefore
we only investigated a fraction of the total number of potential
transcriptomics biomarkers associated with healthy ageing, which will be
described later in this discussion.
The microarray study showed that reduced expression of ASF1A and IL7R
marked both chronological ageing and familial longevity in middle-age. The
follow up experiments for ASF1A included RNAi experiments in c. elegans
(David Gems, personal communication); no homologue gene is present in
worms for IL7R. Two homologues of the ASF1A gene, asfl-1 and unc-85
were knocked down using RNAi in young adult worms and survival was
measured in both the RNAi worms and the controls. Though
downregulation of asfl-1 resulted in a small significant increase in lifespan,
the combination of knocking down both asfl-1 and unc-85 did not result in




To then expand the study of the IL7R pathway in humans, we measured
expression levels of six genes interacting with IL7R according to the
STRING software and tested this network for association with familial
longevity in the LLS (Chapter 4). We found several genes in the network to
be associated with familial longevity in middle-age indeed, independent of
the difference in blood cell proportion and disease prevalence between
offspring of nonagenarians and their partners. Hence we conclude that
expression levels of IL7R in blood may represent a marker of biological age
(detecting differences between healthy and normative ageing). Subsequent
measurement in the future on the complete LLS and additional cohort
studies will enable an extensive survival analysis to be performed to
indicate whether expression levels of these genes mark mortality risks and
to test for the association with morbidity. The same analysis steps have
revealed for example the leucocyte telomere length as a biomarker of
ageing (1;2).
MTOR signalling has been implicated extensively in lifespan regulation in
studies of animal models and in disease prevalence and progression in
both animal models and humans. In our study, MTOR gene expression was
part of the “normative ageing-signature” resulting from the explorative
analysis (Chapter 3). Therefore we further investigated mTOR signalling in
the Leiden Longevity Study (Chapter 5). Expression of genes belonging to
both complexes mTORC1 and mTORC2 or downstream thereof showed
association with chronological age in the LLS. The observed relation of
decreased transcriptional activity of mTORC1 and lifespan extension
described in the literature on animal models was in agreement with the low
expression level in the human longevity families. The increased
transcriptional activity of mTORC2 we observed with chronological ageing
was not described previously. For two of the genes, RPTOR and PRR5L,
belonging to respectively the mTORC1 and mTORC2 part of the pathway,
we found decreased expression to be associated with familial longevity in
middle-age, which association only for RPTOR was independent of
differences between offspring and partners in cell proportions, glucose
levels and prevalence of type 2 diabetes.
The mTOR pathway has been extensively studied in cell lines before, and
previous studies in the LLS cohort demonstrated different cellular
responses to stress in skin fibroblasts of the offspring and control groups.
We questioned whether primary fibroblasts from LLS donors would also
reflect reduced transcriptional activity of the mTOR pathway, altered activity
at the level of protein expression and whether such a cellular model would
allow further studies to link mTOR pathway genes to the metabolic
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characteristics of longevity families. Thus, as a functional follow-up of the
conclusion that gene expression of mTOR pathway genes in blood seem to
mark familial longevity, gene and protein expression of mTOR-related
genes were investigated in cultured primary skin fibroblasts of donors from
the LLS (Chapter 6). Though fibroblasts of LLS offspring of nonagenarians
and controls did show differences in cellular senescence and apoptosis
previously, we were not able to detect differential mTOR gene or protein
expression levels between these groups, neither did we observe any
correspondence of variation in expression of mTOR genes in blood and
fibroblasts of the same subjects in a group. Our main conclusion was that
mTOR signalling in blood and skin fibroblasts appear to be differentially
regulated. We included an indirect oxidative stress challenge by adding
rotenone for 3 days in the fibroblast experiments. This challenge did not
enhance any potential mTOR gene or protein expression difference in the
cells from offspring and controls. Such challenges may be tested more
extensively using different concentration and incubation time of rotenone,
as described in previous senescence and apoptosis experiments within the
LLS study (3).
Potentially suitable next approaches for functional studies include the
investigation of protein expression or downstream processes like
autophagy directly in Peripheral Blood Mononuclear Cells. Challenge tests
such as nutrient deprivation or stress induction in the fibroblast cell system
might otherwise enhance differences between the groups. Another option
would be to investigate the mTOR pathway expression and activity in other
tissues such as fat and muscle in which mTOR signalling is active. In these
tissues nutrient intake, glucose and insulin levels and exercise influence
protein synthesis, energy metabolism and glucose uptake (4), all processes
in which the mTOR pathway is involved and which play a role in biological
ageing and health.
In Chapter 7 we describe an integrative network-based approach to
discover robust markers for normative ageing combining multiple large-
scale expression studies in blood. The combination of co-expression of
genes and protein-protein interaction networks resulted in five robust
networks enriched for “Translational elongation”, “Cytolysis” and “DNA
metabolic process” associated with normative ageing. One of the identified
modules predominantly consisted of ribosomal proteins and translation
elongation factors. This module was found to be down-regulated with
chronological age and suggested age-associated limitation of protein
synthesis. Another major player in protein synthesis and ageing is mTOR
signalling. Not only does mTORC1 regulates protein synthesis, mTORC2
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activity is influenced by ribosomes (5), although the exact way in which this
happens is unclear at this moment. The next step would be to establish
whether the five co-expressed PPI networks that may be considered as
robust markers for normative ageing, are also markers for biological age. In
this regard the network including ASF1A already showed an association
with survival at old age, suggesting their gene expression to be indeed
markers for biological ageing.
Figure 1. Total PPI network for the genes contributing to the mTOR pathway, IL7R
network and the five robust co-expressed PPI modules
Connecting our findings and conclusions
We have identified five networks of which the gene expression levels in
blood are robustly associated with chronological ageing, including genes
involved in “Translational elongation”, “Cytolysis” and “DNA metabolic
process”. In addition three major candidate genes were found for which the
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transcription in blood differed between longevity families and controls, thus
potentially marking the biological age and the rate of ageing: ASF1A, IL7R
and RPTOR. Prospective studies relating the expression levels to morbidity
and mortality will reveal the value of these levels as biomarkers of ageing.
Figure 2. Total PPI network for the genes contributing to the mTOR pathway, IL7R
network and the five robust co-expressed PPI modules and 99 potential marker genes
To prioritize the 236 uninvestigated potential marker genes that resulted
from the explorative analyses in Chapter 3, we explored their relation with
the interactive networks identified in Chapter 4, 5 and 7. By using STRING
software we created a protein-protein interaction network for the genes
contributing to the mTOR pathway, IL7R network and the five robust co-
expressed PPI modules (Figure 1). Next we explored whether the 236
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uninvestigated potential marker genes connected to the normative ageing
networks. We found that 230 genes were recognized by STRING, 8 of
which were already part of the mTOR or IL7R network or were part of a
network found in the meta-analysis in chapter 7 (namely MTOR, IL7R,
ABCE1, ASF1A, DCK, LBH, MPHOSPH10 and ZZZ3) and 99 showed
direct interactions with networks of normative ageing (Figure 2). Thus
almost half of the genes that resulted as potential marker genes from
chapter 3 showing association with chronological age and familial longevity
connected to robust networks of normative chronological ageing resulting
from the meta-analysis, plus the mTOR and IL7R networks. The majority of
the connected genes showed at least two interactions enhancing the
evidence that they connect to these networks. Table 1 shows the 99 genes
prioritized for future replication studies. The other 123 genes do not show
any interaction with the normative ageing network.
Remarkably, five of the interacting genes that have not yet been tested for
replication in Chapter 3, ABCE1, DCK, ASF1A, MPHOSPH10 (MPP10) and
ZZZ3, are part of the robust age-associated co-expressed PPI module F in
the meta-analysis (Chapter 7, Figure 2, module F). This module was not
enriched for any biological process but seems to be related to the
mitochondrion and cell cycle. Since these five genes have not only been
associated with normative chronological ageing in Chapter 3 and the robust
meta-analysis of Chapter 7, but also with familial longevity (Chapter 3),
these genes may be the best next genes to be studied as potential markers
of biological ageing and longevity.
Table 1. The 99 genes prioritized for future replication studies
Gene name
ABI2 CCR6 GSTA1 LPIN1 NOLC1 PLD6 RRS1 TOP1MT
ACVR2B CD7 GTPBP3 LRRK2 NR1D2 PLEKHG4 RUVBL1 TRAF5
ALDH18A1 CDC37L1 H2AFV LSG1 NR3C2 POLR1B RUVBL2 TYMS
ALG9 CDK6 HADH MAP3K15 NUP155 PPAPDC1B SEPT6 UNC5A
ANG CDYL HK3 MAP4K3 PABPC1 PRKCQ SERTAD2 UTP20
ARHGAP5 DBF4 IGFBP6 MLLT3 PAIP2B PUS7 SLC25A16 WRN
ATOX1 DYRK2 INPP5E MPI PAQR8 PYCR2 SMAD3 WWP1
BLOC1S1 EIF1AX INTS2 MPRIP PDHA1 RASGRP1 SPINK2 ZNF420
BNIP3 ENO2 KIF15 MTX2 PEBP1 RBM12B STRBP
C10orf137 ENOSF1 LANCL1 MYC PELP1 RIC8B TAF3
C12orf29 EPHA4 LAT NKRF PGRMC2 RNASE4 TCF12
C7orf23 GABPA LEF1 NOB1 PHLPP2 RPL13A TCF4
CARD11 GNPNAT1 LGALS1 NOG PIK3C2B RPS6KA4 TOB1
Chapter 8
146
Implications and future research
One of the main pathways resulting from animal research and from this
thesis to mark normative ageing is the mTOR signaling pathway, for which
we identified the gene expression of RPTOR in blood to be a potential
biomarker for biological ageing in middle-age. We observed that the
decreased transcriptional activity of the MTOR pathway in members of
long-lived families corresponds to the lower prevalence of cardiovascular
disease and type 2 diabetes (6), and increased sensitivity to insulin (7). As
compared to their partners, matched for age and social and lifestyle factors,
the longevity families further display a beneficial lipid profile (8) and their
cells are better resistant to stress (3). This pattern of phenotypic
characteristics resembles the characteristics of caloric restricted mice (9),
including the lower mTOR signaling and the longer lifespan. The interesting
difference is that in the human studies the longevity family members and
partners do not differ in BMI or in calorie intake. We hypothesized that
members of long-lived families have an endogenously beneficial setting of
their metabolism and hence protection from diseases. The question rises
whether the controls (representing normative ageing subjects) are able to
adjust the settings of their nutrient sensing pathways by behavioral
changes.
Growing Old Together
Based on the finding that nutrient sensing and mTOR signaling as in animal
models is relevant for human ageing, we initiated intervention studies within
the LLS cohort. To investigate whether the partners of the offspring may be
able to improve their metabolic health by diet intervention and physical
activity, we founded the “Growing Old Together” Study. Middle-aged
couples of the Leiden Longevity Study; offspring of nonagenarian siblings
and their partners, are subjected to an intervention of dietary restriction and
physical exercise for 13 weeks, a 25% lowered energy expenditure in total.
By examining the potential biomarkers of biological ageing identified in this
thesis before and after the intervention, we may be able to determine
whether improvement of metabolism is acquired by the intervention, for
which participants this is the case and whether the genes identified in this
thesis contribute to such improvement.
Since blood may not be the best tissue to investigate mTOR signaling, in
the “Growing Old Together” study also abdominal fat and skeletal muscle
tissue are being collected. Since skeletal muscle is the major site of
glucose disposal in response to food intake and insulin, and since an
impairment of glucose uptake in this tissue contributes to type 2 diabetes,
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we will investigate whether expression differences in mTOR genes between
offspring and controls are more pronounced in muscle tissue. Also, we will
investigate which candidate genes for biomarkers for the rate of ageing are
the best in marking metabolic health.
Future indications
In general, altered gene expression levels in the longevity family members
may be the consequence of ageing, or merely a trait shared by the long-
lived families or may truly contribute to human longevity. To investigate
whether changes in potential biomarkers causally contribute to ageing,
gene expression of specific genes should be measured quantitatively in
blood of a large, long-term population-based longitudinal study from the
age of 40 years onwards. Now that we have a number of candidate genes
such studies may indeed be performed to establish the association with
prospective morbidity and mortality. Ideally, longitudinal measurements
should be performed for example every five years, including collection of
information about cell type proportions in the samples and information
regarding the subjects’ health. Such analyses could be done in large
ongoing cohort studies such as the Rotterdam Study cohort (10) and, since
the LLS study was initiated over 10 years ago, includes highly and middle-
aged subjects, also in the LLS study. The future longitudinal study of
genomic biomarkers may include also quantitative measures of epigenetic
variation (such as DNA methylation) and should go hand in hand with
measures of novel physiological parameters of biological ageing, as
reflected by proteomics and metabolomic measures (11). Novel markers of
biological ageing will stimulate studies into identification of determinants
and mechanistic factors causally involved in biological ageing. Potentially
causal factors will need to be investigated in animal models in which all
tissues can be studied and not as in healthy humans, just blood, skin,
muscle and fat tissue. In future studies of human longevity families, next
generation sequencing of both DNA and RNA can provide further insight
into the genetic variation underlying the gene expression differences we
observed and test whether this could form the basis of the familial
longevity.
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The most prevalent diseases in the Western world have in common that
age is the major risk factor. Life expectancy has increased dramatically in
the last two centuries and will continue to rise. The healthy lifespan in
western societies however, is usually not more than 75% of a lifetime.
Many molecular changes occur as a function of chronological age in all
tissues. Such changes could represent a marker of the biological ageing
rate. The most valuable biomarkers of ageing rate would associate not only
with chronological age and health status, but also with morbidity and
mortality in prospective studies. To find these biomarkers we investigated
chronological and biological ageing in long-lived families, collected in the
Leiden Longevity Study (LLS). The LLS consists of nonagenarian sibling
pairs, their middle-aged offspring and the partners thereof which act as
controls. As compared to controls, the offspring has a lower prevalence of
myocardial infarction, hypertension and type 2 diabetes and a lower
mortality risk and are therefore regarded as healthy agers.
Transcriptomic studies for identification of human pathways and biomarkers
of ageing have so far mainly focused on chronological ageing in several
tissues (the largest studies investigated blood) and reported on enrichment
for pathways like immune response, energy metabolism, mitochondrial
processes and post-transcriptional regulation which may harbor potential
biomarkers for chronological ageing. These studies have been reviewed in
chapter 2 of this thesis. In this thesis we aimed for identification of relevant
pathways and potential biomarker profiles that associate with chronological
age in human populations and we tested which of these discriminate
between healthy ageing members from long-lived families and normative
ageing controls by studying the blood transcriptome using various
approaches. Such pathways and biomarkers may harbor determinants of
the biological ageing rate.
In chapter 3 we describe a genome-wide gene expression microarray study
of 47,209 probes (representing 17,896 known genes) within 50 families of
the LLS to screen for genes of which expression changes with age and
associated with biological ageing. We identified 2,953 probes that
associated with chronological age when comparing gene expression
profiles from whole blood samples between 50 nonagenarians and 50
middle-aged controls, the latter representing the general population. From
these, the expression of 360 probes was found to change differentially with
age in offspring of the nonagenarians as compared to controls. In a RT-
qPCR replication experiment utilizing 312 controls, 332 offspring and 79
nonagenarians, we confirmed a ‘‘chronological aging-signature’’ formed of
21 genes, of which reduced expression of ASF1A and IL7R marked familial
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longevity already in middle-age. This indicates that expression changes of
ASF1A and IL7R, which are involved in chromatin modeling and the
immune system respectively, represent early features of familial longevity
and healthy ageing.
The IL7R gene encodes the interleukin 7 receptor, which is important in
immune response processes and critical for T cell development. Increased
expression of IL7R and IL7 has been associated with prevalence of
immune-related diseases. In chapter 4 we explore whether the expression
of the IL7R gene and six interaction partners in blood associated with
familial longevity, and whether the association is dependent on whole blood
cell proportions and immune-related diseases including type 2 diabetes,
COPD and rheumatoid arthritis. Investigating the expression of these seven
genes in blood of the LLS using RT-qPCR resulted in a significant
association of the network in a set-based test with chronological age (p=4.6
x 10-4). IL7R expression was found to be lower in the offspring as compared
to the controls, which is in concordance with the observation that higher
IL7R gene expression in blood is associated with higher prevalence of
immune-related diseases (p-value=0.001). The association of lower IL7R
gene expression with familial longevity was not explained by variation
between the groups in blood cell counts and in the prevalence of the tested
immune-related diseases. Paradoxically, IL7R gene expression decreases
with age and higher IL7R gene expression levels associate with better
survival in old and middle age. Taken together, the IL7R network reflected
by gene expression levels in blood may mark the biological age and health
status of elderly individuals, although the complexity of the mechanism still
requires elucidation.
In addition to the explorative analysis, we also investigated candidate
pathways for human longevity. The pathway that extensively has been
implicated in lifespan extension but also development of disease in model
organisms is mTOR signaling. This pathway has also been associated with
diseases like diabetes and cancer in humans, but its impact on familial
longevity or healthy ageing has not been determined yet. In chapter 5 we
therefore investigated the gene expression level of the mTOR signaling
pathway in blood within the LLS study. Forty genes were measured using
RT-qPCR and as a set it showed significant association with chronological
age when comparing mRNA levels of nonagenarians and middle-aged
controls (p=4.6 x 10-7). Seven out of the 40 mTOR pathway genes had a
significant differential expression of at least 5%. Of these, RPTOR showed
a decreased expression in members of the long-lived families as compared
to controls, already in middle-age, independent of prevalence of type 2
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diabetes and cancer or variation in glucose levels. At the level of
suggestive evidence this was also the case for PRRL5. Taken together, the
mTOR pathway is not only involved in regulation of disease and lifespan in
animal models, but also in humans. The gene expression in blood of
RPTOR is a potential biomarker for biological ageing.
The mTOR pathway has been broadly studied in cell lines before, and
cellular responses to stress in skin fibroblasts of offspring and controls from
the LLS were shown to be associated with familial longevity. Therefore we
questioned whether the mTOR pathway in this cellular model might reflect
the metabolic characteristics of familial longevity. In chapter 6 we described
this functional follow-up of the mTOR signaling results in blood, which was
performed in skin fibroblasts from middle-aged LLS offspring with their
partners as controls. Besides gene expression levels of all 40 mTOR
signaling genes, expression level and phosphorylation of the most
important proteins in the mTOR pathway were measured and analyzed, as
well as total protein content and autophagy markers. However, only
decreased total protein content was observed in offspring of long-lived
individuals compared to controls. Besides not finding the same difference
as was found in blood before, gene expression levels in fibroblasts did not
reflect the corresponding protein levels in cultured fibroblasts or gene
expression levels in whole blood in the same donors. Hence, the effect of
mTOR signaling on human familial longevity may not be present in all
tissues.
In chapter 7 we performed a meta-analysis combining multiple large-scale
expression studies in blood to discover robust markers for chronological
ageing in an integrative network-based approach. The combination of co-
expression of genes and protein-protein interaction networks resulted in
five robust networks significantly associated with normative ageing and
included modules enriched for “Translational elongation”, “Cytolysis” and
“DNA metabolic process”. An independent study in a Dutch cohort resulted
in the validation of four out of five networks, indicating the robustness of our
results. Whether these networks may be considered as markers for
biological ageing as well has yet to be explored.
Striking is that five genes (ABCE1, ASF1A, DCK, MPHOSPH10 and ZZZ3)
of one of the robust networks are also among the 259 possible candidate
markers for biological ageing as described in Chapter 3. An independent
study also shows this network to be associated to survival at old age. As a
relatively unknown group of genes it is important to further investigate this
network in regards to function and relationship with health and ageing.
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In this thesis we identified several pathways that change their gene
expression as a function of chronological age. These may represent
potential biomarkers in blood that associate with chronological age in
human populations, including genes involved in translational elongation,
regulation of transcription and lymphocyte development. We found
indication that genes in these pathways may be relevant for ageing or could
represent biomarkers for biological ageing, including expression levels of
ASF1A, IL7R, IL7 and RPTOR, which discriminate healthy agers (from
longevity families) from normally ageing controls. Our explorative analysis
resulted in 259 possible candidate markers for biological ageing of which
23 have been tested for replication in a larger part of the LLS. Of the yet
untested genes, 99 were part of a large ageing-associated interaction
network based on genes contributing to the mTOR pathway, IL7R network
and the five robust co-expressed PPI modules. These 99, but also 4 other
genes that formed a centrosome network separate from the large network,
need to be validated in a larger part of the study population as possible
markers for biological ageing.
A first step to investigate the biological relevance of the observed
associations of the nutrient sensing mTOR pathway with familial longevity
is initiated by the follow-up of these candidate genes in an intervention
study called “Growing Old Together”. Offspring of nonagenarian siblings
and their partners are subjected to an intervention of dietary restriction and
physical exercise for 13 weeks. By examining the (candidate) biomarkers
for the rate of ageing in blood, but also in muscle and fat, before and after
the intervention, we aim to determine to what extent the controls change
their molecular profile towards that of healthy agers and whether variation
in mTOR expression associates to variation in response to the intervention.
Such studies are ultimately aimed to stimulate middle aged individuals in
the general population to improve their metabolic health and slow down
their biological ageing rate and the gene expression profiles studied in this






Mensen verouderen met een verschillende snelheid. Je kunt het proces
aan de buitenkant zien; ouderen krijgen rimpels, worden grijs, bewegen
stijver en krijgen te maken met diverse leeftijdsgerelateerde ziekten. Ook
aan de binnenkant, in moleculen en cellen van mensen kun je het
verouderingsproces aflezen. Zo verschilt ook de activiteit van genen in het
erfelijk materiaal tussen ouderen en jonge mensen. Door de verschillen
tussen ouderen is de biologische leeftijd niet altijd dezelfde als de
kalenderleeftijd. In een groep mensen van 70 jaar zijn grote verschillen
aanwezig met betrekking tot de gezondheid, het functioneren en
welbevinden, maar ook op het niveau van de cellen en moleculen. De
levensverwachting is zeer sterk gestegen in de laatste tweehonderd jaar en
veel ouderen van nu maken een jongere indruk dan ouderen in vorige
generaties. De stijging in levensverwchting werd veroorzaakt door
omgevinggerelateerde oorzaken zoals verbetering van hygiëne, voeding en
medische zorg. Men kan zich afvragen of erfelijkheid een rol speelt bij het
bepalen van de levensverwachting.
Uit de Leiden LangLeven Studie is gebleken dat kinderen, maar ook de
ouders, van negentigjarige broer-zuster paren 30% minder kans hebben
om te overlijden in vergelijking met mensen van de algemene bevolking uit
hetzelfde geboortejaar. Onder de kinderen (ongeveer 60 jaar oud) van de
negentigjarige broers en zussen uit de langlevende families komen
hartinfarcten, hoge bloeddruk en suikerziekte minder voor dan bij de
partners van deze kinderen. Anders gezegd, de leden van langlevende
families lijken trager te verouderen en biologisch jonger te zijn dan hun
eigen partners die je kunt zien als controlepersonen: leeftijdsgenoten uit
andere families.
Het doel van dit proefschrift was om indicatoren, ook wel biomarkers
genoemd, voor biologische veroudering te vinden in het bloed van
langlevende families en controles van de Leiden LangLeven Studie aan de
hand van genexpressiemetingen waarin de activiteit van genen wordt
bepaald. Deze biomarkers zouden ons kunnen wijzen op de processen die
te maken hebben met de snelheid van veroudering in de mens. Hoofdstuk
2 geeft een overzicht van het onderzoek dat bij aanvang van het promotie
onderzoek is gedaan naar de relatie tussen genexpressieprofielen en
kalenderleeftijd. Echter, in verschillende studies die kalenderleeftijd
bestuderen werden steeds weer andere groepen genen gevonden. Dit kan
komen door verschillen in onderzoekspopulaties, de grootte van de studie,
de onderzochte weefsels en testmethodes. Een aanpak die niet elk gen
apart onderzoekt, maar kijkt naar groepen genen die betrokken zijn bij
veroudering, laat in meerdere studies wel zien welke processen consistent
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lijken te associëren met de kalenderleeftijd (hoofdstuk 2). In dit proefschrift
hebben we verschillende methoden gebruikt om de biomarkers voor
biologische veroudering te vinden. Deze worden in de verschillende
hoofdstukken van dit proefschrift beschreven.
In hoofdstuk 3 beschrijven we een zogenaamde hypothesis-vrije aanpak
waarin we expressieniveaus van bijna 18.000 bekende genen hebben
kunnen meten. Hiervoor onderzochten we bloed van deelnemers van de
Leiden LangLeven Studie: vijftig negentigjarigen, vijftig van hun kinderen en
vijftig partners van de kinderen die als controles fungeren. In deze
studieopzet kunnen we verschillende vergelijkingen maken.
Als eerste die tussen negentigjarigen en mensen van middelbare leeftijd.
We kozen daarvoor de partners van de kinderen (die zijn geen familie van
de negentigjarigen). In deze vergelijking bleken er 1853 genen in hun
expressie te verschillen tussen de twee groepen. Deze genen
vertegenwoordigen óf een kenmerk van kalenderleeftijd (90 versus ± 60
jaar oud), óf een kenmerk van de langlevende families, die je ook in andere
familieleden kunt aantreffen. Wat uniek is in vergelijking met andere studies
is dat we ook de kinderen (middelbare leeftijd) van deze negentigjarigen
konden meten. In de vergelijking van die kinderen en hun partners bleken
259 van de 1853 genen verschillend tot expressie te komen. Aangezien
deze groepen van dezelfde leeftijd zijn, zijn dit waarschijnlijk kenmerken
van langlevende families. De expressie van deze genen heeft mogelijk een
relatie met de biologische leeftijd die in de kinderen van lang levende
families lager is dan die van hun echtgenoten. Deze categorie genen zou
een aanwijzing kunnen geven over de processen die mede bepalen hoe
snel de biologische veroudering verloopt.
Van de 259 genen hebben we er 22 opnieuw gemeten in een groter deel
van de Leiden LangLeven Studie; 79 negentigjarigen, 332 kinderen en 312
partners. Hieruit bleek dat een lagere expressie van de ASF1 anti-silencing
function 1 homolog A (ASF1A) en het interleukine 7 receptor (IL7R) gen
kenmerkend is voor de langlevende families. Dit duidt erop dat de
genexpressie van deze genen, betrokken bij modellering van
chromosomen en immuunsysteem functie, samen gaat met een jongere
biologische leeftijd.
Een juiste werking van de IL7 receptor waar het IL7R gen voor codeert is
erg belangrijk voor ons immuunsysteem. De ontwikkeling van T cellen die
nodig zijn voor een optimale immuun reactie is afhankelijk van de IL7
signalering waarvan de IL7 receptor aan de basis ligt. Om te zien of genen
die met het IL7R gen te maken hebben ook veranderen met biologische
leeftijd, hebben we een IL7R netwerk getest dat bestaat uit IL7R zelf en zes
Chapter 10
158
andere genen die een directe connectie hebben met IL7R. De expressie
van deze genen hebben we getest in de grote groep deelnemers van de
Leiden LangLeven Studie (hoofdstuk 4). Het netwerk als geheel bleek nu
anders tot expressie te komen in leden van langlevende families, in het
bijzonder IL7R zelf. De langelevende families worden gekarakteriseerd
door een relatieve lage genexpressie, onafhankelijk van de samenstelling
van celtypen in het bloed en de aanwezigheid van immuun-gerelateerde
ziekten. We hebben tevens gekeken naar de relatie tussen de IL7R
expressie en overleving gedurende 7 jaar. Nu bleek dat een hoger
expressieniveau gerelateerd is aan een betere overleving op middelbare en
hoge leeftijd. Hieruit blijkt dat de relatie van IL7R genexpressie met
biologische leeftijd enerzijds en gezondheidsstatus anderzijds op het eerste
gezicht tegenstrijdig is. Deze complexe relatie wordt ook bij andere immuun
parameters gevonden in ouderen en moet verder onderzocht worden.
Een andere aanpak die we hebben gebruikt om de relatie tussen
langlevendheid en genexpressie te onderzoeken is de hypothesis-
gebaseerde aanpak. In dieren is het bekend dat mammalian target of
rapamycin (mTOR) signalering de levensduur beïnvloedt. Bij mensen is dit
proces betrokken bij het optreden van ziekten zoals diabetes en kanker. De
basis van mTOR signalering ligt in twee eiwitcomplexen, mTOR-complex 1
en mTOR-complex 2. Deze reageren op onder andere voeding,
energieverbruik (sporten) en het glucoseniveau in het bloed. Tot nu toe is
vooral bewezen dat verlaagde activiteit van het mTOR-complex 1 de
levensduur verlengt (in diermodellen) en dat verhoogde activiteit van
datzelfde complex samen gaat met de ernst van ziekten bij de mens.
De rol van mTOR-signalering bij het bepalen van levensduur bij de mens
was nog niet eerder onderzocht. Dat hebben we in dit proefschrift in de
Leiden LangLeven Studie gedaan (hoofdstuk 5). Expressie van veertig
genen uit de mTOR signalering werd gemeten in 87 negentigjarigen, 337
van hun kinderen en 321 partners daarvan. Hiervan lieten zeven genen een
duidelijk significant verschil zien tussen de negentigjarigen en de partners
van de kinderen. In de vergelijking van kinderen en hun partners vonden
we nu dat op middelbare leeftijd een lagere expressie voor RPTOR en
PRR5L kenmerkend was voor de langlevende families. Als genexpressie
daadwerkelijk een reflectie is van mTOR signalering dan zou een lagere
MTORC1 en MTORC2 expressie bevestigen dat ook in mensen een lage
mTOR signalering samengaat met familiaire langlevendheid.
In hoofdstuk 6 hadden we als doel de mTOR-bevindingen uit hoofdstuk 5,
die gedaan zijn in bloed, te bevestigen op eiwitniveau in cellen uit de huid
(fibroblasten) die bij een huidbiopt van een deel van de studiegroep uit
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hoofdstuk 5 waren verzameld. In de fibroblasten werd niet alleen de
genexpressie gemeten, maar ook de expressie en activiteit van eiwitten die
bij de mTOR signalering betrokken zijn. Behalve een verschil in totale eiwit
hoeveelheid, zagen we in de fibroblasten geen verschil tussen de kinderen
van langlevenden en hun echtgenoten. Het verschil tussen de groepen dat
we aantroffen in het bloed was dus niet aanwezig in huidcellen van
dezelfde mensen. De expressie van genen reflecteerde niet het
corresponderende eiwitniveau in dezelfde cellen. Tevens bleek dat
genexpressie in huidcellen niet correspondeerde met de expressie van
diezelfde genen in bloed. Of dit komt door de gekozen groep mensen, het
kleine aantal mensen dat in deze stap kon worden onderzocht (37 kinderen
en 36 partners), het onderzochte weefsel of de gebruikte technieken, is niet
duidelijk. Het lijkt erop dat de gekweekte huidfibroblasten wat betreft het
samengaan van lage mTOR signalering en familiaire langlevendheid niet
hetzelfde laten zien als bloed.
Bij het vergelijken van verschillende studies naar genexpressie in bloed is
er weinig overeenkomst tussen studies in de gevonden individuele genen,
waarvan de expressie verandert met kalenderleeftijd. Er is meer
overeenkomst tussen de biologische processen waarvan de expressie
verandert met leeftijd. Om te weten te komen welke processen een
consistente rol spelen in veroudering kan onderzocht worden van welke
groepen genen in gezamenlijkheid de expressie verandert bij het ouder
worden, zodat daarna onderzocht kan worden binnen welk proces deze
groep genen een functie vervult. We hebben daarom in hoofdstuk 7 de
datasets van drie grote studies uit de literatuur verzameld waarin
genexpressie werd gemeten in bloed van mensen met verschillende
leeftijden. We hebben gezocht naar die genen die als groep (netwerk) een
verandering in expressie met leeftijd ondergaan in meerdere studies
(zogenoemde meta-analyse). De netwerken van genen die we in de data
vonden zijn gebaseerd op een combinatie van de vergelijkbare
genexpressieniveaus in de op bloed gebaseerde datasets de tot nu toe
bekende eiwit-eiwitverbindingen van de eiwitten waar de genen voor
coderen. Deze combinatie levert netwerken op van genen waarvan we
veronderstellen dat ze in een gezamenlijk biologische proces zijn
betrokken. Vervolgens zijn deze netwerken getest voor differentiële
expressie met kalenderleeftijd, wat resulteerde in identificatie van vijf
netwerken waarvan de expressie consistent over studies verandert met
veroudering. Een onafhankelijke herhalingsstudie in een Nederlandse
groep mensen liet zien dat vier van de vijf netwerken ook in deze studie
veranderde met veroudering. Om te onderzoeken of deze netwerken ook
echt potentiële biomarkers zijn is er een overlevingsanalyse gedaan in de
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LLS welke liet zien dat een van de netwerken, degene die ASF1A bevat,
daadwerkelijk samengaat met overleving op hoge leeftijd.
Opvallend is dat vijf genen (ABCE1, ASF1A, DCK, MPHOSPH10 en ZZZ3)
van het netwerk dat indicatief is voor betere overleving ook voorkomen op
de lijst van genen die gerelateerd zijn aan biologische leeftijd, zoals
beschreven in hoofdstuk 3. Dit netwerk heeft geen duidelijk bekende
biologische functie en is nu een kandidaatbiomarker voor gezonde
veroudering. Het is van belang dit netwerk te onderzoeken in relatie met
gezondheid en veroudering. Tevens is het van belang om de biologische
functie van dit netwerk te achterhalen.
Als we alle resultaten combineren, komen we uit op één groot netwerk van
genen dat zowel de mTOR signalering, het IL7R netwerk, als de vijf
netwerken van de meta-analyse omvat. Dit proefschrift laat zien dat dit
grote netwerk (figuur 1 van hoofdstuk 8) met al zijn genen gerelateerd is
aan veroudering. De hypothese-vrije aanpak beschreven in hoofdstuk 3
heeft in totaal 259 kandidaatgenen opgeleverd als mogelijke marker voor
biologische leeftijd. Voor enkele van deze genen, ASF1A, IL7R en RPTOR,
hebben we laten zien dat verlaagde genexpressie samengaat met een
jongere biologische leeftijd. Er zijn dus veel genen over die nog onderzocht
moeten worden. Om de prioriteit van deze nog te testen kandidaatgenen
aan te geven, hebben we gekeken of ze ook onderdeel zijn van het
bovengenoemde grote verouderingsnetwerk (de combinatie van de
resultaten uit hoofdstukken 4, 5 en 7). Van deze kandidaatgenen hebben er
99 een directe connectie met een of meerdere van de netwerkgenen. Deze
99 zullen dan ook verder onderzocht moeten worden op hun
eigenschappen als mogelijke biomarker voor biologische veroudering.
Een van de belangrijkste processen die aan veroudering wordt gerelateerd
in dieronderzoek en ook in dit proefschrift is de mTOR signalering. We
hebben laten zien dat verlaagde expressie van deze genen onder andere
samen gaat met minder ziektes en een gezonder suiker metabolisme in de
langlevende families. In muizen observeert men een vergelijkbaar beeld als
de voedselinname wordt beperkt; verlaagde mTOR signalering en een
verlengde levensduur. Er is geen verschil in voedselinname tussen leden
van de lang-levende families en hun partners, dus wij concluderen dat deze
families een betere ‘afstelling’ van nature hebben. De vraag is nu, kunnen
de partners iets doen om net zo gezond te worden?
Iemands leefstijl kan de expressie beïnvloeden, mTOR signalering is
bijvoorbeeld zogenaamd ‘nutrient sensing’ en wordt beïnvloed door voeding
en lichaamsbeweging. Naar aanleiding van de bevindingen uit dit
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proefschrift is de Samen Oud Samen Thuis (Growing Old Together) Studie
opgezet waarin de kinderen van langlevende mensen en hun partners een
dieet volgen met verminderde hoeveelheid caloriën en een
bewegingsprogramma. De effecten van deze interventie op gen- en
eiwitexpressie wordt gevolgd in bloed, spier en vet van de personen. Door
middel van het veranderen van eet- en bewegingspatronen proberen we
erachter te komen of de partners zonder de gunstige genen toch net zo
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